Molecular imaging using positron emission tomography in gastrointestinal malignancy by Pakzad, F.
  1 
Molecular Imaging using  
Positron Emission Tomography  
in Gastrointestinal Malignancy 
 
 
A thesis submitted to the University College London  
for the Degree of Doctor of Medicine 
 
 
 
by 
Farrokh Pakzad BSc(Hons) MBBS MRCS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Institute of Nuclear Medicine and  
The Department of Surgery 
Royal Free and University College Medical School 
University College London 
2008  2 
STATEMENT OF ORIGINALITY 
 
The studies described and presented in this thesis are the original work of the author. 
Data collection and analysis relating to the clinical part of this thesis are the sole work 
of  the  author.  Image  analysis  was  however  carried  out  by  senior  grade  nuclear 
medicine physicians and/or radiologists. 
 
All PET, CT scans and PET image/data reconstruction were performed by qualified 
radiographers in accordance with local protocol and clinical guidelines. Radioactive 
tracers  were  synthesised  at  the  MRC  Cyclotron  Unit,  Hammersmith  Hospital, 
London. These were then transported to the Institute of Nuclear Medicine on the day 
of PET scanning. Radiochemical analysis was performed by a radiochemist at the 
Institute of Nuclear Medicine. 
 
No part of this work has been submitted to any other university for consideration for a 
higher degree. 
 
Immunohistochemistry  for  Ki-67  was  carried  out  in  collaboration  with  the 
histopathology department at University College London. Histological analysis was 
performed in conjunction with a senior histopathologist. 
 
All in vitro experiments including cell culture work, gel electrophoresis, western blot 
analyses  and  flowcytometry  results  were  the  sole  work  of  the  author.   3 
CONTENTS                     Page 
Title page                      1 
Statement of Originality                  2 
Table of Contents                         3-12 
Abstract                    13 
Acknowledgements                   14 
Figures and tables                       15-19 
Abbreviations                      20 
Chapter 1 
 
Introduction 
 
1.1  Molecular imaging and cancer                22 
1.2  Approaches to in vivo molecular imaging              24 
1.2.1  Nuclear imaging                    24 
1.2.2  Optical imaging                    25 
1.2.3  Magnetic Resonance Imaging (MRI)              26 
1.2.4  Ultrasound 
1.3  Molecular imaging of cancer with Positron Emission  
Tomography (PET)                   28 
1.3.1  Imaging with PET – the basic principles             29 
1.3.2  The PET detector unit                  29 
1.3.3  Annihilation coincidence detection               29 
1.3.4  Attenuation correction                 30 
1.3.5  Quantitative imaging                  31 
1.3.6  Multimodality imaging with PET/CT              32 
1.3.7  Imaging protocols with PET and PET/CT            33 
1.4  Molecular and cellular targets for PET imaging           35   4 
1.4.1  Aerobic glycolysis, cancer and imaging with PET           37 
1.4.2  [18F]-fluoro-2-deoxy-D-glucose (18F-FDG)            38 
1.5  Cellular proliferation                 41 
1.5.1  The cell cycle                   41 
1.5.2  Proliferation and tumour growth               43 
1.5.3  Assessment of proliferation                  44 
  1.5.3.1   Mitotic index                 45 
  1.5.3.2   Incorporation techniques using nucleotide analogues  45 
  1.5.3.3   DNA cytometry and percentage S-phase determination  45 
  1.5.3.4   Proliferation associated antigens        46 
1.5.4  Tumour heterogeneity – a problem of assessing proliferation    47 
1.5.5  Thymidine analogue PET tracers for imaging cell proliferation    48 
1.6  [18F]-3’-deoxy-3’-fluorothymidine (18F-FLT)        50 
1.6.1  The development of 18F-FLT              50 
1.6.2  The molecular kinetics of 18F-FLT            50 
1.6.3  Cellular trapping of 18F-FLT             51 
1.6.4  18F-FLT as a proliferation PET tracer          52 
1.6.5  Clinical applications of 18F-FLT            53 
1.7  The role of PET in diagnosis and staging of pancreatic cancer    59 
1.7.1  Background                  59 
1.7.2  Clinical features of pancreatic cancer           59 
1.7.3  Routine management of algorithm of patients with suspected  
pancreatic cancer                61 
  1.7.3.1   Basic investigations            62 
  1.7.3.2   Conventional imaging of the pancreas      63   5 
1.7.4  18F-FDG PET in diagnosis of primary pancreatic cancer      68 
1.7.5  Staging of pancreatic carcinoma with 18F-FDG PET      71 
1.7.6  The prognostic significance of 18F-FDG uptake in pancreatic cancer  74 
1.7.7  18F-FDG PET in the detection of recurrent pancreatic cancer    75 
1.7.8  The pitfalls of imaging pancreatobilliary disease with 18F-FDG PET  76 
1.7.9  Pancreatic cancer and image fusion with PET/CT        77 
1.8  The role of PET in diagnosis and staging of colorectal cancer    80 
1.8.1  Background                  80 
1.8.2  Detection of pre-malignant colonic lesions          81 
1.8.3  Screening for colorectal cancer with PET          82 
1.8.4  The role of 18F-FDG PET in the diagnosis of primary  
colorectal cancer                82 
1.8.5  Detection of recurrent and metastatic disease          84 
  1.8.5.1   Locoregional recurrence          84 
  1.8.5.2   Metastatic disease            87 
1.8.6  The impact of dual modality imaging with PET/CT on the  
management of colorectal cancer            89 
1.8.7  Therapy response monitoring with PET          91 
  1.8.7.1   Response to radiotherapy          91 
  1.8.7.2   Response to chemotherapy          92 
  1.8.7.3   Monitoring local ablative therapy        93 
1.8.8  Limitation of imaging colorectal cancer with 18F-FDG PET    94 
1.9  Chapter overview and aims of thesis          95   6 
 
Chapter 2 
 
Materials and methods 
 
2.1  Patient recruitment                98 
2.2  Whole body FDG-PET/CT scans            99 
2.2.1  18F-FDG                  99 
2.2.2  Patient preparation                99 
2.2.3  Acquisition of whole body FDG PET/CT scans        100 
2.3  Whole body FLT-PET/CT scans            101 
2.3.1  Radiosynthesis of 18F-FLT              101 
2.3.2  Dose calibration                102 
2.3.3  Patient preparation and dose administration          102 
2.3.4  Acquisition of whole body 18F-FLT PET/CT images      103 
2.4  Image analysis                104 
2.4.1  Visual analysis                104 
2.4.2  Quantitative analysis                105 
2.5  Computed tomography imaging protocols         108 
2.5.1  Patient preparation                108 
2.5.2  Image acquisition                108 
2.5.3  Image reconstruction and analysis            110 
2.6  Confirmation of diagnosis and follow up          110 
 
 
   7 
Chapter 3 
 
Does 18F-FDG PET/CT play a role in the routine management of 
pancreatic cancer? 
 
3.1  Background                  112 
3.2  Aims                    113 
3.3  Methods                  114 
3.3.1  Patient recruitment                114 
3.3.2  Imaging protocols                114 
3.3.3  Data presentation                 115 
3.4  Results                  116 
3.4.1  Patient demographics               116 
3.4.2  Diagnosis of primary pancreatic lesions          117 
3.4.3  Staging accuracy of 18F-FDG PET/CT in pancreatic cancer     119 
  3.4.3.1   Local (T) and nodal (N) staging        119 
  3.4.3.2   Distant metastases            120 
3.4.4  Additional findings                123 
3.4.5  The impact of 18F-FDG PET/CT on clinical management      124 
3.5  Discussion                  125 
3.6  Conclusion                  131 
 
 
 
 
   8 
 
Chapter 4 
 
Does 18F-FGD PET/CT provide additional information to 
conventional imaging in the management of  
colorectal liver metastases? 
 
4.1  Background                  133 
4.2  Aims                    136 
4.3  Methods                  137 
4.3.1  Patient group                  137 
4.3.2  Imaging protocols                137 
4.3.3  Image analysis                  137 
4.3.4  Clinical Risk Score (CRS)              139 
4.3.5  Data presentation and statistical analysis          139 
4.4  Results                  140 
4.4.1  Patient demographics               140 
4.4.2  18F-FDG PET/CT versus routine ceCT          140 
4.4.3  The impact 18F-FDG PET/CT on management        144 
4.4.4  The impact of CRS on the clinical yield of 18F-FDG PET/CT    146 
4.4.5  The incremental value of PET/CT over that of imaging with PET alone  147 
4.5  Discussion                  150 
4.6  Conclusions                  156 
 
 
   9 
 
Chapter 5 
Targeting proliferation in pancreatic cancer using 18F-FLT PET –  
A comparative study with 18F-FDG. 
 
5.1  Background                  158 
5.2  Aims                    159 
5.3  Methods                  160 
5.3.1  Patient recruitment                160 
5.3.2  Imaging protocols                160 
5.3.3  Image analysis                  160 
5.3.4  Histological analysis                162 
5.3.4.1  Specimen preparation           162 
5.3.4.2  Examination of histological sections       162 
5.3.5  Statistical analysis                163 
5.4  Results                  164 
5.4.1  Patient demographics and tumour characteristics        165 
5.4.2  Detection of primary pancreatic disease – comparison between  
18F-FDG and  18F-FLT PET imaging          166 
5.4.3  Correlation between tracer uptake and proliferative activity     168 
5.4.4  Correlation between tumour SUV‟s and patient survival      172 
5.5  Discussion                  174 
5.6  Conclusions                  179 
 
 
   10 
Chapter 6 
Staging of advanced colorectal cancer using 18F-FLT PET –  
A comparative study with 18F-FDG  
 
6.1  Background                  181 
6.2  Aims                    183 
6.3  Methods                  184 
6.3.1  Patient recruitment                184 
6.3.2  Imaging protocols                184 
6.3.3  Image analysis                  185 
6.3.4  Statistical analysis                185 
6.4  Results                  186 
6.4.1  Patient demographics               186 
6.4.2  Comparison of imaging with 18F-FDG and 18F-FLT PET 
 in detecting malignant lesions            186 
6.4.3  Comparison between lesion tracer SUVs (18F-FDG vs 18F-FLT)    191 
6.5  Discussion                  194 
6.6  Conclusions                  199   11 
 
Chapter 7 
Measuring early adaptive response to 5-flurouracil with 18F-FLT –  
an in vitro study 
 
7.1  Background                  201 
7.2  Aims                    204 
7.3  Material and methods              205 
7.3.1  Materials and cell lines              205 
7.3.2  Routine cell line maintenance             205 
7.3.3  Basic experimental protocol              206 
7.3.4  Defining drug dose parameters            207 
7.3.5  Tracer uptake experiments              208 
7.3.6  Cell cycle phase determination            209 
7.3.7  TK-1 protein expression              210 
  7.3.7.1   Protein extraction            210 
  7.3.7.2   Protein assay              210 
  7.3.7.3   Gel electrophoresis and Western Blot        211 
7.3.8  Statistical analysis                212 
7.4  Results                   213 
7.4.1  Cytotoxic effect of 5-FU and Cisplatin          213 
7.4.2  18F-FLT vs 18F-FDG uptake following 5-FU treatment      215 
7.4.3  Cell cycle changes in 5-FU treated cells          218 
7.4.4  Changes in TK-1 expression              221 
7.5  Discussion                  223 
7.6  Conclusions                  228   12 
 
Chapter 8 
Summary of findings and overall conclusions 
 
8.1  Summary of results                 230 
 
8.2  Conclusions                  236 
 
 
References                        237-259 
Appendices                        260-288 
List of publications                  289 
List of presentations                    290-291 
 
   13 
ABSTRACT 
 
Positron Emission Tomography (PET) with 18F-FDG has emerged as a powerful tool 
in oncology. Furthermore, recent advent of PET/CT and novel tracers are continually 
expanding its role. This thesis investigates its application in two solid cancer models.  
 
In the diagnosing of primary pancreatic cancer, 18F-FDG PET/CT was shown to be 
more  accurate  than  conventional  CT.  It  did  not  add  information  to  locoregional 
staging of disease but  impacted management of patients  with  potentially  operable 
tumours, by accurately confirming the presence / absence of metastases. In the pre-
operative  staging  of  patients  with  colorectal  liver  metastases  (CLM),  18F-  FDG 
PET/CT was also superior to CT in assessing extrahepatic disease, where it again 
impacted management.  The accuracy of detecting hepatic disease was similar for 
both. Compared to PET alone, PET/CT improved the accuracy of lesions localization 
and interpretation.  
 
Next, the feasibility of imaging with the novel thymidine analogue tracer 18F-FLT 
was investigated. Overall, 18F-FLT PET was less accurate than 18F-FDG in detecting 
lesions in both cancer types, thus suggesting it to be an unsuitable tracer for routine 
diagnosis and staging.  In the cohort of pancreatic cancer patients, 18F-FLT uptake 
(SUVs) were found to strongly correlate with the immunohistochemical proliferation 
marker, Ki-67 antigen. This supported 18F-FLT‟s potential role as a surrogate marker 
of proliferation. The prognostic implications of these require further investigation.  
 
Finally, an in vitro model was use to examine early changes in 18F-FLT uptake in 
response to treatment with cytotoxics. At 2 hours following pulse treatment with 5-
fluorouracil, (and before changes in cell numbers and cell cycle phase were seen), a 
dose dependent increase in 18F-FLT uptake was seen.  No change was observed with 
18F-FDG nor following Cisplatin treatment. This adaptive response may have a role 
as  an  early  predictor  of  response  to  5-FU  (and  potentially  other  antimetabolites), 
which requires further investigation.  
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CHAPTER 1 
 
Introduction   22 
1.1 Molecular imaging and cancer 
The modern management of cancer relies heavily on cross-sectional imaging, a role 
routinely  played  by  anatomical  imaging  modalities  such  as  ultrasound,  Computed 
Tomography (CT) or Magnetic Resonance Imaging (MRI). These imaging techniques 
detect pathology based on anatomical distortion of normal structures. Such changes in 
morphology however are the defined end-products of a complex series of molecular 
events,  which  derive  oncogenesis.  Consequently,  since  biochemical  aberrations 
precede  anatomical  changes,  there  has  been  a  tremendous  amount  of  interest  in 
developing  techniques  for  detecting  cancers  earlier  in  the  disease  process.  This 
paradigm  shift  has  been  spurred  on  by  advances  in  genomics  and  proteonomics, 
which has in turn paved the way for the emergence of a novel imaging discipline 
coined “molecular imaging”.   
 
The term molecular imaging (MI) represents the convergence of several biomedical 
disciplines  that  include  image  capture  techniques,  cellular  and  molecular  biology, 
chemistry, medical physics, biomathematics and bioinformatics. Its principal aim is to 
interrogate the biochemical processes of disease without breaching the integrity of the 
living subject. Although several different approaches to molecular imaging have been 
developed,  the  core  principles  of  probe  labelling  and  signal  amplification  have 
emerged from techniques used in nuclear imaging.  
 
The key component of MI is the molecular probe, which ideally not only has a high 
affinity for its target, it can also overcome biological delivery barriers to produce high 
resolution images. Broadly, there are 3 types of molecular probes (figure 1.1):    23 
a)  The compartmental probe:  These non-specific probes may be used in 
measuring  changes  in  blood  volume  and  perfusion.  As  the  compartmental 
distribution  of these  probes  changes  over  time,  a  fast  image  acquisition  is 
required.  
b)  Targeted  probes:  These  more  specific  probes  are  targeted  against  a 
specific  molecule,  enzyme  or  receptor.  They  may  represent  labelled  small 
molecules, peptides, enzyme substrates or antibodies. 
c)   “Smart” probes: The most specific of probes, they are designed to be 
detected only after they have interacted with their substrate. This results in 
reducing the signal-to-noise ratio often encountered with other probes. More 
recent addition to this group are the paramagnetic nanosensors that can be 
used to detect oligonucleotides sequences in DNA or RNA.  
 
Figure 1.1: Three main classes of imaging probe used in molecular imaging (Adapted 
from Jaffer and Weissleder 2005).   24 
 
On reaching the target, the signal from the probe is amplified in order for it to be 
detected outside the living system. In this respect, signal amplification defines the 
molecular  imaging  technique.  For  example,  in  nuclear  imaging  such  as  Positron 
Emission  Tomography  (PET),  signal  amplification  is  achieved  with  the  use  of 
positron  emitting  radiopharmaceuticals  that  emit  high  energy  photons,  whereas 
optical imaging employs emitted light from the targeted biological source.  
 
 
1.2 Approaches to in vivo molecular imaging 
In developing a molecular imaging strategy for a specific disease, the key question to 
be answered is ;  
“What is the most appropriate molecular imaging system that would provide the 
required spatial resolution, sensitivity and the depth of penetration?”  
(Jaffer and Weissleder 2005). 
 
So far, four broad category of imaging techniques have emerged as forerunners in the 
molecular imaging race. Each technique bears inherent advantages and limitations, 
which are briefly outlined below. 
 
1.2.1 Nuclear Imaging 
Nuclear imaging techniques include Single Photon Emission Computed Tomography 
(SPECT) and Positron Emission Tomography (PET). The main advantages of these 
techniques are their intrinsic high sensitivity and unlimited depth of penetration. The 
versatility of nuclear imaging techniques also lie in their ability to target potentially 
any biochemical or molecular event, through the incorporation of radioactive isotopes   25 
with  naturally  occurring  biochemical  agents.  PET  in  particular  can  also  be 
quantitative and produces higher resolution tomographic images compared to SPECT.  
The main limitations of nuclear imaging techniques are their spatial resolution and the 
risk  of  radiation  exposure  to  the  patient  and  the  health  care  professionals. 
Furthermore, the preparation of PET radiopharmaceuticals requires a cyclotron, which 
is costly and may not be readily available.  
 
1.2.2 Optical Imaging 
Optical imaging is still in its relative infancy. Advances in this field have resulted 
from  developments  in  mathematical  modelling  of  tissue  light  properties  and  the 
development  of  near  infrared  probes.  Compared  to  other  molecular  imaging 
modalities, optical imaging is cheap and can achieve a spatial resolution of 1-2 mm. 
However, its application can be limited by the poor tissue penetration properties of 
light, thus making it unsuitable for imaging solid visceral organs. 
Optical imaging technology can be broadly divided into 2 groups: 
a)  Fluorescence  imaging:    This  is  based  on  the  absorbance  of  light  at  one 
wavelength (thus requiring a light source) and emission at a lower wavelength. 
b) Luminescence imaging: This process is analogous to the lucerferin/luciferase 
reaction that results in bioluminescence in a male firefly (Photinus pyralis). It 
therefore does not require an external light source.  
 
Near infra red (NIR) light is best suited to imaging in vivo as it maximizes tissue 
penetration and minimizes autoflorescence from non-targeted tissue. An application 
of this in the pre-clinical setting has been with the use of “smart” NIR fluorochromes   26 
have been developed for quantifying specific enzyme activities such as the cathepsin 
B family (Weissleder et al. 1999) .  
 
1.2.3 Magnetic Resonance Imaging (MRI) 
The fundamental principle behind imaging with MRI is that unpaired nuclear spins 
align themselves when placed in a strong magnetic field. A temporary radiofrequency 
pulse then results in a change in alignment of the spin, which on return to the baseline 
is recorded as an electromagnetic flux.   
 
The main advantage of MRI as a molecular imaging technique is its ability to provide 
molecular and anatomical information within a single imaging mode. It also produces 
high-resolution  images  (<1mm)  and  has  a  good  depth  of  penetration  (>10cm). 
However it suffers from an inherently lower sensitivity than other molecular imaging 
techniques, a feature that can be overcome by specific signal amplification to create a 
higher  target  to  background  contrast.  Several  paramagnetic  (eg:  gadolinium)  and 
supramagnetic (eg: iron oxide) agents have been developed that can help overcome 
this. 
 
1.2.4 Ultrasound 
Imaging with ultrasound (US) uses the echogenic properties of high frequency sound 
waves to create images of different density tissue at different debts. Similar to MRI, 
US offers high resolution (<1mm) images that can be co-registered with the molecular 
data in the same sitting. A number of imaging agents have been developed that use 
microbubbles, liposomes or perfluorocarbon emulsions as scaffolds. The limitation of   27 
these  is  the  relative  large  size  of  the  imaging  particles,  which  can  restrict  tissue 
penetration and limits their application to imaging vascular organs.  
 
 
As the main focus of this thesis is the role of PET as a molecular imaging tool, other 
emerging  technologies  will  not  be  reviewed  in  any  more  detail  than  that  already 
covered in this chapter.    28 
1.3  Molecular  imaging  of  cancer  with  Positron  Emission 
Tomography (PET) 
1.3.1 Imaging with PET - The basic principles 
PET can be thought of as a camera that can take images of high energy  -rays that are 
emitted from inside the subject (Gambhir 2002). The principal component of imaging 
with PET is the radiopharmaceutical agent (also known as a ligand or tracer). The 
tracer molecule is formed by incorporating a positron emitting isotope (radionuclide) 
into  a  metabolically  active  molecule.  15O,  13N,  11C,  64Ga  and  18F  are  some 
commonly available isotopes with varying radioactive half-lives. 18F in particular has 
a  half-life  of  110  minutes  and  has  proved  the  most  practical  isotope  for  routine 
clinical use to date.  
 
The radionuclide has an unstable nucleus. It decays to reach a stable state by emitting 
positrons (an antimatter counterpart of an electron). Once expelled from the nucleus, a 
positron  travels  a  short  distance  (~1mm)  and  collides  with  an  electron  in  the 
surrounding tissues. This mutual annihilation results in production of two high energy 
(511 KeV) photons or  - rays, which are emitted at almost 180
o to each other. The 
detection  of  two  simultaneous  photons  by  the  PET  scanner  by  a  process  called 
coincidence detection, is subsequently used to reconstruct tomographic PET images.  
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1.3.2 The PET detector unit 
The core components of the PET detector unit consists of: 
  - a ring of scintillation crystals to detect “coincidence events” 
  - an external radiation source used for attenuation correction of the emission 
  data 
  -  a  computer  system  to  reconstruct  the  raw  data  into  3  dimensional 
  tomographic images.  
Most  dedicated  PET  cameras  in  use  today  use  Bismuth  Germinate  Oxide  (BGO) 
crystals, which are best suited for high energy photons of 511 KeV. Although the 
quoted spatial resolution of 3
rd generation PET scanners is approximately 6-8 mm
3, 
there  are  several  newer  detector  units  emerging  in  the  market  with  improved 
resolution. A more detailed description of this aspect of PET technology would be 
beyond the scope of this thesis. 
  
1.3.3 Annihilation coincidence detection 
As  outlined  earlier,  the  two  -rays  released  following  the  annihilation  event  are 
emitted at  almost  180
O  to  each other.  If these two photons are detected within a 
certain time of each other (known as the coincidence time window), it is then assumed 
that they both originated from the same point source. The position of the annihilation 
event can then be estimated along a line joining the two detection positions.  Images 
acquired by the PET scanner are therefore a collection of these 'coincidence events', 
which are reconstructed using  a set  of mathematical  algorithms  to  produce three-
dimensional images of the subject. The images from a PET camera are often shown in 
colour, which represent  -ray events of the same energy. The colour scale is thus used 
to reflect the concentration of the isotope.   30 
1.3.4 Attenuation correction 
Attenuation is the loss of detection of true coincidence events as a result of tissue 
absorption of energy or random scattering of photons outside the field of view of the 
detector. Despite higher energy photons used in PET, attenuation is a bigger problem 
with PET compared to SPECT imaging. With PET, coincidence detection means that 
the  average  photon  path  distance  from  emission  to  detection  is  greater  than  for 
SPECT. Loss of counts due to attenuation increase image noise, image artefacts, and 
image distortion (figure 1.2). Therefore attenuation correction of data is required for 
accurate qualitative (visual) and quantitative measurement of PET tracer activity. 
 
 
Figure 1.2: Images demonstrating the difference between non-attenuated and 
attenuated corrected PET images. Note sharper, less noisy image in the latter. 
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In order to address the above, an attenuation map of the subject is obtained, which is 
used  as  mathematical  template  for  attenuation  correction.  Early  generation  PET 
scanners commonly used an external  -ray source to acquire an attenuation map. The 
major disadvantage of this was the length of time it took for obtaining transmission 
scans (in excess of 30 minutes).  The recent introduction of dual modality PET/CT 
scanners have been principally aimed at producing CT attenuation maps that can be 
acquired  much  more  quickly  (over  30  seconds)  and  produce  less  noisy  images. 
PET/CT is explained further in later sections. 
 
1.3.5 Quantitative imaging 
Imaging with PET has above all the advantage of being quantitative. As the amount of 
tracer  uptake  mirrors  the  relative  activity  of  the  targeted  biochemical  process, 
measurement  of  emitted  radioactivity  allows  “quantification”  of  the  biochemical 
process in question.  
 
The most common means of tracer semi-quantification is with the use of Standardised 
Uptake Values (SUV). These calculated units relate to the activity concentration per 
tissue volume and are corrected for the amount of injected tracer and the body habitus 
(weight, surface area) of the patient. The latter allows differences between individuals 
and the amount of injected tracer activity to be taken into account. It must however be 
noted that tracer activity in a region of interest is not static, and SUVs do not account 
for  tissue  /  tracer  dynamics  over  time.  This  can  be  addressed  with  the  use  of 
dynamically acquired data and application of compartmental models that give a better 
assessment of tracer biodistribution. SUVs provide a ready measure of the amount of 
tracer uptake at a specific time point, making it a more suitable technique for use in   32 
routine clinical practice. Although compartmental modelling provide more specific 
means of quantifying tissue dynamics of tracer uptake  in vivo, they require serial 
arterio-venous blood samples that are not only invasive for the patient, but are time 
consuming. This technique is therefore solely reserved for tracer analysis in the pre-
clinical (research) setting and not the routine clinical practice.   
 
1.3.6 Multimodality imaging with PET/CT 
One  of  the  disadvantages  of  imaging  with  PET  has  been  its  lack  of  anatomical 
resolution,  which  can  limit  the  accuracy  of  lesion  localization  and  lesion 
characterization. This limitation of PET has now been addressed with the introduction 
of dual modality PET/CT scanners. In 2001, the first dual modality (hybrid) PET/CT 
scanner  was  developed  primarily  as  a  proof  of  concept  that  concurrent  image 
acquisition  with  PET  and  CT  was  possible.  Today‟s  dedicated  PET/CT  scanners 
essentially consist of a multidetector spiral CT, attached to the front of a standard PET 
detector unit (Figure 1.3).   33 
 
 
Figure 1.3: Dedicated dual modality PET/CT scanner used at our institution. The 
detector unit is shown with the outer casing removed, demonstrating the relative 
position of the CT and PET component of the scanner.   
 
The PET and the CT images are acquired sequentially and in the same sitting. This 
allows for minimal patient movement between the two scans, which in turn allows 
accurate co-registration of the biological and anatomical data. The CT component is 
also used for attenuation correction of PET images. This has not only helped produce 
sharper  and  clearer  images,  it  has  also  reduced  PET  acquisition  times  by 
approximately  25  minutes.  Consequently,  this  has  resulted  in  better    patient 
compliance and increase in scanner throughput.  
 
1.3.7 Imaging protocols for PET and PET/CT 
Patient preparation prior to imaging with PET (and PET/CT) is dependant on the 
tracer being used. With 18F-FDG, the patient is routinely fasted for at least 4 hours 
and  measures  are  taken  to  ensure  normo-glycaemia.  This  is  important  as  for  two 
reasons:  abundance  of  serum  glucose  can  compete  with  18F-FDG  and  result  in   34 
incidence of false negative findings; activity of the GI tract after eating can result in 
non-specific  18F-FDG  and  diagnostic  uncertainty.  As  active  muscle  tissue  also 
metabolise  significant  amounts  of  glucose,  a  muscle  relaxant  (diazepam)  is  also 
routinely  administered  to  reduce  high  levels  of  non-specific  uptake.  In  using  an 
alternative tracer such 18F-FLT, such measures are often not required. This will be 
 discussed further in later chapters.  35 
1.4 Molecular and cellular targets for PET imaging 
One of the key advantages of imaging with PET is the ability quantify potentially any 
biochemical event in vivo. In targeting specific cellular and molecular pathways of 
cancer with PET, several assumptions are often made. These assumptions stem from 
the fact that although under specific conditions labelled analogues mimic their natural 
counterpart, there may be notable exceptions. For a tracer to be a successful imaging 
probe for PET, it must fulfil the following criteria (Gambhir 2002):  
1) The positron emitting isotope must not dissociate easily from the molecule 
of interest as this may result in the free isotope being imaged and not the 
labelled tracer. 
2)  The  isotope  labelling  must  not  alter  the  biological  properties  (such  as 
transport, elimination or affinity for the target) of the parent molecule.  
3) The tracer must clear rapidly from non-target sites, without which it would 
be impossible to image sites of specific targeting.  
 
To date, a number of labelled analogues  have  been developed that target  cellular 
properties ranging from glucose metabolism  to apoptosis. Some of the commonly 
investigated tracers other than 18F-FDG and their targets are listed in table 1.1 The 
focus of this thesis is to investigate the role of imaging with two PET tracers; the 
routine  glucose  analogue  [18F]-fluoro-2-deoxy-D-glucose  (18F-FDG)  and  the 
thymidine  analogue  [18F]-3‟-doxy-3‟-fluorothymidine  (18F-FLT).  The  latter  in 
particular has emerged as a potential PET tracer for measuring cellular proliferation. 
In the following sections, the above two tracers will be described in more detail.     36 
 
Table 1.1: Non 18F-FDG tracers and biochemical targets  37 
1.4.1 Aerobic glycolysis, cancer and imaging with PET 
One  of  the  properties  common  to  all  invasive  cancers  is  that  of  altered  glucose 
metabolism.  In  normal  untransformed  cells,  glucose  is  converted  to  gluocose-6-
phosphate  by  hexokinase  and  then  to  pyruvate,  generating  2  ATP  molecules  per 
glucose. In the presence of oxygen, pyruvate is oxidized in mitrochondria to produce 
36  additional  ATP  molecules  per  glucose.  In  the  absence  of  oxygen,  pyruvate  is 
reduced to lactate, which is exported out of the cell without energy production. This 
latter step known as glycolysis is inhibited by mitochondria (Pasteur effect), where 
pyruvate is oxidized to CO2 and H2O. In cancer cells however, the conversion of 
glucose to lactic acid occurs despite the presence of oxygen. This phenomenon is 
known as aerobic glycolysis and has been coined the “Warburg effect”, named after 
the  German  biochemist  Otto  Warburg.  In  investigating  the  metabolic  properties 
unique to cancer cells, Warburg set out to answer one fundamental question:  
 
“If the carcinoma problem is attacked in its relation to the physiology of 
metabolism, the first question is: In what way does the metabolism of growing 
tissue differ from the metabolism of resting tissue?”  Otto Warburg (1924). 
 
Following a series of observations in a rat model and later in human cancer cell lines, 
Warburg concluded that the predominant metabolic pathway in cancer cells is that of 
glucose  metabolism  by  aerobic  glycolysis  (Warburg  1931).  Although  his  initial 
hypothesis  that cancer  resulted from  impaired  mitochondrial metabolism  has  been 
disproved, observations of enhanced glycolysis in cancer cells has been repeatedly 
verified. Initial interest in tumour glycolysis was overshadowed by the widespread 
application  of  molecular  and  genetic  techniques  in  investigating  cancer  biology.   38 
However, the subject of glycolysis was once again re-kindled with the emergence of 
PET and the glucose analogue tracer 18F-FDG.   
 
Although the rate of glycolysis can be controlled at several steps, most studies to date 
have  indicated  the  predominant  role  of  glucose  transport  and  phosphorylation  in 
controlling the glycolytic flux.  The resultant demand of malignant cells for glucose 
has  been  shown  to  be  met  by  an  activation  of  the  glucose  reliant  hexose 
monophosphate pathway, which provides the backbone for DNA and RNA synthesis, 
(Webber 1977a, 1977b), and an increased expression of glucose transporters (Flier et 
al. 1987; Hatanaka 1974), of which GLUT 1 has been shown to be the predominant 
element (Hiraki et et. 1981).  
 
1.4.2 [18F]-fluoro-2-deoxy-D-glucose (18F-FDG) 
The  simple  rationale  for  blocking  accelerated  glycolysis  and  thus  tumour  growth, 
initially lead to the development of the drug 2-deoxy-D-glucose (DG). However, as 
DG  also  blocked  brain  glycolysis,  it  could  not  be  routinely  used.  Later  however, 
Sokoloff  et  al.  (1977)  used  14C-labelled  DG  for  imaging  local  cerebral  glucose 
metabolism. Substitution of hydroxyl group in the 2-position with 18F later lead to 
the development of [18F]-fluoro-2-deoxy-D-glucose (18F-FDG). 
 
The first application of FDG was in the 1980‟s where it was used in the assessment of 
the degree of malignancy in cerebral tumours (Di Chiro 1987). By the 1990‟s, FDG 
labelled with 18F had swiftly become the mainstay of imaging with PET, where its 
application extended beyond neuro-oncology to the detection of a wide variety of 
solid cancers.   39 
Following intravascular injection and passive diffusion into the interstitial space, 18F-
FDG is transported into cells by specific glucose transporters (GLUT-1). It is then 
phosphorylated  by  hexokinase  to  form  FDG-6-phosphate.  As  18F-FDG  lacks  the 
hydroxyl group at position 2, FDG-6-phosphate cannot undergo further glycolysis. It 
therefore becomes metabolically redundant and subsequently intracellularly trapped 
(Figure 1.4). 
 
Figure 1.4: Phosphorylation pathway of 18F-FDG (Czernin and Phelps 2002) 
 
When interpreting 18F-FDG PET images, normal uptake of tracer within the body 
also needs to be considered. The brain has a high physiological glycolytic index and 
often exhibits extremely high 18F-FDG accumulation. Such high background levels 
limit the use of this tracer for detecting cerebral metastases. The uptake of 18F-FDG 
by  the  myocardium  is  driven  by  the  abundance  if  insulin  sensitive  glucose 
transporters (mainly GLUT-4). This uptake is generally variable, decreasing in the 
fasting state and increasing in the presence of insulin. This pattern is also seen in 
skeletal muscle. As for this, imaging protocols such as those used in this thesis ensure   40 
a state of euglycaemia in the patient and during the uptake phase of the tracer, the 
patients are required to limit their movement and to remain undisturbed in a darkened 
room. Finally the renal excretion of 18F-FDG also limits its use in imaging renal tract 
tumours and the intense accumulation of the tracer within the bladder can at times 
obscure the detection of adjacent 18F-FDG avid disease within the pelvis.  
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1.5 Cellular proliferation 
One  of  the  hallmarks  of  cancer  is  uncontrolled  proliferation.  Over  the  last  few 
decades, significant effort has been focused on understanding this process as it is a 
key determinant of how a cancer behaves clinically. Through advances in molecular 
and genetic analysis of cancer we now have a better understanding of the various 
regulatory mechanisms that control cellular proliferation. These have and are being 
exploited  for  use  as  diagnostic,  prognostic  and  therapeutic  tools  in  cancer 
management. Efforts at quantifying proliferative activity have also extended to the 
field of molecular imaging with PET where novel tracers have been developed to 
target various steps of the proliferative activity. The development of “proliferation” 
PET  tracers  have  been  essentially  borne  out  of  the  in  vitro  use  of  thymidine  for 
determining DNA turnover. One such PET tracer is the thymidine analogue 18F-3‟-
deoxy-3‟-fluorothymidine  (18F-FLT).  18F-FLT  potentially  brings  quantitative 
imaging of tumour proliferation from the bench to the routine clinical practice. In 
order to understand the kinetics of 18F-FLT in targeting proliferation, some of the key 
concepts such as cellular growth and the cell cycle need to be reviewed.  
 
1.5.1 The cell cycle  
The concept of cellular proliferation has evolved from early days of light microscopy 
where mitotic figures were observed in eukaryotic cells. From this, it was postulated 
that cells exist in one of two states; either in a state of cellular division during mitosis 
or remain in an inactive state (interphase). Later breakthrough work by (Howard and 
Pelc 1951) lead to the concept of the cell cycle. They concluded that the cell cycle 
consisted of four stages during  which DNA synthesis  (S  phase)  and cell division   42 
(mitosis, M phase) were separated by two gap phases, G1 and G2 respectively (figure 
1.5).  
 
 
Figure 1.5: The cell cycle 
 
The cell cycle is a highly conserved and ordered set of events, tightly controlled by a 
series of positive (cyclins) and negative (tumour suppressor genes such as P53 or 
retinoblastoma (Rb)) effectors. Collectively, these regulatory proteins are responsible 
for the timely transition of cells through the cell cycle, while arresting propagation of 
DNA mutations through their communication with the cells‟ fail safe mechanisms 
such as DNA mismatch repair proteins and the apoptotic pathway. 
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1.5.2 Proliferation and tumour growth 
Understanding the growth rate of a tumour is an important step in understanding the 
spectrum of cancer behaviour observed clinically. It has been shown that tumours 
with  rapidly  proliferating  cells  are  associated  with  a  poorer  long  term  survival 
(Tubiana et al. 1984; Murray and Kirschner 1989; Pardee 1989; Tubiana and Courdi 
1989). Furthermore, the rate of proliferation can be indicative of the sensitivity of a 
tumour to cycle-dependent cytotoxics, which may in turn direct clinicians in adjusting 
adjuvant strategies. In order to quantify proliferative activity of a tumour, one must 
understand its temporal  relationship with the cell cycle and its resultant effect on 
tumour growth.  
 
Growth is the overall increase in cell number, which is the net effect of cell gain by 
proliferative activity and cell loss by apoptosis or necrosis (van Diest et al. 1998). 
Proliferative activity (P) on the one hand is the result of cell cycle activity, which in 
turn consists of the speed of the cell cycle (which is inversely proportional to the 
generation time (T)), and the growth fraction (G). Mathematically, the relationship 
between proliferative activity and the growth fraction can be summarised as; 
P=G/T. 
 
In other word, a high proliferative activity can be the result of either a high growth 
fraction or short generation time, or both. This is an important consideration as many 
of the methods used in assessing proliferative activity are in fact quantifying growth 
fraction, whereas owing to its complexity, cell cycle time is often ignored.  
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1.5.3 Assessment of proliferation 
To  date,  several  in  vitro  and  in  vivo  techniques  have  been  investigated  for  the 
assessment of proliferative activity. Each technique carries an inherent advantage and 
disadvantage, which will be briefly outlined below. 
 
1.5.3.1 Mitotic index 
Interphase, which consists of G1, S and G2 phases, is the longest part of the cell 
cycle.  However,  cells  during  this  phase  cannot  be  morphologically  recognised 
whereas  those  in  mitotic  phase  (M  phase)  can  be  identified  by  the  presence  of 
chromosomal sets that are known as mitotic figures. Counting mitotic figures is one 
of the oldest  ways  of assessing proliferation.  It can  easily be used in  the routine 
clinical setting, requiring only an adequate microscope and a well-stained H&E slide. 
The most commonly used technique for counting mitotic figures is by expressing the 
number of mitoses seen within a pre-defined number of high power fields (eg: 10) or 
per unit area (eg: 2 mm
2), thus giving rise to a mitotic index.  
 
Despite its popularity, quantifying the mitotic index of a specimen has its limitations. 
The  M  phase  of  cell  cycle  can  be  widely  varied  in  duration,  particularly  in  an 
aneuploid  population  of  cells.  Therefore,  number  of  mitoses  observed  do  not 
necessarily correlate with the rate of cell proliferation in a linear fashion. This may 
also explain the partial correlation observed between other proliferation indices such 
as  the  Ki67  labelling  index  (Isola  et  al.  1990;  Di  Stefano  et  al.  1991)  and 
Bromodeoxyuridine (BrdU) incorporation assays (Weidner et al. 1993). Furthermore, 
mitosis counting is subject to reproducibility errors unless strict tissue fixing, staining 
and counting protocols are used.    45 
1.5.3.2 Incorporation techniques using nucleotide analogues 
Incorporation techniques use radiolabeled nucleotide analogues to measure the rate of 
DNA synthesis and thus cellular growth. Thymidine labelled with tritium has often 
been considered as the gold standard marker of S-phase cells, as thymidine is a the 
only  nucleotide  that  is  exclusively  incorporated  into  DNA  and  not  RNA.  More 
recently other nucleotide analogues have been employed of which bromodeoxyuridine 
(BrdU) is the most widely used. Such incorporation techniques have been applied to 
autoradiography (3H-thymidine) and immunohistochemistry (BrdU). In vitro, pulse 
labelling of cancer cells can also be used to determine the proportion of cell entering 
the S-phase over a period of time, thus giving a measure of cell cycle time. In the 
clinical setting, the use of 3H-thymidine is not popular as it involves handling of a 
radioactive  substance.  Autoradiography  can  also  be  a  cumbersome  and  lengthy 
procedure  (it  may  take  up  to  a  week  to  develop  the  images).  Use  of 
immunohistochemistry with BrdU is also subject to limitation and errors of tissue 
sampling.  
 
1.5.3.3 DNA cytometry and percentage S-phase determination 
In DNA cytometry, nuclei are stained with a stoichiometric DNA binding stain, which 
allows the amount of DNA present to be measured. The two applications of this are 
with the use of a flow-cytometry, which uses a fluorescence dye on a suspension of 
cells and static cytometry where the optical density of stained cells fixed on a slide, 
are measured. Both techniques produce DNA histograms, which are representations 
of the cells within different phases of the cell cycle (G0/G1, S and G2/M phase). 
Although strictly speaking, the proliferative fraction includes cells in both the S and 
G2/M phase, the most commonly used proliferation variable is the S-phase fraction.    46 
Historically, estimation of S-phase fraction by flow cytometry has been regarded as 
being more reliable due to its higher resolution DNA histograms. However, recent 
sophisticated hardware and software solutions have made % S-phase estimates from 
static cytometric histograms a valid alternative. Overall, the reliability of % S-phase 
determination  by  cytometry  is  dependent  on  software  variables  that  determine 
different cycle phases and the inter-observer variability in interpreting them. Several 
large studies have therefore been carried out in order to provide a consensus on what 
parameters  are  used  for  cytometric  analysis  (Bergers  et  al.  1997a;  Bergers  et  al. 
1997c). Notably however, factors such as cell fixation delays do not interfere with % 
S-phase measurements (Donhuijsen et al. 1990; Bergers et al. 1997b).   
 
 
1.5.3.4 Proliferation associated antigens 
 
Identification  of  cellular  antigens  that  are  upregulated  in  proliferating  cells  has 
provided yet another relatively easy means of quantifying proliferative activity. The 
proliferating cell nuclear antigen (PCNA) is one such protein, expression of which is 
upregulated  during  active  proliferation.  Although  several  studies  have  shown  a 
correlation between PCNA and other proliferation markers such as S-phase fraction 
(Visscher et al. 1992; Siitonen et al. 1993), mitotic index (Siitonen et al. 1993) and 
Ki67 staining , this has not been consistently seen. This may be due to the fact that 
PCNA is also involved in DNA repair (Masih et al. 2008). Malignant cells are often 
undergoing  active  DNA  repair,  which  has  lead  to  the  observation  that  in  some 
tumours 100% staining of cells with PCNA is seen. As for this, the routine use of 
PCNA as a routine marker of proliferation in cancer cells has fallen out of favour. 
 The Ki67 antigen is another nuclear antigen, coded by a gene on chromosome 10. It 
is expressed in the G1, S and G2 phases of the cell cycle but not G0. Initial work with   47 
the  Ki67  antigen  was  carried  out  on  frozen  sections,  but  recently  a  number  of 
antibodies, namely MIB-1, have been developed that allow the antigen to be detected 
on  paraffin  embedded  sections  and  archived  material  (Cattoretti  et  al.  1992; 
McCormick et al. 1993). As with most immunohistochemical techniques, adequate 
staining  methodology  is  required  to  obtain  reproducible  results.  A  number  of 
automated  scanning  techniques  are  also  employed  to  produce  quick  and  reliable 
results.  To date, a number of studies  have shown Ki67 labelling score (index) to 
correlate with % S-phase fraction (Isola et al. 1990; Lee et al. 1992) and mitotic index 
(Barnard et al. 1987; Isola et al. 1990; Marchetti et al. 1990; Di Stefano et al. 1991; 
Sahin et al. 1991).   
 
 
1.5.4 Tumour heterogeneity – a problem of assessing proliferation 
 
One  of  the  limiting  factors  of  assessing  tumour  proliferation  with  the  above 
techniques is the inherent heterogeneity of a tumour mass. This has been reported for 
several tumour types, which may be one of the reasons for the apparent contradictory 
results seen in the literature. Generally it is considered that the highest proliferative 
part  of  a  tumour  determines  its  clinical  behaviour.  Therefore  in  order  to  obtain 
clinically meaningful results, the most active part of the tumour mass needs to be 
sought.  
 
With  morphological  methods  of  analysis,  the  problem  of  heterogeneity  can  be 
overcome by examining the tumour mass for the most proliferative area. However, in 
the routine clinical setting this may also not be feasible, as surgery and thus whole 
tumour resection may not be indicated in all patients. Where sampling of a tumour by 
way of percutaneous biopsy can yield diagnostic information, targeting the biopsy to   48 
the most proliferative area of the tumour is near impossible with current localization / 
imaging techniques. This highlights the advantage of molecular imaging with PET, 
whereby the focal abnormality being targeted is localized and tracer uptake quantified 
accord to its differential tracer uptake kinetics compared to surrounding tissues. The 
“hot spot” seen on the PET scan therefore theoretically represents the focus of tumour 
with the highest proliferative activity.  
 
1.5.5 Thymidine analogues PET tracers for imaging cell proliferation 
The understanding that emerged from the use of labelled thymidine eventually led to 
the development of the first proliferation PET tracer, 11C-Thymidine. The advantage 
conferred by radiolabelling thymidine is that as the native compound, it is readily 
taken up by cells and incorporated into DNA. Several pilot studies in patients have 
demonstrated the feasibility of using 11C-thymidine PET in imaging tumours and 
their response to treatment. Eary et al. (1999) demonstrated the use of 11C-thymidine 
for imaging proliferation in primary and recurrent brain tumours. van Eijkeren et al. 
(1992) investigated the role of 11C-thymidine in monitoring response to therapy in 13 
patients with head and neck cancers. In a small study of 4 patients with small cell lung 
carcinoma and 2 with high grade sarcoma,  Shields et al. (1998b) also showed that a 
persistence of 11C-thymidine uptake one week post treatment can be predictive of 
progressive  disease.  More  recently,  Wells  et  al.  (2002)  showed  that  PET  derived 
parameters  of  11C-thymidine  uptake  in  patients  with  advanced  intra-abdominal 
malignancy correlated  with  Ki67  labelling, thus  supporting its  role as a surrogate 
marker of proliferation. 
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Despite early promising results, 11C labelled thymidine has been deemed impractical 
for routine clinical use. This has been due to the fact that thymidine can only be 
labelled with 11C, which has a short half-life (approximately 20 minutes) and its 
synthesis is complex and expensive. Furthermore, 11C is rapidly metabolised in vivo 
to  carbon  dioxide  and  a  series  of  complex  metabolites,  quantification  of  which 
requires the use of complex kinetic models (Mankoff et al. 1998; Eary et al. 1999). 
This process of kinetic modelling is time consuming and requires extensive work by 
the imaging team, which again makes its routine clinical use impractical. 
 
The above however lead the search for other more suitable labelled nucleotides for 
imaging  proliferation with PET. Two of the more extensively studied agents are 18F-
3‟-doxy-3‟-fluorothymidine  (18F-FLT)  and  18F-1-(2‟-doxy-2‟-fluoro-beta-D-
arabinofuranosyl)-thymidine. In both 18F-FLT and 18F-FMAU, placing fluorine in 
the 2‟ or 3‟ position of the deoxyribose sugar, stabilises the molecules‟ glycosidic 
bonds, thus preventing degradation (Shields 2006). However, both agents undergo 
glucuronidation,  which  can  further  complicate  the  dynamic  distribution  of  these 
tracers (Shields et al. 2005). 
 
As the focus of this thesis is the comparison of imaging with 18F-FLT and 18F-FGD 
PET,  there  will  not  be  any  further  review  of  the  role  of  18F-FMAU  in  imaging 
proliferation will not be covered further. 
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1.6 [18F]-3’-doxy-3’-fluorothymidine (18F-FLT) 
1.6.1 The development of 18F-FLT 
FLT (Alovudine) was initially developed as an anti-retroviral agent for the treatment 
of  patients  with  human  immunodeficiency  virus  (HIV)  (Flexner  et  al.  1994). 
However, it was soon withdrawn from phase II clinical trials due to its high levels of 
myelotoxicity.  As  mentioned  previously,  radiolabeled  FLT  was  found  to  be  more 
stable to cellular degradation than its native counterpart thymidine, and therefore, its 
use as a potential PET tracer quickly generated a large body of interest. Wilson et al. 
(1991) were the first to describe the 18F labelling of FLT.  Later, modifications of its 
radiosynthesis by Grierson and Shields (2000) lead to the development of a more 
simplified,  reproducible  and  clinically  feasible  approach  to  synthesising  18F-FLT 
(Machulla et al. 2000).  
 
1.6.2 The molecular kinetics of 18F-FLT 
It  is  believed  that  18F-FLT  enters  cells  by  a  complex  mechanism  of  facilitated 
transport, similar to that observed in vitro from studies with labelled thymidine. There 
are two transport mechanisms involved; equilibrative transporters that mediate both 
the  influx  and  efflux  of  nucleosides  (Belt  et  al.  1993)  and  concentrative  Na
+-
dependent carriers which have been described to mediate only influx (Vijayalakshmi 
and  Belt  1988).  While  concentrative  transporters  are  mostly  expressed  in  normal 
tissues, equilibrative transporters have been found in large numbers in tumour cells 
(Belt et al. 1993).  
 
It is yet unclear which equilibrative transporters play a dominant role in 18F-FLT 
uptake. However, transport of 18F-FLT into cells seems to follow a biphasic kinetic   51 
pattern,  with  a  rapid  initial  accumulation  that  correlates  with  the  rate  of  FLT 
phosphorylation by the enzyme thymidine kinase (TK). This is followed by a slower 
rate of accumulation, which may be due to competing efflux mechanisms (Scwartz et 
al. 2001). 
 
 1.6.3 Cellular trapping of 18F-FLT 
The initial rapid accumulation of 18F-FLT within cells is thought to be associated 
with its rate of phosphorylation that is controlled by the enzyme thymidine kinase 
(TK).  Thymidine  kinase  is  present  in  cells  in  two  isomeric  forms;  cytosolic  TK 
known as TK-1 and its ribosomal counter-part, TK-2. TK-1 has a higher affinity for 
thymidine  than  TK-2.  It  is  the  rate  limiting  enzyme  of  the  salvage  pathway  of 
pyrimidine synthesis  and exhibits  a complex cell cycle regulated expression.  It  is 
virtually undetectable in quiescent cells (G0) but its levels peaks at the end of the 
G1/S-phase and finally return to background levels by the end of the M-phase of the 
cell cycle (Sherley and Kelly 1988; Munch-Petersen et al. 1995; Grierson et al. 2004).  
In  vitro,  TK-1  activity  has  been  reported  to  be  3-4  times  higher  in  cancers  cells 
compared to their benign counterparts (Boothman et al. 1994). The phosphorylation 
of  18F-FLT  by  TK-1  results  in  formation  of  negatively  charged  18F-FLT 
monophosphate.  In  a  way  analogous  to  the  cellular  trapping  of  18F-FDG  by 
hexokinase,  18F-FLT  monophosphate  is  intracellularly  trapped  (Figure  1.6).  The 
accumulated radioactivity can then be detected with PET.  
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Figure 1.6: The mechanism of cellular trapping of 18F-FLT compared to that of 
Thymidine (dTh) – [Abbreviations: MP=monophosphate; DP=diphosphate, 
TP=triphosphate] 
 
 
1.6.4 18F-FLT as a proliferation PET tracer 
The link between 18F-FLT uptake and thymidine kinase is the fundamental basis that 
supports its role as a surrogate marker of proliferation. In vitro, a strong association 
between the rate of 18F-FLT uptake and TK-1 activity has been demonstrated. In a 
human lung carcinoma cell lines, Rasey and colleagues showed a strong correlation 
between  18F-FLT  uptake,  cell  growth,  S-phase  fraction  (SPF)  and  TK-1  activity 
(Rasey et al. 2002). Similarly, Barthel et al. (2005) showed a significantly lower 18F-
FLT  uptake  in  TK  deficient  mouse  lymphoma  tumours  as  compared  to  their  TK 
proficient  variants.  In  a  panel  of  22  asynchronously  growing  cancer  cell  lines, 
Toyohara et al. (2002) also showed 3H-FLT uptake to strongly correlate with both   53 
SPF (r=0.76) and 3H-thymidine uptake (r=0.88, P<0.0001), thus supporting the role 
of FLT as a proliferation PET tracer.  This group also found that over 90% of 3H-
thymidine was incorporated into DNA compared to negligible levels (0.2%) of [3H]-
FLT. The reason for this is the fact that FLT acts as a chain terminator of DNA due to 
its lack of 3‟-hydroxyl side group.  
 
Unlike thymidine, which represents the totality of DNA turnover, FLT seems to target 
the first step of the DNA salvage pathway. This has raised the question of whether 
TK-1 activity accurately reflects cellular proliferation. So far it is understood that the 
relative contribution of the salvage and the de novo pathways of DNA synthesis vary 
in different tumour types. In a study on a panel of 6 malignant cell lines, Schwartz et 
al. (2003) showed the uptake of labelled FLT and thymidine to correlate with TK-1 
activity, only in cells with TK-1 dependent proliferative activity. In two of the cell 
lines, proliferation seemed to be less TK-1 dependent and thus the correlation was 
poor. Furthermore, other studies  have shown that  antimetabolite chemotherapeutic 
agents such as 5-fluorouracil and methotrexate result in a paradoxically increase in 
TK-1 activity possibly as a result of their effect on the pyrimidine salvage pathway 
(Dittmann et al. 2002). This paradigm will be further investigated in later chapters but 
as it stands, there are indications that in certain situations, 18F-FLT uptake may not 
reflect proliferative activity.  
 
1.6.5 Clinical applications of 18F-FLT 
To date, several studies have examined the feasibility of imaging with 18F-FLT PET 
in the routine clinical setting. Much of the published data so far are from studies with 
relatively small patient numbers. Although 18F-FLT has been shown to be a feasible   54 
tracer  for  visualising  a  range  of  solid  and  haematological  cancers,  it  has  been 
consistently found show a lower degree of cellular accumulation compared to 18F-
FDG. In organs such as the lungs and the brain where background 18F-FLT uptake is 
low, this appears to be less of a problem. However in the liver or bone marrow where 
background 18F-FLT uptake is high (the former being due to the glucuronidation of 
18F-FLT in hepatocytes), this can result in under-detection and staging inaccuracy 
(Dittmann et al. 2003; Francis et al. 2003b). The above is demonstrated in figure 1.7 
where the whole body distribution of 18F-FDG and 18F-FLT can be seen in within 
normal organs and that of a primary rectal cancer.   55 
 
 
Figure 1.7: Comparative 18F-FDG (top row) and 18F-FLT (bottom row) PET 
images in the same patient with a locally advanced rectal carcinoma. 
a) Maximum intensity projections (MIP) demonstrating the difference in whole body 
distribution between 18F-FDG and 18F-FLT. Note high background uptake in the 
liver (L) and the bone marrow (BM) on 18F-FLT PET (K = Kidney; B = Bladder) 
b) Sagittal sections showing uptake of tracers at the primary rectal site (P) 
c) Axial PET and PET/CT fused slices demonstrating 18F-FDG and 18F-FLT avid 
pelvic lymph nodes (LN). Note, only one nodal site was positive on 18F-FLT PET. 
 
 
Several studies have also aimed at validating 18F-FLT PET as a means of quantifying 
proliferative  activity  of  a  tumour.  There  are  two  potential  applications  of  this  in 
oncology; firstly is the potential for identifying high-risk patients that would most 
benefit from adjuvant treatments and secondly, it potentially provides the clinician 
with an alternative surrogate marker of response to treatment.  Table 1.2 summarises   56 
the results of publishes series to date that investigated the correlation between 18F-
FLT uptake and other independent  proliferation indices.  Although majority of the 
results support the hypothesis that 18F-FLT may be a useful marker of proliferation,  
 discrepancies in the data warrant a closer consideration.  
 
 
Table 1.2: Summary of studies examining the role of 18F-FLT PET in imaging a range 
of cancers. Their correlation with other indirect measures of cellular proliferation 
are tabulated. [NSCLC = Non-small cell lung cancer, NHL=Non-Hodgkins 
lymphoma, SPF=S-phase fraction, *= not significant)
Type of malignancy  
(no. of patients) 
Proliferation 
index 
Correlation 
 (R value)  Reference 
 
Pulmonary nodules (n=30) 
 
Ki-67  0.87  Buck et al. 2002 
NSCLC (n=11) 
 
a)Ki-67; b) SPF 
 
a)0.84; b)0.69 
 
Vesselle et al. 200) 
 
NHL  (n=11) 
 
Ki-67 
 
0.95 
 
Wagner et al. 2003 
Colorectal carcinoma (n=13) 
 
Ki-67 
 
0.8 
 
Francis et al. 2003a 
Melanoma (n=10) 
 
Ki-67 
 
NA  (Cobben et al. 2003) 
Soft tissue Sarcoma (n=20) 
 
Mitotic index; 
Ki-67 
0.55-0.75  (Cobben et al. 2004a) 
Laryngeal cancer (n=21) 
 
NA  NA  (Cobben et al. 2004b) 
Breast cancer (n=14) 
 
Ki-67 
 
0.1-0.14
*  (Smyczek-Gargya et al. 2004) 
Glioma (n=26) 
 
Ki-67 
 
0.82  (Choi et al. 2005) 
Oesophageal (n=10) 
 
Ki-67 
 
0.75  (van Westreenen et al.2005)   57 
Aside from quantifying proliferation, 18F-FLT has also been proposed to be of 
clinical value due to its cancer specificity compared to 18F-FDG. While 18F-FDG is 
a highly sensitive tracer, it lacks specificity as the tracer also accumulates in 
inflammatory tissue, which also exhibits a high glycolytic activity. It is postulated that 
as peripheral inflammatory cells are terminally differentiated, they have a relatively 
lower proliferative activity and thus accumulate significantly less 18F-FLT compared 
to 18F-FDG. Should 18F-FLT be a more specific tracer, it could allow for a more 
accurate assessment of local lymph nodes, potentially differentiating between reactive 
and metastatic lymphadenopathy. Alternatively, it may be of value in conditions 
where an inflammatory mass may result in false positive 18F-FDG uptake (eg: mass 
forming pancreatitis vs mass due to pancreatic cancer).  
 
The hypothesis that 18F-FLT is a more cancer specific tracer has been tested by van 
Waarde et al. (2004) using an animal model of tumour versus inflammation. The 
biodistribution of 18F-FLT and 18F-FDG were compared in Wistar rats bearing C6 
glioma xenografts in the right shoulder as well as an area of sterile inflammation 
induced by injecting turpentine into the animals’ thigh muscle. Within the tumour 
mass, there was significant accumulation of both tracers, although tumour : normal 
tissue  ratios  were  higher  for  18F-FDG  compared  to  18F-FLT  (13.2  vs  3.8 
respectively). On the other hand, 18F-FDG accumulation in the inflamed thigh was 
4.8 times higher than the tumour bearing side, compared to 1.3 (+/- 0.4) fold increase 
for 18F-FLT. A more recent study of 18F-FLT imaging in staging primary squamous 
cell carcinoma of the head and neck  yielded slightly contradictory results.  In this 
study 18F-FLT uptake was demonstrated in both reactive as well as metastatic lymph 
nodes  (Troost  et  al.  2007).  However  interestingly,  all  PET  positive  lymph  nodes   58 
(including those that were reactive in nature) showed an abundance of staining for Ki-
67 antigen and iododoxyuridine suggesting yet again that 18F-FLT is a proliferation 
tracer.  As  for  18F-FLT’s  tumour  specificity,  this  requires  further  validation.  59 
1.7 The role of PET in diagnosis and staging of pancreatic cancer  
1.7.1  Background 
Worldwide, pancreatic cancer ranks 13
th in incidence, yet it is the 8
th of commonest 
cause of cancer death. Over 90% of pancreatic tumours are ductal adenocarcinoma 
and  another  2-5%  constitute  neuroendocrine  and  acinar  tumours.  In  the  UK, 
pancreatic adenocarcinoma has an incidence of 9 per 100,000 population. Although 
pancreatic cancer rates have declined by 17% over the last 3 decades, in women its 
incidence has remained fairly static, representing the 8
th commonest cancer in women. 
Surgery remains the only potential for long term survival. However, less than 20% of 
the  patients  are  candidates  for  a  curative  resection  as  the  majority  present  with 
advanced  disease  (Li  et  al.  2004).    As  early  detection  of  pancreatic  cancer  is 
associated  with  a  better  outcome,  imaging  studies  that  can  detect  small  isolated 
lesions  would  be  of  immense  value.  Accurate  diagnosis  and  staging  allows 
appropriate clinical decision making and ensures that surgery is performed in patients 
who benefit most from it Despite recent advances in the management of pancreatic 
cancer, its overall 5 year survival rate has remained at around 0.4-4% (Jemal et al. 
2003). This perhaps highlights the limitations of our current diagnostic and staging 
techniques.  
 
1.7.2 Clinical Features of pancreatic cancer 
Symptoms of pancreatic malignancy are often non-specific and tend to be ignored by 
both the patient and the doctor. For this reason patients commonly present with late 
stage disease. As the disease progresses, the patient develops painless jaundice and an 
associated weight loss. In over 80 % of patients abdominal pain is a late presenting 
symptom, which is commonly epigastric and diffuse in nature and thought to occur as   60 
the result of involvement of celiac and superior mesenteric plexus (DiMagno 1999). 
Another  cardinal  symptom  is  referred  pain  to  the  back,  which  is  indicative  of 
retroperitoneal involvement.  
Painless jaundice is the principal clinical feature that prompts further investigation. 
Physical signs of pancreatic cancer, which often indicate advanced and inoperable 
disease, may include:  
  Presence of an abdominal mass 
  Palpable gall bladder (Courvosier‟s sign) 
  Supraclavicular lymphadenopathy (Verchow‟s node), 
  Splenomegaly (as a result of portal or splenic vein obstruction) 
  Ascites or Peripheral oedema (due to portal vein involvement or obstruction) 
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1.7.3  Routine  management  algorithm  of  patients  with  suspected  pancreatic 
cancer 
Figure  1.8  summarises  the  current  routine  management  algorithm  for  patients  in 
whom pancreatic cancer is suspected. Some of these steps are outlined in more detail 
in the sections that follow. 
 
 
Figure 1.8: The management algorithm of suspected pancreatic cancer (Takhar et al. 
(2004)).   62 
 
1.7.3.1 Basic investigations 
Haematological and biochemical parameters 
Laboratory findings in patients with pancreatic cancer are non-specific. Anaemia and 
hypoproteinaemia reflect the chronic nature of the condition. Global derangement of 
liver enzymes  is  also  seen in  patients  presenting with  obstructive jaundice.  It  has 
however been suggested that a disproportionately high increase in transaminase may 
be associated with extensive liver metastases.  
 
Prolonged biliary obstruction also leads to malabsorption of fat-soluble vitamin K and 
subsequent reduction of vitamin K dependant clotting factor by the liver. Assessment 
of  clotting  function  is  therefore  imperative.  Pancreatic  atrophy  also  results  from 
prolonged  obstruction  of  the  pancreatic  duct  by  the  tumour.  Frank  diabetes  or 
impaired glucose tolerance have has been reported in up to 70% of patients (Saruc 
and Pour 2003).  
 
Serological markers 
Carbohydrate antigen 19-9 (CA 19-9) is the most commonly used serological marker 
in  pancreatic  cancer.  In detecting pancreatic  cancer, CA 19-9 has  a sensitivity of 
about 80% (35;36). Its specificity is also high (60-70%), although raised levels can be 
detected  in  other  gastrointestinal  malignancies  as  well  as  benign  conditions  such 
pancreatitis (Willett et al. 1996; Yeo et al. 2002; Ozkan et al. 2003). For this reason, 
CA 19-9 has not been accepted as an independent test for diagnostic purposes. It is 
however of use as a prognostic tool, in detecting recurrences following surgery and 
for monitoring response to chemotherapy.  
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1.7.3.2 Conventional imaging of the pancreas 
Ultrasonography (USS) 
Transabdominal ultrasound is often the first line screening investigation in patients 
presenting  with  jaundice.  It  can  provide  information  about  the  size  and  site  of  a 
tumour, diameter of the biliary tree and the site of obstruction. It can also give an 
accurate assessment of the liver for metastases, where its detection accuracy has been 
reported  to  be  comparable  to  CT  (Minniti  et  al.  2003).  Use  of  Doppler 
ultrasonography  can  also  provide  a  reasonable  indication  of  vascular  patency  and 
vessel  infiltration  by  the  tumour  and  therefore  give  some  indication  of  local 
resectability (Clarke et al. 2003). USS however has several limitations. It is operator 
dependable and its accuracy is significantly affected by the patient‟s body habitus, 
presence of ascites or interposed gas filled loops of bowel. Furthermore, its accuracy 
in correctly identifying pancreatic cancer has been shown to be variable and can range 
from 57 to 81% (Haycox et al. 1998).  
 
Recently, novel techniques such as echo enhanced Doppler sonography (Rickes et al. 
2002)  and  coded  phase  inversion  harmonic  ultrasonography  have  shown  promise 
(Kitano et al. 2004).. Sensitivity of 95% has been reported in detecting pancreatic 
tumours of less than 2 cm  with  the latter. These techniques are not  yet  routinely 
available and require further validation.  
 
Contrast enhanced computed tomography (ceCT) 
The current modality of choice for diagnosis and staging of pancreatic cancer is fine 
slice  (1-3  mm),  contrast  enhanced  dual  phased  multidetector  CT  (ceCT).  ceCT 
provides  superior  definition  than  USS  and  gives  accurate  assessment  of  local   64 
infiltration.  Current  CT  criteria  for  unresectability  include  the  presence  of  distant 
metastases (to the liver, lungs or the peritoneum), involvement of adjacent organs 
such  as  the  stomach  or  the  colon  and  encasement  or  occlusion  of  peri-pancreatic 
vasculature (Smith and Rajan 2004). With these criteria, CT has been demonstrated to 
be  almost  100%  accurate  in  predicting  non-resectability  (Fuhrman  et  al.  1994). 
However, the positive predicative value of CT for detecting resectable disease is low, 
so much so that up to 50% of patients deemed to have an operable tumour on CT are 
found to have inoperable disease at laparotomy (Rickes et al. 2002). Other limitations 
of  CT  lie  in  detection  characterisation  of  small  (<2cm)  lesions,  detection  of  sub-
centimetre liver metastases, accurate differentiation of a malignant lesion from mass 
forming  chronic  pancreatitis  and  finally,  the  assessment  of  cystic  tumours.  The 
advantage conferred by newer generation mutidetectot CT scanners is the ability to 
perform high resolution multiplanar reconstructions of manipulated that can further 
enhance the accuracy of visualising local anatomy (Smith and Rajan 2004).  
 
Magnetic Resonance Imaging (MRI) 
Over  the  recent  years,  MRI  has  been  increasingly  used  for  imaging  pancreatic 
tumours. In particular, magnetic resonance cholangiopancreatography (MRCP) has 
been shown to be able to demonstrate the anatomy of the biliary tree better than CT. It 
has  also  been  shown  to  be  as  sensitive  as  Endoscopic  Retrograde 
cholangiopancreatography  (ERCP)  in  detecting  pancreatic  cancer  (Adamek  et  al. 
2000). Gadolinium enhancement can also be of value. However, with the advent and 
success of MDCT, its use in routine practice remains questionable (Hanbidge 2002). 
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Endoscopic retrograde cholangiopancreatography (ERCP) 
ERCP  has  superseded  percutaneous  transhepatic  cholangiography  (PTC)  as  the 
modality of choice for imaging the biliary tract. Its advantage over PTC is that it 
avoids puncturing the liver with its associated risk of bile leak and haemorrhage. It 
also allows visualization of adjacent organs such as the stomach and duodenum and 
the ampulla. 
Pre-operative duct delineation is usually necessary to verify the exact position of the 
obstruction  and  to  exclude  obstruction  at  multiple  levels,  all  of  which  can  be 
accurately performed with ERCP (Conio et al. 2001). When used appropriately, it can 
lead to a definite diagnosis and can be of additional value in detecting small (<2cm) 
lesions (Graham et al. 1994). 
 
A  principal  advantage  of  ERCP  over  other  imaging  techniques  is  that  it  confers 
therapeutic  as  well  diagnostic  advantage.  Brushings  /  biopsy  specimen  can  be 
obtained and stent insertion can be performed, all at the same time. 
  
The main complication resulting from ERCP is acute pancreatitis, which has been 
reported to occur with a median incidence of 8.7% (range 1.6 – 17.7) (Mariani 2003).  
While the condition often has a mild natural history following ERCP, severer forms 
of pancreatitis have been reported (Fung et al. 1997).  
 
Endoscopic ultrasonography (EUS) 
This relatively new procedure involves the use of a high frequency ultrasound that has 
been  modified  for  use  endoscopicaly.  By  placing  the  probe  in  the  stomach  or 
duodenum, in close proximity to the pancreas, the whole organ can be visualized.    66 
When  compared  to  CT,  EUS  has  been  shown  to  have  a  superior  sensitivity  and 
specificity, particularly in evaluating tumours <3cm in diameter (Mertz et al. 2000). It 
is  also  a  highly  accurate  way  of  determining  local  vascular  invasion  and  peri-
pancreatic lymph node involvement, although the results in this respect are similar to 
ceCT.  
 
EUS  is  set  to  play  a  much  larger  role  in  the  management  of  pancreatic  cancer. 
However at present, the cost of the equipment and lack of trained endoscopists is 
limiting its widespread use in the UK.   
 
1.7.3.3 Staging categories of pancreatic cancer 
Following the establishment of diagnosis, determining the stage of a pancreatic cancer 
becomes the most important factor in deciding which treatment pathway is followed. 
Currently contrast enhanced pancreatic protocol CT is the first line investigation of 
choice  in  the  staging  of  pancreatic  cancer,  while  other  modalities  are  used  as  an 
adjunct. The universally used staging system for pancreatic cancer is the American 
Joint Committee on Cancer (AJCC) TNM staging system. Table 1.3 summarises the 
TNM staging and its equivalent grouping system for pancreatic cancer.   67 
 
A               
Tumour (T)  Description                  
TX  Primary tumour cannot be assessed          
T0  No evidence of primary tumour          
Tis  Carcinoma in-situ            
T1  Tumour limited to pancreas <2cm in size in any direction        
T2  Tumour limited to pancreas >2cm in any direction        
T3  Any size tumour, extension beyond the pancreas (duodenum, bile duct)       
   but not coeliac axis or superior mesenteric artery        
T4  Tumour involving coeliac axis or superior mesenteric arteries        
Regional Lymph 
nodes (N)                     
NX  Regional lymph nodes cannot be assessed          
N0  No regional lymph node metastases          
N1  Regional lymph node metastases          
Distant 
metastases (M)                     
MX  Distant metastases cannot be assessed          
M0  No distant metastases            
M1  Distant metastases            
                      
 
B               
Stage 
group  Description              Equivalent  
TNM stage 
Stage 0  Carcinoma in-situ        Tis, N0, M0    
Stage IA  Tumour confined to pancreas, <2cm, no nodal spread    T1, N0, M0    
Stage IB  Tumour confined to pancreas, >2cm,no nodal spread    T2, N0, M0    
Stage IIA  Tumour extending beyond pancreas but not into local vessels    T3, N0, M0    
Stage IIB  Tumour confined to pancreas or local extension,  
local lymph node spread  T1-3, N1, M0    
Stage III  Local spread beyond pancreas into vessels,  
+/- nodal spread, no distant spread  T4, Any N, M0 
Stage IV  Spread to distant sites           Any T, Any N, M1 
               
 
Table 1.3: Tabulated summary of (A) the TNM staging system and (B) the stage 
grouping of pancreatic cancer  68 
1.7.4  18F-FDG PET in diagnosis of primary pancreatic cancer 
Anatomical imaging modalities outlined in previous sections, have formed the corner 
stone of diagnosis and staging of pancreatic cancer. However, many challenges still 
remain.  These  in  particular  include  the  definitive  diagnosis  of  small  tumours  and 
differentiating malignant from benign inflammatory lesions (eg: due to mass forming 
chronic pancreatitis or secondary to post-treatment fibrosis). The emergence of PET 
technology has therefore set out to address some of these limitations.  
 
Much of the present evidence supporting the use of PET in pancreatic cancer has been 
with the use of the tracer 18F-FDG. As normal pancreas has low glucose utilisation, 
foci of abnormal 18F-FDG uptake can be easily visualised as focal areas of increased 
tracer activity (Berberat et al. 1999). Suggestions that 18F-FDG would be of value in 
the  diagnosis  of  malignant  pancreatic  lesions,  have  come  from  early  studies  that 
showed  quantitative  and  selective  over-expression  of  GLUT-1  transporters  in 
pancreatic cancer specimens compared to benign tissue (Higashi et al. 1997; Reske et 
al. 1997). Since then, a number of studies evaluated the clinical role of 18F-FDG PET 
in primary pancreatic disease. Zimny et al. (1997) examined the accuracy of  18F-
FDG PET in determining the diagnosis in 106 suspicious pancreatic masses. In their 
series, 70% were histologically confirmed to be adenocarcinoma and 30% to be due 
to chronic pancreatitis. Overall, 18F-FDG PET accurately detected 63/74 of cases 
with malignancy and 27/32 cases of benign disease, giving it an overall sensitivity 
and specificity of 85% and 84% respectively.  
 
Compared  to  conventional  imaging,  18F-FDG  PET  has  been  shown  to  be  more 
accurate in making the initial diagnosis of pancreatic cancer. Inokuma et al. (1995) 
compared 18F-FDG PET with CT, transabdominal US and EUS in 35 patients with   69 
proven carcinoma. While 18F-FDG PET correctly identified 33 (94%) patients with 
cancer, CT, US and EUS identified 31 (89%), 31 (89%) and 28 (80%) respectively. In 
another study that compared 18F-FDG PET with CT and MR, the sensitivity of 
18F-
FDG PET was found to be lower than CT but better than MR. The specificity of PET 
however, was superior to both (Koyama et al. 2001). 
 
A  major  limitation  of  morphological  imaging  techniques  is  their  inability  to 
confidently  characterise  small and cystic lesions.  The presence of focal 18F-FDG 
activity irrespective of lesion morphology therefore provides a significant advantage. 
One  study  has  suggested  18F-FDG  PET  to  be  superior  to  CT  in  detecting  small 
lesions less than 2cm in size (Rose et al. 1999). Here, PET‟s sensitivity was shown to 
be almost 100% compared to 18% for CT. This finding however, was in a relatively 
small patient group (n=14) and requires further validation, particularly in the light of 
recent advances in fine slice CT technology.  
 
More  recently,  Sperti  et  al.  (2005)  examined  the  usefulness  of  18F-FDG  PET  in 
differentiating malignant from benign pancreatic cysts. In 50 prospectively recruited 
patients, 18F-FDG PET was more accurate in detecting a malignant cyst (94% for 
18F-FDG PET versus 80% for CT). The limitation of this study was the fact that it 
represented a small and heterogenous group of malignant cystic lesions. Therefore 
drawing conclusions regarding 18F-FDG PET‟s diagnostic accuracy should be done 
with  care.  However,  the  significant  finding  was  that  31  out  of  33  (94%)  benign 
lesions demonstrated no 18F-FDG uptake was demonstrated and thus the diagnosis of 
benign disease was correctly made. This has significant implications for the use of 
18F-FDG PET in assessing asymptomatic, high-risk patients.    70 
 
One of the key strengths of imaging with PET is its quantitative nature, which may be 
used to further bolster its diagnostic accuracy. Several authors have described tracer 
semi-quantification with Standardized Uptake Values (SUVs) to improve qualitative 
assessment of PET detected lesions. Time dependant changes in tracer uptake also 
have been shown to improve 18F-FDG PET‟s specificity. Nakamoto et al. (2000) 
showed that at 2 and 3 hours post-tracer injection, malignant lesions showed a higher 
18F-FDG retention index than benign lesions. Combining the tracer retention index 
with tumour SUV measurements at 2 hours post-injection, improved PET‟s diagnostic 
accuracy from 83% to 92%. This interesting finding was demonstrated in one study of 
47 patients and thus merits further investigation. Furthermore, the limitation of any 
quantitative approach in making the correct diagnosis is in defining a precise cut-off 
value for tracer uptake parameters. Since benign and malignant lesions in the pancreas 
can exhibit a wide range of tracer uptake, quantitative image analysis is yet to be 
proven to be absolute. As for this, the routine practice of image interpretation with 
PET has leant towards qualitative (visual) assessment, where patterns tracer uptake 
(eg: focal vs diffuse) can be incorporated.  
 
Overall there is considerable evidence to support the usefulness of 18F-FDG PET in 
imaging the pancreas. A review of published data produced by Gambhir et al. (2001) 
found that in 387 patient‟s studied, the overall sensitivity and specificity for 18F-FDG 
PET was 94% and 90%, as compared to 82% and 75% for CT. 
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1.7.6  Staging of pancreatic carcinoma with 18F-FDG PET 
Local (T) staging 
Poor spatial resolution of 18F-FDG PET limits the local (T) staging of pancreatic 
cancer. Therefore, anatomical imaging modalities particularly with ceCT and EUS, 
are better suited to demonstrate the relationship between the tumour, adjacent organs 
and vascular structures. At present there is no data to support the usefulness of dual 
modality PET/CT in local (T) staging.  
 
Locoregional lymph node (N) staging 
In  nodal  (N)  staging  of  disease,  both  18F-FDG  PET  and  ceCT  perform  poorly. 
Reported sensitivities and specificities for 18F-FDG PET have varied between 46-
71% and 63-100% respectively (Bares et al. 1994; Bares et al. 1996; Diederichs et al. 
2000). One possible reason for the apparent low sensitivity of 18F-FDG PET is the 
close proximity of the  peri-pancreatic lymph  node basin  and the primary tumour, 
which can obscure and thus hinder detection (Bares et al. 1994; Bares et al. 1996). 
 
Locoregaional  lymphadenopathy  is  commonly  encountered  following  biliary 
instrumentation  (ERCP,  stent  insertion)  or  following  a  bout  of  acute  on  chronic 
pancreatitis.  However,  it  must  be  noted  also  that  in  majority  of  patients  with 
radiological evidence of lymph node disease, the presence of an inoperable tumour 
ethically prevents extensive sampling of positive nodes. Therefore, the true accuracy 
of 18F-FDG PET in  detecting lymph  node disease cannot  be reported  accurately. 
Therefore  given  the  non-specific  nature  of  18F-FDG,  histological  confirmation  of 
PET positive lymph nodes is essential. 
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Staging of distant disease (M stage) 
The  major  impact  of  18F-FDG  PET  on  staging,  is  its  ability  to  identify  distant 
metastases (M stage). The liver is the commonest organ to be affected followed by the 
lungs and the bone marrow. Direct spread into the peritoneum commonly occurs and 
is often missed on conventional anatomical imaging. Diederichs et al. (2000) showed 
that in 89 patients with pancreatic malignancy, the sensitivity and specificity of 18F-
FDG PET for detecting hepatic metastases to be 70% and 95%, missing one sub-
centimetre liver lesion. 18F-FDG PET also detected occult peritoneal metastases in 
25% of the cases, once again missing poorly localized and microscopic spread. In a 
similar study, Frohlich et al. (1999) who looked at the detection of liver metastases 
with 18F-FDG PET in 168 pre-operative patients, also found 18F-FDG PET to have 
an overall sensitivity of 68%. In fact, dichotomizing the data into groups with hepatic 
lesions less than or greater than 1cm, showed PET‟s sensitivity to be 43% and 97% 
respectively.  In  their  series  overall  specificity  was  high  (95%),  but  significant 
intrahepatic cholestasis was a cause of false positives.  
 
Table 1.4 summarises some of the published series of 18F-FDG PET in diagnosis and 
staging of pancreatic cancer.   73 
 
 
Table 1.4 Summary of studies comparing the detection accuracy of 18F-FDG PET 
and conventional imaging with CT in diagnosing and staging of pancreatic cancer 
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1.7.7
  The prognostic significance of 18F-FDG uptake in pancreatic cancer 
There are indications that current methods of tumour staging (TNM) for pancreatic 
cancer are inadequate. For example when compared to other more common cancers, 
node negative pancreatic cancer still caries a poor outcome. This may be due to the 
fact that patients are understaged histopathologically or that our current clinical and 
radiological methods are incomplete. As a result, a number of other factors have been 
assessed  as  potential  predictors  of  survival  in  pancreatic  cancer,  some  of  which 
include; tumour stage and grade (Lim et al. 2003), R0 resection (Wittekind et al. 
2002; Lim et al. 2003), levels of the tumour marker CA19-9 (Sperti et al. 1993) and 
more  recently,  the  detection  of  circulating  tumour  cells  (Vogel  et  al.  2002).  The 
ultimate aim is to be able to stratify patients into groups that would most benefit from 
neoadjuvant and adjuvant treatments. 
 
In addition to its role in staging, quantifying the metabolic activity of the tumour with 
PET may have significant clinical implications. Nakata et al. (2001) compared the 
survival  of  patients  with  high  and  low  18F-FDG  SUV  levels  in  14  patients  with 
pancreatic cancer. Using an SUV threshold of 3 (corresponding to the mean 18F-FDG 
SUV level in the series) they found that mean survival period for those with SUV>3.0 
was 5 months, compared to 14 months for those with an SUV of <3.0.  In a similar 
study with a larger patient numbers (N=60), a high SUV (>4.0) was again associated 
with a shorter survival, with only 7% (2/29) surviving beyond 12 months compared 
with  32%  (10/31)  with  SUV  <4.0  (Sperti  et  al.  2003).  Also,  in  the  subgroup  of 
cancers that were resected, low and high SUV values were associated with  mean 
survival figures of 386 and 224 days respectively. Multivariate analysis revealed that 
tumour  stage  and  SUV  were  the  only  two  significant  independent  predictors  of   75 
survival, when compared to factors such as age, tumours grade or type of treatment 
received.  
 
One small study by Maisey et al. (2000) (n=11) investigated the role of tumour SUVs 
in predicting survival from 5-fluorouracil (5-FU) based chemotherapy. At 1 month 
post-treatment, 6 out of 11 patients showed no detectable 18F-FDG activity in the 
tumour  and  demonstrated  better  overall  survival.  In  4  of  the  6  responders,  a 
correlation with symptomatic improvement also was seen. 
 
Measuring proliferation of a tumour is also another potential prognostic indicator. 
There  may  be  a  potential  for  alternative  tracers  such  as  11C-thymidine  or  the 
thymidine analogue 3‟-doexy-3‟-[18F]-fluorothymidine (18F-FLT) in prognosticating 
pancreatic cancer, but at present no published series are available.  
 
1.7.7  18F-FDG PET in detection of recurrent pancreatic cancer 
Serial measures of tumour marker levels (CA 19-9) are a sensitive indicator of disease 
recurrence.  However,  differentiating  recurrent  disease  from  post  surgical  / 
radiotherapy changes with CT or MRI is difficult. Molecular imaging on the other 
hand can detect  focal  tracer accumulation regardless of morphology. To date few 
studies have examined the use of 18F-FDG PET in detecting disease recurrence. In 
their study of suspected pancreatic cancer, Rose et al. (1999) examined 8 patients with 
rising  tumour  marker  levels  and  indeterminate  ceCT  findings.  18F-FDG  PET 
correctly identified recurrent disease in all, with 4 occurring in the surgical bed and 4 
as new liver metastases. More recently, Ruf et al. (2005) showed that in 31 patients 
with suspected recurrent disease, 96% of local recurrences were detected with 18F-  76 
FDG as compared to 23% with CT or MRI In detecting metastatic disease in the liver, 
CT and MRI was more sensitive, particularly in identifying small lesions. However, 
18F-FDG PET additionally helped to detect additional occult disease in non-regional 
and extra-abdominal sites, thus resulting to a change in management. 
 
There are therefore indications that 18F-FDG PET may be useful in differentiating 
fibrosis  from  recurrent  disease,  in  whole  body  re-staging  of  the  patient  and  in 
identifying the focus of recurrence, where there is a rise in tumour marker levels in 
the face of a negative or equivocal finding by conventional imaging.  
 
1.7.8  The pitfalls of imaging pancreatic disease with 18F-FDG PET 
In  imaging  pancreatic  disease  with  18F-FDG  PET,  serum  glucose  levels  are  an 
important  consideration, especially  when pancreatic insufficiency and diabetes are 
commonly found in this cohort of patients. High serum glucose levels are believed to 
compete with 18F-FDG for glucose transporters sites and thus reduce the sensitivity 
of detecting malignant lesions. In 106 patients with suspected pancreatic carcinoma, 
Zimny et al. (1997) found that 10 out of 11 false negative 18F-FDG PET results 
occurred  in  hyperglycemic  patients,  thus  resulting  in  a  sensitivity  of  98%  in 
euglycemic patients as compared to 63% in hyperglycaemic patients.  
 
Lesion  size  also  poses  a  further  challenge.  The  sensitivity  of  18F-FDG  PET  in 
detecting sub-centimetre lesions can be low. This problem is not exclusive to that of 
pancreatic pathology and represents the partial volume effect on a signal from a small 
lesion.  This  problem  has  been  partly  addressed  with  the  advent  of  dual  modality   77 
PET/CT  and  density  attenuation  correction.  Future  developments  in  PET  detector 
technology are also set to increase the spatial resolution of PET. 
 
Several benign clinical conditions may also result in focal 18F-FDG accumulation 
and thus result in false positive findings. 18F-FDG despite its exquisite sensitivity is 
not tumour specific and uptake by inflammatory tissue is often encountered. Although 
18F-FDG PET has been shown to be better than anatomical imaging in differentiating 
benign from malignant lesions, focal accumulation in areas of active pancreatitis can 
commonly be seen. In the face of elevated CRP levels, specificity of 18F-FDG PET 
has been reported to be as low as 50% (Shreve 1998). It is therefore recommended 
that CRP levels are routinely checked prior imaging the pancreas with PET. Non-
specific 18F-FDG uptake is also seen following biliary instrumentation (eg: stenting), 
following  haemorrhage  into  a  pancreatic  pseudocyst  and  secondary  to  portal  vein 
thrombosis or retroperitoneal fibrosis. This is once again another area that PET/CT 
fusion  is  set  to  impact,  where  the  addition  of  anatomical  data  can  improve  the 
accuracy and certainty of image interpretation. 
 
1.7.9  Pancreatic cancer and image fusion with PET/CT 
To date, only two studies have examined the role of PET and CT image fusion in 
pancreatic cancer. In a study by Lemke et al. (2004), digital image fusion of CT and 
18F-FDG PET was carried out in a prospective series of 104 suspected pancreatic 
lesions.  They showed that  image fusion  improved the sensitivity of both  imaging 
modalities  (CT:  76.%;  PET:  84.4%  and  fused:  89.1%).  Sensitivity  of  detecting 
infiltration of adjacent  tissues  also  improved over that of CT alone, however this 
occurred  at  the  expense  of  reduced  specificity.  This  is  a  particularly  undesirable   78 
situation  as  over  staging  the  disease  can  deny  a  patient  a  potentially  curative 
resection.  Image  fusion  also  resulted  in  a  slight  (but  statistically  insignificant) 
improvement in sensitivity for detecting lymph node metastases (Sensitivities: PET 
=25.8%,  CT=25.8%  and  PET/CT  fused  =32.3%),  but  the  specificities  remained 
unchanged (75%).  
 
 More recently, Heinrich et al. (2005) investigated the role and cost-effectiveness of 
imaging with integrated PET/CT scanners on the management of 59 patients with 
potentially resectable pancreatic cancer  . The important point of note in this study 
was that PET/CT was acquired with a low dose, unenhanced CT scan according to 
current routine protocols. Overall, the capability of 18F-FDG PET/CT in detecting 
pancreatic cancer was found to be in keeping with other studies that used PET in 
isolation. Furthermore, 5 patients (16%) were found to have CT occult metastases 
which  resulted  in  avoidance  of  futile  surgery  and  subsequent  cost  saving.  In  fact 
PET/CT was shown to be cost effective despite patients requiring other investigations 
(eg:  EUS/CT  guided  biopsies,  staging  laparoscopy)  to  confirm  the  nature  of  PET 
detected lesions.  
  
The major challenge of managing pancreatic cancer is its late presentation. Currently 
there are no established screening programs that would identify the disease early and 
at present, there is  no justification for using 18F-FDG PET as a population wide 
screening tool. Although a number of above mentioned studies suggest 18F-FDG PET 
to be of value in earlier diagnosis of pancreatic cancer, these need to be interpreted 
within  the  context  of  the  natural  history  of  the  disease.  In  the  majority  of  cases, 
initiation  of  investigations  occurs  following  development  of  clinical  signs  and   79 
symptoms  that  may  indicate  advanced  disease.  Therefore,  by  the  time  the  patient 
undergoes some form of imaging, there is an 80% chance that the disease has become 
unresectable. It therefore becomes clear that at present, the true impact of 18F-FDG or 
PET/CT on management appears to occur at initial diagnosis and staging and not as a 
screening tool. 
 
As compared to CT, a review of published data by Gambhir et al. (2001) suggested 
PET to result in a change in management of between 36% to 50%. The strength of 
biological  imaging  lies  in  its  ability  to  detect  pathology,  irrespective  of  lesion 
morphology. This property allows 18F-FDG PET to detect small or cystic lesions and 
to differentiate between benign from malignant disease. In this setting, 18F-FDG PET 
can alter management by providing a more accurate diagnosis.  
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1.8  The role of PET in diagnosis and staging of colorectal cancer 
 
1.8.1  Background     
Worldwide, an estimated 1 million cases of colorectal cancer (CRC) were diagnosed 
in 2002. This accounts for more than 9% of all newly diagnosed cancers. In the UK in 
2005,  there  were  36,766  new  cases  of  colorectal  cancer  registered,  two  thirds 
occurring in the colon and remaining one third in the rectum. Over 80% of cases 
occur in patients over the age of 60 years with it being more common in males than in 
females (Statistics 2005). Up to 45% of patients with CRC can present with advanced 
disease (Dukes stages C and D) at initial diagnosis. Of those with earlier disease who 
receive a curative resection, some 30-40% still go on to develop a local recurrence or 
metastatic disease (Sugarbaker 1990). Therefore early diagnosis and accurate staging 
represents the principal determinant of successful management of CRC.   
 
The  gold  standard  in  diagnosing  primary  colorectal  cancer  is  endoscopy.  This  is 
followed  by  computed  tomography  (CT),  which  is  routinely  used  for  staging, 
surveillance  for  metastases  and  detection  of  recurrent  disease.  Other  conventional 
imaging tools such as Ultrasound,  Magnetic Resonance Imaging (MRI) and more 
recently,  CT  pneumocolonography  are  routinely  applied  according  to  institutional 
preferences and availability. Overall however, the indications are that conventional 
imaging modalities seem to play a sub-optimal role in the management of colorectal 
cancer and hence much attention has been focused on molecular imaging techniques 
such as Positron Emission Tomography. 
 
PET offers the clinician both an alternative and complementary means of assessing 
the gastrointestinal tract. While 18F-FDG has represented the most successful and   81 
widely  used  PET  radiopharmaceutical  in  oncology,  molecular  profiling  with 
alternative tracers and the advent of dual modality PET/CT are all re-shaping the way 
we manage colorectal cancer.  
 
1.8.2   Detection of pre-malignant colonic lesions with PET 
Adenomatous  polyps  are  benign  neoplasms  of  colonic  mucosa.  Amongst 
asymptomatic  patients  of  average  risk,  its  prevalence  is  approximately  10%  from 
sigmoidoscopy and 25% from colonoscopy series (Giacosa et al. 2004). World wide 
however, this figure varies between different countries. Colonic adenomas are well 
established as precursors of CRC (Fearon and Vogelstein 1990), where the prevalence 
in these patients is approximately 1%. Barium enema and colonoscopy represent the 
gold  standard  of  detecting  these  lesions,  the  later  offering  therapeutic  as  well  as 
diagnostic benefit. More recently CT pneumocolonography has also emerged as an 
alternative  and  accurate  way  of  detecting  polyps  in  patients  unsuitable  for 
colonoscopy.  
 
Adenomatous  polyps  exhibit  an  enhanced  glycolytic  activity  and  therefore  the 
incidental detection of polyposis has been frequently reported with 18F-FDG PET 
(Tatlidil et al. 2002). In a retrospective study by Yasuda et al. (2000), 18F-FDG PET 
was shown to have a true positive rate of only 24%. This figure did rise to 90%, 
particularly in polyps greater that 13mm in size suggesting that smaller polyps (<1cm) 
may not be accumulating enough 18F-FDG to be detected at the resolution limit of 
PET. Although PET/CT may help in localization of intra-luminal lesions, the size and 
18F-FDG avidity of the polyp would remain a limiting factor. 
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Overall, while 18F-FDG PET or PET/CT are not indicated for routine detection of 
colonic  polyps,  focal  18F-FDG  accumulation  in  the  colon  should  be  further 
investigated.  
 
1.8.3  Screening colorectal cancer with PET 
To date, the use of 18F-FDG PET in screening for CRC has been reported by one 
study of 3600 patients (Yasuda et al. 2000). Here, the prevalence of CRC was 2.1% 
and  18F-FDG  PET  had  a  true  positive  and  false  negative  rate  of  54%  and  46% 
respectively. These figures coupled with the cost, availability and radiation exposure 
risk of 18F-FDG do not  justify the routine use of 18F-FDG PET or PET/CT for 
screening purposes.  
 
1.8.4  Role of 18F-FDG PET in the diagnosis of primary colorectal cancer 
The role of 18F-FDG PET in routine preoperative diagnosis of primary CRC has only 
been reported in small patient numbers. Abdel-Nabi et al. (1998) reported 18F-FDG 
PET to have a sensitivity and specificity of 100 and 48% (n=48). Similarly Mukai et 
al. (2000) reported a true positive rate of 98.5% (n=24). False positives often arise due 
to focal areas of 18F-FDG accumulation in for example diverticulitis or adenomatous 
polyps.  Where  physiological  tracer  uptake  in  the  bowel  is  encountered,  lack  of 
anatomical localization with PET can also lead to diagnostic uncertainty. This has 
been addressed with PET/CT and although its clinical impact in primary CRC has not 
yet been conclusively evaluated, early results have shown that PET/CT can improve 
the certainty of lesion characterisation by 30% and the accuracy of staging by 11% 
(Cohade et al. 2003a). 
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Conventional anatomical imaging modalities remain the cornerstone for staging CRC. 
Local (T-staging) of the tumour cannot be reliably carried out with PET due to its 
limited resolution and the effect of partial volume averaging of the 18F-FDG signal. 
Although at present PET/CT imaging protocols limit the diagnostic capability of its 
CT component, future developments may allow PET/CT to confer advantages over 
CT or MRI imaging alone.   
 
In terms of lymph node staging (N stage), the sensitivity of 18F-FDG PET has been 
shown to be similar to that of CT and overall poor (sensitivity of 22-29%) (Abdel-
Nabi et al. 1998; Mukai et al. 2000). As the presence of lymph node metastases on CT 
are detected according to size criteria, image fusion with PET/CT can help further 
confirm the presence of disease, even in non-enlarged lymph nodes. A pitfall of this 
however is false positive results where 18F-FDG may accumulate in reactive lymph 
nodes.  
 
In pre-operative staging, 18F-FDG PET has performed best in detecting hepatic and 
extra-abdominal metastases. Sensitivities and specificities of 88-91% and 91-100% 
have been reported, as compared to 38% and 97% for CT (Abdel-Nabi et al. 1998; 
Kantorova et al. 2003). This can lead to a change in treatment modality and the extent 
of surgery (Kantorova et al. 2003).  
 
Overall, the indications are that 18F-FDG PET or PET/CT play a limited role in the 
routine diagnosis and staging of primary CRC. However, in high-risk patients, its 
accuracy in detecting extra-colonic disease may result in avoidance of futile surgery.  
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1.8.5  Detecting recurrent and metastatic disease 
1.8.5.1 Locoregional recurrence 
After  apparent  curative  resection  of  the  primary  tumour,  the  recurrence  rate  for 
colorectal cancer is between 30 to 40%, the majority of which occur within the first 3 
years after surgery (Scheele et al. 1990; Sugarbaker 1990). Of these, approximately 
25% are isolated loco-regional recurrences, which may be amenable to resection. In 
order  to  minimize  unnecessary  morbidity  and  mortality  from  surgical  treatment, 
accurately identifying the extent of recurrent disease is vital for appropriate patient 
selection.  
 
In detecting and staging recurrent disease, 18F-FDG PET has been shown by several 
groups to be superior to conventional imaging with CT. Table 1.5 summarises some 
the results from such studies.  
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A particular challenge of anatomical imaging modalities has been in differentiating a 
post surgical scar from local recurrence. The reported accuracy of 18F-FDG PET in 
detecting pelvic recurrences is 95% as compared to 65% with CT (Schiepers et al. 
1995). In particular, Valk et al. (1999) demonstrated the sensitivity and specificity of 
18F-FDG  PET  to  be  93%  and  98%,  where  as  for  CT  it  was  69%  and  96% 
respectively. In their study, this lead to significant cost saving through avoidance of 
futile surgical intervention. Image fusion with PET/CT further adds to the diagnostic 
accuracy of 18F-FDG PET. It is particularly effective in characterising a pre-sacral 
mass,  with  quoted  sensitivity  of  100%  and  specificity  of  96%  (Even-Sapir  et  al. 
2004). 
  
Intensive follow-up after curative resection, with regular imaging (US or CT) and 
tumour marker levels has been shown to correlate with improved survival (Renehan et 
al. 2002). Measurement of serum carcinoembryonic antigen (CEA) levels is a simple 
method that can give a first indication of tumour recurrence in approximately 60%, 
with a mean sensitivity of 80% (range 17-89%). However, up to 30% of patients have 
been reported not to express the antigen.  One of the areas where 18F-FDG PET plays 
a significant role is in the assessment of patients with rising CEA levels and negative 
conventional imaging. Flanagan el al. showed 18F-FDG PET to have positive and 
negative  predictive  values  of  89%  and  100%  respectively  (Flanagan  et  al.  1998). 
Flamen et al. (1999) also reported similar findings, but their false positive rate of 21% 
was of significance. The question remains as to whether all patients with a rising CEA 
should receive an 18F-FDG PET scan. A pitfall of this approach is the false positive 
rate of CEA, which occurs in up to 16% of cases. But on the other hand, routine 18F-
FDG PET/CT as a first line imaging, followed by further investigation directed by   87 
PET/CT,  is  also  a  valid  argument  (Wahl  2004;  Yap  et  al.  2004).  This  paradigm 
requires a more in depth examination. 
 
1.8.5.2  Metastatic disease 
The liver is the commonest site for CRC metastases, which can occur in up to 40% of 
patients  after  a  curative  resection  of  primary  disease.  Of  these,  less  than  5%  are 
amenable to surgical resection and a median 5 year survival figure of about 30% 
(range 12-41%) has been quoted (Stehlin et al. 1988; Schlag et al. 1990; Doci et al. 
1991; Fegiz et al. 1991; Yamaguchi et al. 1993; Gayowski et al. 1994; Scheele et al. 
1995; Jamison et al. 1997; Rees et al. 1997; Fong et al. 1999a; Liu et al. 2002; Kato et 
al. 2003).  Although solitary liver metastases confer a better prognosis, with more 
aggressive regimes that include pre-operative (neoadjuvant) chemotherapy, two-stage 
hepatic resections (Adam et al. 2000),  intra-operative radiofrequency ablation (Elias 
et al. 2005) and selective portal vein embolization (Azoulay et al. 2000; Elias et al. 
2002),  wider  indications  for  surgery  and  thus  improved  survival  figures  are 
continually  achieved.  None  the  less,  the  accuracy  of  pre-operative  assessment  of 
hepatic and extra-hepatic tumour burden becomes the main determinant of outcome.  
 
Ultrasonography and ceCT currently represent the first line imaging modalities of 
choice in the assessment of liver metastases. MRI may represent an alternative to the 
above particularly in assessing indeterminate lesions found on routine imaging. As 
compared  to  CT,  18F-FDG  PET  has  been  consistently  shown  to  have  a  superior 
sensitivity and specificity in detecting liver metastases. Some of the published results 
to date are again summarised in table 1,.5. A meta-analysis by Huebner et al. (2000)   88 
gave 18F-FDG PET a weighted average sensitivity of 90.86% (86.2% - 95.62%) and 
specificity of 96.97% (92.5% -100%) for detecting hepatic colorectal metastases  
 
The principal advantage of 18F-FDG PET is the fact that biological signals of disease 
can be detected before morphological changes become apparent. This can often result 
in  detection  of  unsuspected  metastases  which  can  occur  in  13-36%  of  cases  and 
clinical impact of 14 to 65% (Adson et al. 1984; Beets et al. 1994; Schiepers et al. 
1995; Lai et al. 1996; Ogunbiyi et al. 1997; Ruhlmann et al. 1997; Flanagan et al. 
1998; Flamen et al. 1999; Imdahl et al. 2000; Staib et al. 2000; Strasberg et al. 2001). 
 
In whole body imaging, Valk et al. (1999) showed the sensitivity of 18F-FDG PET to 
be higher than CT at all sites, except for the lungs where the two were equivalent. The 
difference  in  detection  rates  were  greatest  in  the  abdomen,  pelvis  and  the 
retroperitoneum where almost 30% of lesions missed on CT were detected with 18F-
FDG  PET.  Lai  et  al.  (1996)  also  reported  similar  findings  but  their  study  also 
suggested 18F-FDG PET to be superior in detecting malignant lung deposits.  
 
A point of note however is that the majority of these studies prospectively analysed 
the 18F-FDG PET data and compared it to retrospectively reviewed CT results. The 
CT scans were also carried out using different imaging protocols thus resulting in 
significant  heterogeneity  of  the  data.  Therefore,  although  18F-FDG  PET  over  all 
demonstrated an exquisitely high detection rate, its comparison with CT data requires 
a more careful consideration.  
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More recently, it has been suggested that pre-operative assessment of patients with 
liver metastases correlates with improved long term survival. By improving patient 
selection for surgery, 18F-FDG PET has been reported to result in 5-year survival 
rates  of  up  to  58%  as  compared  to  a  median  of  30%  for  conventional  imaging 
(Fernandez  et  al.  2004).  The  question  remains  as  to  whether  18F-FDG  PET  and 
PET/CT should be routinely used in pre-operative assessment of liver metastases. One 
factor that may be of significance is the “clinical risk score” of the patient (Fong et al. 
1999a). A recent study by Schussler-Fiorenza et al. (2004) suggested that patients 
with a clinical risk score of 0 and an isolated hepatic metastasis should only “undergo 
conventional imaging before surgical exploration”. This is backed-up by other recent 
papers that have shown 18F-FDG PET and PET/CT to provide similar information 
regarding  liver  metastases  as  for  contrast  enhanced  multidetector  CT.  However, 
detection of unrecognised extrahepatic disease and intrahepatic recurrences following 
prior  liver  surgery  remains  the  strengths  of  18F-FDG  PET  and  PET/CT  imaging 
(Selzner et al. 2004; Truant et al. 2005).  
 
Clearly, the emerging CT technology is continually narrowing the gap between the 
capability of CT and that of 18F-FDG PET in detecting colorectal liver metastases. 
Despite this, in characterising lesions less than 1cm, there is no consensus on the best 
imaging modality that should be used. 
 
1.8.6  The impact of dual modality imaging with PET/CT on the management of 
colorectal cancer 
 
The  incremental  value  of  18F-FDG  PET/CT  over  18F-FDG  PET  alone  has  been 
demonstrated in a retrospective study by Cohade et al. (2003a). In 45 patients, 18F-  90 
FDG PET/CT achieved a 50% reduction in the proportion of equivocal and probable 
lesions, a 25% improvement in lesion localization and 11% increase in accuracy of 
staging (from 78% to 89%). Interpretation of the CT component of PET/CT alone was 
also shown by the same group to provide valuable additional information. Similar 
results were also reported in a larger series of 204 patients with suspicious malignant 
lesions, of which 34 patients had a GI malignancy.  
 
More recently, a comparison between whole body 18F-FDG PET/CT and MRI (in a 
range  of  solid  malignancies  including  CRC)  revealed  that  overall,  PET/CT  was 
superior in all staging categories. However interestingly, MRI was superior to 18F-
FDG PET/CT in detecting liver and bone metastases (Antoch et al. 2003). Currently 
the  limitation  of  PET  lies  in  detecting  small  (<5mm)  liver  lesions,  where  high 
resolution MRI may perform better.  
 
The impact of accurately diagnosing and staging CRC is clear. As larger prospective 
series emerge, the true clinical value of dual modality imaging will become more 
apparent. The area where PET/CT shows real promise is in directing the subsequent 
investigation and treatment of patients. The superior sensitivity of PET, coupled with 
anatomical information provided by the CT scan, can for example help increase the 
yield of image guided biopsies (Yap et al. 2004). With the biological boundaries of 
the tumour volume in mind, surgeons can also perform more precise resections and 
radiotherapy  planning  can  also  be  altered,  ultimately  providing  more  of  a  patient 
specific treatment (Ciernik et al. 2003). 
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1.8.7  Therapy response monitoring with PET 
Measuring tumour response to treatment based on morphological parameters has been 
a widely debated subject (RECIST & WHO criteria). For this reason, quantitative 
imaging of tumour metabolism with 18F-FDG PET confers important  advantages. 
However, the evidence to date for the use of 18F-FDG PET in treatment response is 
small.  
 
1.8.7.1 Response to radiotherapy 
It has been shown that a reduction in 18F-FDG uptake correlates better with palliative 
benefit  of  radiotherapy  than  CEA  levels  (Haberkorn  et  al.  1991).  Early  on  after 
radiation treatment, an increase in 18F-FDG uptake is seen which is attributed to the 
local  inflammatory  response  induced.  Although,  a  clear  time  point  has  not  been 
demonstrated, presence of activity at 6-8 weeks following radiotherapy is often taken 
as  an  evidence  of  residual  disease.  In  locally  advanced  rectal  cancer  treated  with 
chemoradiation, Guillem et al. (2004), demonstrated that a reduction in mean 18F-
FDG  SUV‟s  at  4-5  weeks  post  chemo-irradiation  to  be  a  predictor  of  long  term 
outcome Furthermore, presence of hypermetabolic foci up to 6 months after radiation 
therapy of rectal tumours, can be a strong indicator of disease recurrence (Moore et al. 
2003).  
 
As  previously  mentioned,  one  of  the  specific  advantages  of  PET/CT  is  in  aiding 
radiotherapy planning. The addition of metabolic boundaries to anatomical data can 
lead  to  significant  alteration  of  Gross  Tumour  Volumes  (GTV)  estimations,  thus 
subsequently  improving  the  effectiveness  of  treatment  with  potential  reduction  of 
unwanted side-effects (Yap et al. 2004).    92 
1.8.7.2 Response to chemotherapy 
5-fluorouracil (5-FU) has been the most successful and widely used chemotherapeutic 
agent in colorectal cancer for over 40 years. However overall response rates to it in 
advanced disease have been poor. Newer agents such as Oxaliplatin or Irinotican can 
have reported response rates of up to 70%, but are also associated with debilitating 
side effects. The need for appropriate patient selection is therefore clear and hence the 
ability of PET to potentially detect early biological response is significant.  
 
The evidence to date has been encouraging. Findlay et al. (1996) examined 18F-FDG 
uptake parameters in 27 liver metastases (tumour : normal liver ratio (T:L) and SUVs) 
at 1,2 and 4-5 weeks post treatment with 5-FU A reduction in T:L ratio of 67% and 
99%  was  observed  in  responders  as  compared  to  non-responders  respectively 
(p<0.01).  Use  of  18F  labelled  fluorouracil  (18F-FU)  has  also  yielded  interesting 
results. Early evidence in human studies demonstrated that responsive tumours were 
associated with a high 18F-FU uptake than the non-responders (Moehler et al. 1998). 
 
18F-FDG PET has also been recently used to determine biological response to novel 
antibody  based  agents.  An  example  is  Bevacizumab,  an  anti-VEGF  monoclonal 
antibody recently licensed for use in the treatment of advanced colorectal cancer. A 
reduction in tumour 18F-FDG uptake has been shown to correspond with reduction in 
blood supply as measured using dynamic CT and histopathological findings (Goessl 
and Grozdanovic 2004).  
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1.8.7.3 Monitoring local ablative therapy 
Local  ablative  therapy  of  colorectal  liver  metastases  is  an  increasingly  accepted 
means of treating liver and lung metastases not amenable to resection.  Where liver 
metastases  have  been  treated  by  radiofrequency  ablation,  18F-FDG  PET  is  more 
accurate than CT for early recognition of incomplete tumour destruction (Donckier et 
al. 2003; Barker et al. 2005; Veit et al. 2006). 
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1.8.8  Limitations of imaging with 18F-FDG PET 
One of the key limitations of imaging with 18F-FDG PET is lesion size where lesions 
less  that  1cm  may  be  frequently  missed  due  to  partial  volume  effects.  This  is 
particularly important in the liver, as there is currently no single imaging modality of 
choice for detecting such small metastases. False negative findings also commonly 
occur in mucinous tumours. This has been attributed to the relatively low cellularity 
of this tumour type and possibly as a result of the abundant mucin (which is rich in 
poly-mucosaccharides)  competing  with  18F-FDG  for  uptake  sites  (Berger  et  al. 
2000).   
 
Activated macrophages and inflammatory tissue also have a high uptake of 18F-FDG 
and this may lead to false positive findings. This is of significance in inflammatory 
bowel disease or in a mass resulting from diverticulitis. Granulomatous diseases such 
as sarcoidosis and tuberculosis may also produce false positive results that may result 
in unnecessary invasive investigations in order confirm them . 
 
Finally, as normal bowel also demonstrates background 18F-FDG uptake, this can 
occasionally lead to diagnostic uncertainty. Careful clinical assessment, appreciation 
of the pattern of uptake and correlation with CT findings with PET/CT can all help 
avoid false interpretations (Delbeke and Martin 2004).  
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1.9  Chapter overview and aims of thesis 
So far, the principals behind molecular imaging and various modalities that are used 
have been reviewed. The role of conventional imaging and that of 18F-FDG PET and 
PET/CT has also been outlined. As a molecular imaging tool, PET has set the scene 
from which this discipline continues to expand.  
 
In the following chapters, I examine the role of PET and PET/CT in the management 
of primary pancreatic cancer and advanced colorectal cancer. In the first instance, the 
routine use of PET/CT using the glucose analogue tracer 18F-FDG will be examined. 
Later chapters examine the potential use of the novel thymidine analogue PET tracer 
18F-FLT, in imaging the above two malignancies. In the penultimate chapter, an in 
vitro model of colorectal cancer is also used to investigate the hypothesis that 18F-
FLT  can  be  use  to  monitor  response  to  cytotoxics,  as  a  tool  in  monitoring  and 
potentially predicting chemotherapy response.  
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CHAPTER 2 
 
Materials and Methods 
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Chapter foreword 
To avoid repetition, this chapter serves to outline the basic methodology used both for 
imaging  with  PET/CT  using  the  tracers  18F-FDG  and  18F-FLT,  as  well  as  the 
imaging  protocols  used  in  routine  contrast  enhanced  CT  scanning.  For  each 
subsequent  chapter  (chapter  3-6),  methodology  directly  relevant  to  the  individual 
study protocols is outlined in more detail. 
 
In chapter 7, I used an in vitro cell line model of colorectal cancer to examine changes 
in uptake of 18F-FLT and 18F-FDG in response to treatment with 5-fluoroyracil (5-
FU) and Cisplatin. This chapter is regarded as a stand-alone section and therefore the 
experimental methodology is described separately.  
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2.1  Patient recruitment 
In chapters 3 and 4, the incremental value of 18F-FDG PET/CT over that of routine 
contrast  enhanced  multidetector  CT  was  examined.  Here,  the  data  was  analysed  
retrospectively from a prospective database of routine referral for PET/CT imaging. 
Patients were referred for an 18F-FDG PET/CT scan from the each of the respective 
pancreatic  and  colorectal  multidisciplinary  team  (MDT)  meetings  with  suspected 
advanced cancer. A description of inclusion and exclusion criteria is outlined in each 
of the relevant chapters. 
   
Studies comparing imaging with 18F-FDG and the novel tracer 18F-FLT PET were 
performed following approval from the joint Local Ethics Committees of University 
College London (UCL) and University College London Hospital NHS Trust (UCLH) 
(appendix  A).  The  relevant  approval  from  the  Administration  of  Radioactive 
Substances Advisory Committee (ARSAC) was also obtained (appendix B). Patients 
who took part were recruited prospectively from surgical and oncology outpatient 
clinics.  Studies  were  performed  following  full  informed  consent  of  the  patients 
(Appendix C)  
   
All  patient  data sets  were stored within a departmental  computer using Microsoft 
Excel
TM software. The data were handled in accordance with the Data Protection Act. 
None of the investigations pertaining to this thesis hindered the routine investigation 
or treatment of the patients involved. 
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2.2  Whole body 18F-FDG-PET/CT scans 
2.2.1  18F-FDG 
The 18F-FDG used for studies in thesis was obtained from P.E.T Net 
Pharmaceuticals, which utilizes the cyclotron at Mount Vernon Hospital (UK). Prior 
to patient administration, a written notification from P.E.T Net Pharmaceuticals was 
obtained to ensure that the tracer had passed quality control. On delivery, 
documentation regarding the volume of liquid dispensed into the 18F-FDG vials, the 
time at which the 18F-FDG was measured prior to dispatch and the total assayed 
activity of the tracer was provided by the cyclotron unit.  The routine practice of 
tracer handling, dose calibration and dispensing followed departmental Standard 
Operating Procedures (SOP) detailed in appendix D. Using a dose calibrator and a 
decay chart a dose of up to 400MBq was prepared for patient injection.  
   
2.2.2  Patient preparation 
All patients were asked to starve for at least 6 hours prior to the 18F-FDG PET/CT 
study to achieve normoglycaemia. A patient information sheet was used to record a 
brief history of the patient as well as the patient‟s height (cm) and weight (kg) that 
was  subsequently  used  for  quantitative  image  analysis  using  standardised  uptake 
values  (SUVs).  Blood  glucose  levels  (mmol/l)  were  checked  on  a  commercial 
glucometer (Glucometer Elite, Bayer Pharmaceuticals, UK). A glucose level of less 
than 10 mmol/l was accepted as a cut off value. This was in line with the clinical 
imaging protocols set out by the Institute of Nuclear Medicine (UCLH, London, UK). 
The injected dose of tracer and the residual activity left in the syringe post injection 
were also recorded so an accurate administered dose could be calculated. 
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Prior  to  injection,  venous  access  was  achieved  through  a  16-gauge  cannula  in  a 
forearm vein. Unless contraindicated, 5mg of diazepam was routinely administered to 
all patients to aid relaxation and to reduce the uptake of 18F-FDG in skeletal muscle. 
Once injected, and in order to further minimize non-specific tracer uptake, the patient 
was  left  undisturbed  in  the  darkened  patient  preparation  room  for  45-60  minutes. 
Immediately prior to scanning, the patients were asked to empty their bladder in order 
to  reduce  high  intensity  signal  artefacts  from  the  bladder  (18F-FDG  is  renally 
excreted).  
   
The patient was positioned on the scanning bed with feet facing away from the gantry 
and with a pillow placed under the knees for comfort. Ideally, patient‟s arms were 
placed above their head, out of the way of the thorax and the abdomen. Where this 
was not possible due to physical difficulty, the arms were placed on either side and 
strapping was used to help support the arms and to keep them still.  
 
2.2.3  Acquisition of whole body 18F-FDG PET/CT scans 
Whole body 18F-FDG PET imaging was performed in 2D mode using the Discovery 
LS
TM  dual modality PET/CT scanner (GE medical systems, Milwaukee, USA). The 
PET emission datasets were attenuation corrected utilising the CT capability of the 
Discovery LS
TM (Visvikis et al. 2003). Spiral CT scans were acquired using a speed 
of rotation of 0.8 s, couch movement of 22.5 mm per rotation and a slice thickness of 
5  mm.  The  CT  images  were  subsequently  converted  to  maps  of  PET  attenuation 
coefficients using a bilinear transformation (Visvikis et al. 2003). Transaxial emission 
images  of  4.3×4.3×4.25mm
3  (matrix  size  128×128×35)  were  reconstructed  using   101 
ordered subsets expectation maximisation (OSEM) with two iterations and 28 subsets. 
These slices were re-orientated to produce whole body coronal and sagittal images. 
            
2.3  Whole body 18F-FLT PET/CT scans 
2.3.1  Radiosynthesis of 18F-FLT 
The 18F-FLT used for studies in this thesis was obtained from Hammersmith Imanet 
(Hammersmith Cyclotron Unit, UK). The method of synthesis was a fully automated 
nucleophilic  fluorination  with  18F-fluorine,  using  the  commercially  available  kit, 
Tracerlab  FXF-N  (GE  Medical  Systems)  (Figure  2.1).  The  complex  radiochemistry 
leading up to this method of 18F-FLT synthesis is beyond the scope of this thesis. The 
routine handling of the tracer again followed departmental SOPs detailed in appendix 
D. 
 
   
Figure 2.1: Tracerlab FXF-N (GE Healthcare) automated fluorination kit  
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2.3.2  Dose calibration 
Prior  to  dispatch,  the  18F-FLT  would  undergo  quality  control  testing.  The  end 
product  had  a  radiochemical  purity  of  >95%  and  a  specific  activity  of  >300 
GBq/mmol.  On  arrival  the  18F-FLT  was  assayed  using  the  dose  calibrator  in  an 
identical manner as described for 18F-FDG (section 2.2.1). 
 
2.3.3  Patient preparation and dose administration 
For 18F-FLT scanning, patients were not asked to starve, as a glycaemic state has no 
influence  on  the  rate  and  the  amount  of  tracer  uptake.  The  rest  of  the  patient 
preparation was as described for 18F-FDG in section 2.2.2. 
 
18F-FLT was injected via a peripheral vein, at a dose of up to 400 MBq. There are 
currently no established protocols that define the optimal dose of 18F-FLT suitable 
for routine clinical use. Radiation dosimetry studies of 18F-FLT PET imaging  have 
suggested that the effective radiation dose received from a 10mCi (375 MBq) dose of 
18F-FLT is in keeping with acceptable levels of radiation exposure for most nuclear 
medicine  investigations  (Vesselle  et  al.  2003).  They  also  suggested  that  a  tracer 
activity dose as low as 5 mCi (185 MBq) could provide an adequate image quality at 
60 minutes post-injection.   
 
For all 18F-FLT studies in this thesis, the maximum available dose of tracer was 
administered. In reality however, week-to-week variations in radiosynthesis meant 
that we were provided with a wide range of tracer doses. In order to standardise our 
imaging parameters (which is  particularly important  for quantitative analysis), the 
highest available dose was injected into the patient. As a compromise, care was taken   103 
to adhere to strict timing of image acquisition, which was performed at 60 minutes 
post-injection. As will be outlines in further sections, quantitative analysis was carried 
out using the SUV method, which gives a measure of tracer uptake corrected for 
differences in administered dose and patient size.  A dose of less than 5 mCi (185 
MBq) was deemed too low for acquiring an adequate image as also suggested by 
previous reports (Vesselle et al. 2003). 
 
 2.3.4  Acquisition of whole body 18F-FLT PET/CT images 
The same hardware was utilised to acquire whole body 18F-FLT images as has been 
previously described (section 2.2.3). Static 2D images were acquired at 60 minutes 
post-tracer injection.  The datasets were also attenuated corrected in the same manner.   104 
2.4  Image analysis 
Tomographic imaging with PET/CT allows reconstruction and analysis of the image 
sets in three orthogonal planes (axial, coronal and sagittal). In this thesis, all image 
sets  were  viewed  and  analysed  using  the  Xeleris  PET/CT  workstation  (GE 
Healthcare). Two methods of image analysis were performed; visual (qualitative) and 
quantitative. These are described in more detail below. 
 
2.4.1  Visual analysis 
18F-FDG and 18F-FLT PET images were acquired approximately 60 minutes post-
injection of tracer,  which correspond  to  the plateau phase of tracer accumulation. 
Visual  analysis  of  PET  images  relies  on  the  detection  of  focal  areas  of  tracer 
accumulation above that of the surrounding tissue. With 18F-FDG, high physiological 
accumulation of tracer uptake is frequently seen in brain and myocardium as these 
organs  normally  have  high  rates  of  glucose  metabolism.  More  variable  levels  of 
physiological tracer uptake are often seen in the liver, spleen, stomach, intestines, 
bone marrow and skeletal muscle. 18F-FDG is also renally excreted and therefore 
accumulation of tracer is seen throughout the urinary tract.  
 
Although  visual  analysis  is  a  simple  technique  that  is  routinely  used  for  image 
analysis in the clinical setting, it is limited by inter- and intra-observer variability. To 
account for this, all image sets were analysed by two experienced (consultant grade) 
nuclear  medicine  physicians  and  results  were  reached  by  consensus.  Where 
applicable, focal areas of tracer accumulation were graded on a 5-point scale to allow 
statistical correlation between the results of the two observers (0=definitely negative, 
1=probably negative, 2=equivocal, 3=probably positive, 4=definitely positive).    105 
Comparisons  between  18F-FDG  and  18F-FLT  studies  were  made  on  whole  body 
image sets on a lesion-by-lesion basis. Comparisons between the detection rate of 
PET, PET/CT and routine ceCT studies were also made on a patient-by-patient basis. 
 
2.4.2  Quantitative analysis 
In  addition  to  obtaining  qualitative  data,  semi-quantitative  methods  have  been 
developed  for  measuring  tracer  uptake.  One  such  method  is  calculation  of 
standardized uptake value (SUV), which is carried out using the following formula; 
 
inj
SUV
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where (A) is the average tumour activity concentration kBq/ml, (W) is the patient‟s 
body weight in kg and (Ainj) is the injected activity in kBq (Takeuchi et al. 1999; 
Graham et al. 2000). 
 
The  above  parameters  allow  correction  of  tissue  tracer  uptake  for  variations  in 
injected activity and patient‟s body weight. The resultant SUV value thus represents  
an index of tracer accumulation within a tissue, which for example can be used to 
differentiate benign from malignant pathology. Serial measurements can also be used 
to quantify response to treatment.  
 
SUV calculations are now automated as they are a standard function incorporated into 
most PET workstation software. For the purposes of this thesis, SUV measurements 
were performed using a fixed (1cm) region of interest (ROI). As there are currently no 
standardised  methodologies  for  SUV  determination  of  a  tumour,  therefore  three   106 
different  SUV  measurement  strategies  were  used  which  are  detailed  below  and 
illustrated in figure 2.1. 
1)  SUVMax – determines the maximum pixel value within the selected 1 cm ROI 
2)  SUVMean(single  slice)  –  determines  the  average  SUV  value  within  a  1cm  ROI 
centred on the slice with the maximal 18F-FDG uptake (ie: the one with the SUVMax) 
3)  SUVMean(multiple  slices) – determines an average of mean SUV values  2 slices      
above and below the slice with the maximum SUV 
 
 
Methods 1 & 2 
   
                    Method 3 
Figure 2.1: Comparison between methodologies for determining tumour SUV 
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Previous work at our unit (data not presented) had shown methods 2 and 3 to yielded 
similar results with strong correlation. Maximum pixel values (SUVMax) tended to 
give a more reproducible measure. Method 3 on the other hand takes an average 
reading across several adjacent axial image slices, and thus considered to better 
account for tumour heterogeneity. Therefore two methods of SUV determination were 
used in this thesis, which is referred to as SUVMax and SUVMean.   108 
2.5  Computed Tomography imaging protocols 
2.5.1  Patient preparation 
i) Contrast enhanced CT scan of the thorax, abdomen and the pelvis 
Patients were asked not to eat anything for four hours prior to the scan but were 
allowed to drink non-fizzy drinks up to one hour before the scan. No other special 
preparations were required. Oral contrast agents were given just prior to scanning of 
the abdomen and the pelvis. 
 
ii) Pancreatic protocol CT 
Patients were asked to fast prior to the scan as for a routine imaging the abdomen and 
the pelvis detailed above. 200-500 ml of water was given to the patient orally, 30 
minutes before the scan; water acted as a negative contrast agent, helping to distend 
the stomach and the duodenum.  
 
2.5.2  Image acquisition 
i) Abdomen, pelvis and liver 
Scans of the abdomen and pelvis were acquired using the Siemens Somatom Plus 4, 
multidetector  (4  slice)  spiral  CT  (Siemens  AG  Medical  Engineering  Group, 
Forchheim, Germany). Images were contrast enhanced with 100 ml of intravenous 
iodinated contrast material (Omnipaque 350, Nycomed Amersham plc, Amersham 
Place, Little Chalford, Buckinghamshire) infused via a peripheral vein at 4mls/sec. 
and a delay of 45 seconds. Enhancement of the bowel was also carried out using oral 
contrast material as outlined above (2.5.1). 
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The scanning protocol of the abdomen and the pelvis involved imaging at 120 kV, 
140-280 mA and 1mm collimation. Bi- or triphasic imaging of the liver was carried 
out  at  delays  of 20s,  50s,  180s  and using  a 2.5mm collimation. All  images  were 
reconstructed at 3 and 5mm slice thickness.  
 
ii) CT scan of the chest 
Standard, non-contrast enhanced scans were performed as detailed above. 
 
iii) Contrast enhanced pancreatic protocol CT  
An unenhanced scan of the abdomen was first obtained to determine the upper and the 
lower boundaries of the pancreas and to detect pancreatic calcification. Using a bolus 
track technique, the pancreas was imaged at peak arterial phase. Briefly, a region of 
interest was placed over a representative section of the pancreas. The patient was then 
given  a  bolus  infusion  of  20-50  mls  of  iv  contrast  material  (Ominopaque  350  at 
5mls/sec.),  while  dynamic  CT  acquisition  was  performed  over  the  single  slice 
containing the ROI. Using the software integrated into the CT workstation, the time at 
which  the  pancreas  achieved  maximal  enhancement  was  calculated.  Contrast 
enhanced images of the entire pancreas were then acquired at the peak arterial phase 
and at 120 keV, 140-280 mAs and 1mm collimation. Images of the pancreas were 
reconstructed at 1 and 3mm slice thickness. Portal-venous phase images of the liver 
were also acquired at 60 seconds delay, 2.5 mm collimation and reconstructed at 5mm 
slice thickness. 
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2.5.3  Image reconstruction and analysis 
All data was processed on the CT scanner Siemens workstation where images were 
reconstructed accordingly. Images were usually formatted into the transaxial plane, 
but when necessary coronal and sagittal prints were produced.   
A senior radiologist (specialist registrar or consultant grade) evaluated all images. In 
addition, all CT scans were presented at a weekly CRC MDT meeting where they 
were  re-evaluated  by  a  Radiologist  of  consultant  grade.  All  films  were  visually 
analysed.  
 
 
2.6  Confirmation of diagnosis and follow-up 
All patients studied in this thesis were managed in a multidisciplinary team (MDT) 
setting, in accordance with Department of Health (DoH) guidelines for optimal cancer 
management.  The  MDT  consisted  of  both  medical  and  allied  health-care 
professionals.  This  included  radiologists,  nuclear  medicine  physicians,  surgeons, 
oncologists  and  cancer  specialist  nurses.  This  group  made  consensus  decisions 
regarding the clinical management of complex cases and therefore formed an ideal 
forum to present both the PET/CT and the CT data in order to decide management 
based on the relevant clinical information.  
 
All  diagnoses related to  this  thesis  were confirmed by histology and/or following 
clinical, radiological or surgical follow-up of the patient, within the respective MDT 
forums of the cancer being studied.     111 
CHAPTER 3 
 
Does 18F-FDG PET/CT play a role 
in the routine management of 
pancreatic cancer? 
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3.1 Background 
Contrast enhanced computed tomography (ceCT) is at present the first line imaging 
modality of choice for diagnosing and staging pancreatic cancer. Multi-detector spiral 
CT allows fast  image  acquisition with  thin collimated sections  that  gives  ceCT  a 
positive predictive value for tumour detection of over 90% and an ability to correctly 
identify non-resectability in almost 100% of the cases (Freeny et al. 1993; Bluemke et 
al. 1995; Diehl et al. 1998; Freeny 2001). Despite this, ceCT has been shown to have 
limitations that can potentially result in mis-staging of the disease. A study by Saisho 
and Yamaguchi (2004) in fact showed ceCT staging to be accurate in 65.7%, while 
under-staging 25.7% and over-staging 8.6% of the cases. 
 
Several studies to date have suggested PET to be of value in the routine management 
of  pancreatic  cancer.  18F-FDG  PET  has  been  demonstrated  to  be  superior  to 
conventional  imaging  modalities  in  assessing  small  pancreatic  tumours  (<2cm) 
(Delbeke et al. 1999), differentiating benign from malignant disease (Imdahl et al. 
1999)  and  particularly,  in  accurately  determining  the  extent  of  extra-pancreatic 
disease (Zimny et al. 2000; Jadvar and Fischman 2001; Nakata et al. 2001). What 
imaging  with  PET  lacks  is  the  anatomical  information  that  would  allow  precise 
localisation  of  PET  positive  lesions.  This  limitation  has  been  addressed  with  the 
introduction  of  dual  modality  PET/CT  scanners.  However  to  date,  there  is  little 
evidence supporting the use of the 18F-FDG PET/CT in the routine assessment of 
pancreatic cancer.   113 
3.2 Aims 
The aims of this study were: 
1.  to compare the diagnostic and staging accuracy of 18F-FDG PET/CT to that 
of conventional imaging with ceCT. 
2.  to  evaluate  the  impact  of  routine  PET/CT  imaging  on  the  management 
algorithm of pancreatic cancer.  
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3.3 Methods 
3.3.1 Patient recruitment 
This study was a retrospective analysis of consecutive patients referred for an 18F-
FDG PET/CT scan between 2003 and 2005. Patients were included in the analyses 
who meet the following two inclusion criteria: 
1)  A patient with a suspected diagnosis of pancreatic cancer 
2)  The  patient  having  undergone  a  contrast  enhanced  pancreatic  protocol  CT 
(ceCT) scan within 2 weeks of the 18F-FDG PET/CT study. 
 
The primary outcome measure in this study was the impact of 18F-FDG PET/CT on 
the  management  of  this  cohort  of  patients.  Consequently,  the  finalised  PET/CT 
reports provided to the referring clinicians were retrospectively compared with the 
ceCT  results.  Patient  management,  as  decided  by  consensus  by  the  hepatobiliary 
multidisciplinary  team  was  recorded  and  correlated  with  clinical,  radiological  and 
surgical outcomes. Patients were followed-up for a median duration of 13 months 
(range of 2-24 months).   
 
3.3.2 Imaging protocols 
a) 18F-FDG PET / CT 
Imaging protocols for 18F-FDG PET/CT scans are detailed in section 2.2.  
 
Images were acquired at a median of 58 minutes (range 48-65 minutes) post-injection 
of tracer. A median dose of 378 (range 300-410) MBq of 18F-FDG was administered. 
Patients were required to drink 200 ml of water, 5 minutes prior to being placed on 
the scanner bed. This step was only undertaken in acquiring PET/CT images of the   115 
pancreas, with water acting as a negative contrast agent in delineating the duodenum. 
No intravenous contrast agents were used.   
 
All  images  were  analysed  qualitatively  (visually)  by  a  senior  (consultant  grade) 
nuclear medicine physician. A lesion was deemed positive for malignancy if its 18F-
FDG PET activity was greater than the background. A lesion with activity less than or 
equal to the background was deemed negative. 
 
b) Contrast Enhanced Pancreatic Protocol CT (ceCT) 
Patient preparation and imaging protocols for pancreatic protocol ceCT are described 
in  chapter  2.5.  All  ceCT  scans  were  reported  by  a  senior  (consultant  grade) 
radiologist.  Information  was  provided  regarding  the  presence  or  absence  of  a 
pancreatic mass, degree of suspicion of malignancy, local (eg: vascular) invasion, 
presence of peri-pancreatic lymphadenopathy and extrapancreatic disease.  
 
3.3.3 Data presentation 
Imaging results are classified as true positive (TP), false positive (FP), true negative 
(TN) and false negative (FN). Sensitivity, specificity, accuracy, positive and negative 
predictive  values  were  calculated  using  standard  formulae.  The  difference  in 
detection  accuracy  of  the  two  imaging  modalities  were  compared  using  the 
McNemar„s test for correlated proportions. Two tailed p values of <0.05 were  
considered as  statistically significant.  116 
3.4 Results 
3.4.1 Patient demographics 
51 patients were included in this analysis. There were 32 males, 19 females with a 
median age of 62 years (range 30-82 years). Patient demographics are summarized in 
table 3.1.  
 
          (%) 
Age (median , range)  62 yrs (30-82)  - 
       
       
Sex (M:F)    1.7 : 1  - 
       
Site of pancreatic mass     
Head    47  (92%) 
Body    2  (4%) 
Tail    2  (4%) 
       
Histological diagnosis     
Adenocarcinoma    39  (76%) 
Benign    9  (18%) 
   
(1 Tuberculous cyst, 
8 mass forming chronic pancreatitis)   
       
Final stage group 
(n=39)       
IA/B    7  (18%) 
IIA/B    12  (31%) 
III    9  (23%) 
 IV     11  (28%) 
       
 
Table 3.1: Summary of patient demographics with suspected pancreatic cancer 
 
The final diagnosis was histologically confirmed in 48 patients (94%). Of these, as 39 
(76%) were adenocarcinoma and 9 (18%) were found to be benign. In 3 patients (6%) 
where  histological  analysis  was  not  performed,  pancreatic  lesions  were  later 
confirmed to be benign by clinical and radiological follow-up for a median duration 
of 10 months (range 8-19 months). 
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3.4.2 Diagnosis of the primary pancreatic lesion 
Imaging results were compared on a lesion-by-lesion basis for all pancreatic lesions. 
Table 3.2 compares the imaging accuracy of 18F-FDG PET/CT and ceCT.  
 
 
 
 
 
 
 
 
 
 
Table 3.2: The detection accuracy of 18F-FDG PET/CT compared to ceCT.  
(TP: true positive, TN: True negative, FP: False positive, FN: False negative, PPV: 
positive predictive value, NPV: negative predictive value) 
 
PET/CT  resulted  in  2  false  negative  (both  histology  showing  mucinous 
adenocarcinoma) and 3 false positive results (one tuberculous cyst of the pancreas, 2 
due to chronic pancreatitis). In 9 cases (18%) pancreatic lesions seen on eCT were 
reported  as  equivocal  but  highly  suspicious  for  malignancy.  Of  these,  7  lesions 
showed no focal 18F-FDG accumulation thus suggesting benign disease. Histology 
confirmed these lesions to be due to chronic pancreatitis, thus correctly corresponding 
to the diagnosis made by 18F-FDG PET/CT.  Figure 3.1 illustrates one such example.   
As indicated above, the remaining 2 lesions were also falsely positive on 18F-FDG 
PET/CT.  Overall for ceCT therefore, there were 7 false positive and 1 false negative 
        
18F-FDG  
PET/CT 
 
   ceCT 
                   
TP      37      38 
TN      9      5 
FP      3      7 
FN      2      1 
Total      51      51 
             
Sensitivity(%)      95      97 
Specificity (%)      75      42 
PPV (%)      93      84 
NPV (%)      81      83 
Accuracy (%)      90      84 
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result (the latter being a subcentimetre primary lesion later found on EUS guided 
biopsy to be adenocarcinoma).  
 
 
 
Figure 3.1: Transaxial ceCT image (a) demonstrating a poorly enhancing mass in the 
uncinate process of the pancreas, with involvement of per-pancreatic vessels (V= 
Superior mesenteric vein (SMV); A= Superior mesenteric artery (SMA)). No uptake of 
18F-FDG was observed in the PET (b) and PET/CT (c) fused images. The mass was 
later proven on histology to be due to mass forming chronic pancreatitis. 
 
The sensitivity of 18F-FDG PET/CT was similar to ceCT (95% vs 97% respectively; 
 p=1.0; McNemar‟s test). The specificity of 18F-FDG PET/CT was superior to 
ceCT,  but  this  difference  did  not  reach  statistical  significance  (75%  vs  42% 
respectively; 
2=2.25, p=0.1336).  Overall accuracy of both  imaging modalities were 
also similar (18F-FDG PET/CT=90 vs ceCT=84; 
2=0.80, p=0.371) 
a)  ceCT                b) 18F-FDG PET         c) 18F-FDG PET/CT   119 
3.4.3 Staging accuracy of pancreatic cancer with 18F-FDG PET/CT 
3.4.3.1 Local (T) and nodal (N) staging   
Of the 39 proven pancreatic cancers, initial staging with ceCT deemed 10 cases (26%) 
to be locally resectable (T 1-2, stage I). At the time of surgery, 3 cases were found to 
be inoperable. Thus ceCT underestimated the extent of local disease in 8% of cases. 
In  local  staging,  18F-FDG  PET/CT  did  not  conclusively  provide  any  additional 
information  to  ceCT.  This  occurred  as  the  combination  of  PET‟s  limited  spatial 
resolution, the non-diagnostic nature of the CT component of PET/CT and the lack of 
intravenous  contrast  enhancement  to  delineate  vascular  structures  preventing  from 
accurately determining the exact size and local spread of the tumours. 
 
The ceCT criteria for detecting spread to loco-regional lymph nodes routinely use the 
short  axis  diameter  of  the  node  as  marker  of  abnormal  lymphadenopathy.  In  this 
study, macroscopically enlarged (> 7 mm) lymph nodes were detected in 5 patients, 
all of whom were confirmed to  have a pancreatic carcinoma. Although in  all the 
above cases, the enlarged nodes were seen on the CT component of PET/CT, they 
were reported as positive lymph nodes only if focal accumulation of 18F-FDG was 
demonstrated on the PET/CT scan. As for this, 18F-FDG PET/CT identified loco-
regional lymph nodes in 3 of the above 5 patient (60%). As histological sampling of 
these  lymph  nodes  were  not  carried  out  for  any  of  the  above  5  patients,  it  is 
impossible to determine the accuracy of 18F-FDG PET/CT in correctly staging nodal 
disease. In fact in two of the 5 patients, there was a biliary stent in situ. Therefore 
without  histological  examination,  it  was  impossible  to  ascertain  whether  the  peri-
portal  lymphadenopathy  detected  on  both  the  ceCT  and  18F-FDG  PET/CT  were 
reactive or due to malignant spread. In addition to the above, histology from resected   120 
tumour  specimen  in  3  further  patients  (6%)  showed  microscopic  peri-pancreatic 
lymph  node  spread  (N1  disease).  None  of  these  were  detected  by  either  imaging 
modality. 
 
3.4.3.2 Detection of distant metastases 
The prevalence of metastatic disease (stage IV disease) in this series was 28% (11/39 
patients) with histological / radiological follow-up confirming the presence of a total 
29 metastatic lesions. Table 3.3 summarises the distribution of extrahepatic lesions 
detected by the two imaging modalities. 
 
Of the 39 patients with confirmed malignancy, 5 (13%) had indeterminate hepatic 
lesions, which were highly suspicious for metastases. Of these, 18F0FDG PET/CT 
correctly interpreted the lesions as benign in 4 cases (10%) and one as a malignant 
deposit. In one patient, ceCT incorrectly detected liver and lung metastases, whereas 
18F-FDG  PET/CT  showed  no  tracer  uptake  in  either  lesion.  Histology  was  in 
concordance with the PET/CT findings, resulting in down-staging of the patient from 
M1 to M0. In 7 patients (18%), 18F-FDG PET/CT detected ceCT occult metastases 
thus upstaging the patient from M0 to M1 disease. An example is illustrated in figure 
3.2. In 3 patients solitary metastases to the liver were noted on the ceCT. In these 
cases,  18F-FDG  PET/CT  localized  additional  metastatic  deposits  missed  by  ceCT 
both  in  the  liver  and  at  extra-abdominal  sites.  This  however  did  not  change  the 
radiological stage of the patients. Therefore overall, 18F-FDG PET/CT resulted in an 
alteration of staging of 12 out of 39 patients (31%) by down-staging 13% (5 cases, 
including 4 with equivocal ceCT results) and upstaging 18% of cases. False positive 
findings with 18F-FDG PET/CT occurred in 3 patients (8%). These were as a result of   121 
18F-FDG  uptake  in  mediastinal  granuloma,  a  reactive  hilar  lymph  node  and  a    
vertebral  lesion  which  was  found  to  be  negative  on  bone  scintigraphy  and  bone 
marrow biopsy. In one patient (3%), a liver metastasis was clearly identified on the 
ceCT scan but one which did not take up any 18F-FDG. This was later histologically 
confirmed to be a mucinous adenocarcinoma.  
 
  
ceCT detected                          
metastases 
18F-FD PET/CT detected 
metastases 
Indeterminate ceCT 
findings 
Indeterminate liver lesion  Negative (benign) 
Indeterminate liver lesion  Negative (benign) 
Indeterminate liver lesion  Negative (benign) 
Indeterminate liver lesion  Negative (benign) 
Indeterminate liver lesion  Liver (segment IV) and lung  
(?Haemangioma)  metastases 
Downstaged disease 
     
Liver and lung metastases  Negative  
     
   Negative  Liver (segment IV)   
Upstaged disease   Negative  Liver (segment VI) 
(ceCT occult 
metastases) 
Negative  Liver (segment VIII) 
Negative  Liver (segment VII), 
peritoneal deposits 
   Negative  Peritoneal deposits 
False positives  Negative  Mediastinal lymph node 
   Negative  Hilar lymph node 
   Negative  Bone lesions (body of T4) 
        
False negatives  Liver metastasis (segment VIII)  Negative (mucinous adenoca) 
        
PET\CT detecting 
additional metastases 
Liver  Liver/lung/bone/peritoneum 
Liver (segment VIII)  Liver (segment I, III, VIII) 
Liver  Liver, bone (scapula & 
humerus)    
 
Table 3.3: Summary of the distribution of metastatic deposits detected by ceCT and 
PET/CT 
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 Figure 3.2: Whole body 18F-FDG PET/CT image of a patient with a carcinoma of 
the head of the pancreas (shown on the Maximum Intensity Projection (MIP) image 
(a)  –  thick  black  arrow).  An  indeterminate  sub-centimetre  liver  lesion  seen  on 
ceCT(b) was found to be 18F-FDG avid, thus representing a metastatic deposit. This 
is shown on the PET (c) and the PET/CT (d) fused images (lesion circled in each 
image). 18F-FDG PET/CT also detected a ceCT occult lung metastasis (not shown) 
thus resulting in upstaging the patient from M0 to M1.  
 
a)  MIP  c)  18F-FDG PET 
b)  ceCT 
d)  18F-FDG PET/CT   123 
3.4.4 Additional findings 
In one patient, focal 18F-FDG accumulation was localised to the ascending colon on 
the  PET/CT.  There  was  however  no  corresponding  abnormality  noted  on  ceCT. 
Colonoscopic examination revealed a 2cm sessile polyp, which was later found on 
histology to be a tubulo-villous adenoma with high-grade dysplasia and no evidence 
of invasiveness (Figure 3.3) 
 
 
Figure 3.3: Maximum intensity projection (MIP) of 18F-FDG PET (a) and the 
concurrent 18F-FDG and 18F-FDG PET/CT fused images of the primary pancreatic 
lesion (b,c). A second area of focal 18F-FDG accumulation was also detected in the 
right lower quadrant of the abdomen. This was localized on the18F-FDG PET/CT 
fused images to a loop of colon (d,e). Colonoscopic examination showed a 2cm sessile 
polyp (f).  
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3.4.5 The impact of 18F-FDG PET/CT on clinical management 
As  presented  earlier,  in  9  of  the  51  patients  (18%)  the  ceCT  report  indicated  an 
equivocal but highly suspicious mass in the pancreas. In 7 of these cases (14%), 18F-
FDG PET/CT correctly characterized these lesions as benign therefore a futile course 
of  treatment  for  a  carcinoma  was  avoided.  Of  the  39  patients  with  confirmed 
malignancy, 18F-FDG PET/CT changed the clinical stage of the disease in 12 (31%). 
This however resulted in a change in management of only 2 patients (5%). These 
were cases with apparently resectable pancreatic tumours on ceCT, but where 18F-
FDG  PET/CT  detected  occult  metastases.  The  remaining  10  (26%)  patients  were 
found to have a locally advanced and inoperable disease based on the initial ceCT 
criteria  and  therefore  detection  of  either  ceCT  occult  metastases  or  additional 
extrapancreatic  deposits  did  not  change  the  subsequent  management.  Overall 
therefore, 18F-FDG PET\CT directly resulted in a change in management of 9/51 
patients (18%).  
 
If the 18F-FDG PET/CT findings were considered alone, false findings would have 
had a negative impact on the management of 5 patients (10%). 2 patients (4%) with a 
false negative primary lesion would have been incorrectly treated conservatively, and 
3 patients (6%) with false positive distant metastases would have been incorrectly 
managed  palliatively.  In  the  latter  3  patients,  the  extrapancreatic  lesions  were 
histologically  confirmed to  be benign disease and thus  the primary tumours were 
resected.  
   125 
3.5 Discussion 
In  this  study,  ceCT  and  18F-FDG  PET/CT  showed  comparable  sensitivities  for 
detecting  primary  pancreatic  lesions  (97%  and  95%  respectively).  The  lower 
sensitivity of 18F-FDG PET/CT resulted from two false negative PET/CT findings, 
both of which were histologically found to be mucinous adenocarcinoma. This low-
grade  uptake  of  18F-FDG  in  mucinous  tumours  which  has  been  attributed  to  the 
relatively low cellularity of mucinous tumours and the abundance of glycopeptide rich 
mucin that is thought to compete with 18F-FDG for binding sites (Berger et al. 2000).  
 
While of comparable sensitivity, the specificity of 18F-FDG PET/CT was superior to 
that  of  ceCT  (78%  vs  42%  respectively),  although  this  difference  did  not  reach 
statistical significance. Lesion characterisation with ceCT is limited by the fact that 
morphological features cannot reliably distinguish benign from malignant pathology. 
As PET targets biological changes associated with malignancy, focal abnormalities 
can be detected independent of morphology. In this series, equivocal ceCT findings in 
7 patients (14%) with a pancreatic mass were correctly confirmed as benign following 
a  negative  18F-FDG  PET/CT  result.  Conversely,  the  presence  of  focal  tracer 
accumulation  in  small  lesions  such  as  those  in  the  liver,  were  more  accurately 
confirmed with 18F-FDG PET/CT. It is however important to note that the PET/CT 
findings cannot be considered in isolation due to false positive and false negative 
results.  As previously  mentioned, false negative results  may be seen in  mucinous 
tumours.  More  commonly  however,  false  positive  findings  occur  due  to  the 
accumulation of 18F-FDG in areas of active or chronic inflammation as macrophages 
and  activated  lymphocytes  exhibit  an  enhanced  glycolytic  rate  and  thus  a  higher 
cellular uptake of 18F-FDG (Ishimori et al. 2002; Kaim et al. 2002). The pattern of   126 
uptake of 18F-FDG in areas of inflammation is often low-grade and diffuse, which 
together with the clinical history and the presence of pancreatic calcification seen on 
the CT component of PET/CT, may help in avoiding diagnostic uncertainty. Until 
such time a more specific PET tracer emerges, focal areas of 18F-FDG uptake in 
equivocal cases require histological verification. 
 
This  study purposefully did  not  use semi-quantitative analysis of tracer uptake in 
detecting malignant lesions.  The use of Standardised Uptake Values (SUVs) of a 
lesion has been suggested to improve PETs specificity, where several studies have 
shown SUV values for inflammatory lesions to be lower than that for malignant ones. 
Using a cut-off SUV value of 4 for malignant lesions and SUV of 3-4 for chronic 
pancreatitis, Imdahl et al. (1999) showed 18F-FDG PET to be able to differentiate 
between cancer and inflammation with a sensitivity of 96% and 100% respectively. In 
a larger series of patients with a suspected pancreatic cancer (n=86; 65 malignant, 21 
benign) Koyama et al. (2001) found that a serum glucose corrected SUV threshold of 
2.2 gave the optimal diagnostic accuracy for 18F-FDG PET. Delayed imaging during 
the glycolytic plateau phase of 18F-FDG uptake has also been suggested to improve 
specificity  but  this  requires  further  validation  (Nakamoto  et  al.  2000).  The  main 
limitation  of  using  SUVs  in  the  routine  assessment  of  PET  images  is  the  as  yet 
undetermined  standardized  SUV  threshold  that  defines  malignancy.  Furthermore, 
there are no standardized protocols that define how an SUV should be measured as 
this also has a significant bearing on the values obtained. Consequently, as this study 
mirrored our routine clinical practice of imaging with 18F-FDG PET/CT, quantitative 
analysis was not employed.  
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The main determinant of operability of a tumour is its extent of local peri-pancreatic 
spread  and  vascular  involvement.  While  ceCT  has  been  shown  to  be  accurate  in 
detecting inoperable lesions, its positive predictive value in detecting resectability can 
be poor. In our series for example, ceCT underestimated the extent of local disease in 
8% (3/39) of all malignant cases, or in other words, 33% (3/10) of all cases deemed 
operable by ceCT. Despite this shortcoming, ceCT remains the imaging of choice for 
local (T) staging of disease as 18F-FDG PET/CT did not confer an advantage.  The 
inability  of  18F-FDG  PET/CT  to  accurately  stage  local  disease  (T  staging)  is 
multifactorial. Firstly, the positron-emitting source from a lesion is not a point source 
and therefore the borders of the tumour cannot be defined according to the boundaries 
of the 18F-FDG “hot-spot”. Furthermore, the CT component of PET/CT is solely 
used as a means of lesion localization, which is acquired at a low power and thicker 
slice  width  to  minimize  radiation  exposure  to  the  patient.  The  resultant  poor 
resolution  CT  images  therefore  prevent  an  accurate  assessment  of  local  tumour 
invasion to be made. Lastly, at the time of this study our local imaging protocols did 
not routinely use intravenous contrast material when acquiring the PET/CT images. 
This  was  in  large due to  anecdotal evidence suggesting that high-density contrast 
material may result in image artefacts and therefore interfere with the interpretation of 
18F-FDG PET data (Cohade et al. 2003b; Visvikis et al. 2003). Once again therefore, 
an accurate assessment of local vascular involvement (and thus tumour resectability) 
could not be made with our current PET/CT imaging protocols. There is emerging 
evidence to suggest that contrast material may be successfully used as part of the 
routine PET/CT imaging protocol. This however requires formal investigation and 
validation.  
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In  assessing  local  lymph  node  involvement,  morphological  imaging  with  ceCT  is 
limited by the fact that lymph node size is a poor predictor of malignant spread. In 
this respect molecular imaging with PET (theoretically) confers an advantage as it 
may  detect  tumour  spread  to  lymph  nodes  based  on  their  metabolic  activity  and 
irrespective of their size. In lung cancer, 18F-FDG PET has been frequently reported 
to be superior in detecting mediastinal nodal spread (Patz et al. 1995) so much so that 
it is now become a mandatory investigation in the routine pre-operative assessment of 
lung tumours. In pancreatic cancer the evidence to date seems to indicate that 18F-
FDG  PET  may  be  unsuitable  for  routine  staging  of  loco-regional  lymph  nodes 
(Diederichs et al. 2000; Heinrich et al. 2005). Results from our study were severely 
limited  by  the  fact  that  routine  histological  sampling  of  abnormal  looking  lymph 
nodes was not carried out. As a result, the exact sensitivity and specificity for nodal 
staging could not be reported for either ceCT or PET/CT. Assessment on a patient-by-
patient basis revealed 5 cases where suspiciously enlarged loco-regional lymph nodes 
were seen on the ceCT images. Of those, only 3 cases (60%) demonstrated significant 
18F-FDG accumulation to be deemed positive. In further 3 cases that underwent a 
successful resection, histology confirmed the presence of microscopic lymph node 
spread (N1 disease), but none of these were detected by either imaging modality.  
 
Despite  the  limitations  of  our  study,  our  findings  concur  with  previous  reports, 
suggesting 18F-FDG PET/CT to be of limited value in staging loco-regional lymph 
node involvement. While theoretically 18F-FDG PET may be useful here, there are 
several potential factors at play that can limit the accuracy of 18F-FDG PET/CT in 
detecting lymph node disease. It is generally accepted that the spatial resolution of 
PET is limited to detecting lesions larger than 1cm, although that quoted by many   129 
manufacturers  is  between  0.5-0.8cm.  This  is  believed  not  to  be  an  accurate 
generalization as lesion detectability with PET is dependent on the metabolic activity 
of  disease  and  not  size.  The  challenge  faced  by  detecting  lymph  node  disease  is 
therefore likely to be one of the volume of metastatic disease within the node, which 
is often small, thus accumulating relatively less tracer. Such low-grade tracer uptake 
is consequently subject to partial volume effects, which can diminish the sensitivity of 
PET. Furthermore, a weak tracer signal from the loco-regional nodal basin may be 
obscured by  the intense tracer uptake  within the primary  lesion,  thus  resulting in 
positive lymph nodes being missed. It is clear that the sample size of our study and 
many of those published in the literature are too small to allow this to be adequately 
assessed.  Therefore  given  the  evidence  to  date,  the  indications  are  that  18F-FDG 
PET/CT  plays  a  limited  role  in  nodal  staging  of  pancreatic  cancer.  There  may 
however be a role for PET/CT image fusion in assessing lymph node disease where 
image  fusion  may  augment  the  accuracy  of  lymph  node  staging  by  combining 
metabolic  and  morphological  criteria.  Future  validating  studies  are  required  to 
confirm this.   
  
One of the frequently reported advantages of imaging with 18F-FDG PET has been 
the  whole  body  evaluation  of  metastatic  spread.  Foci  of  18F-FDG  uptake  can  be 
detected with great sensitivity in the liver, lungs and the bones, owing to the high 
degree of contrast that is achieved between the lesion and the surrounding normal 
tissues (Nishiyama et al. 2005). In our series, 18F-FDG PET/CT resulted in detection 
of occult metastases in 7 out of 39 (18%) patients that had histological confirmation 
of malignancy. Majority of lesions missed on ceCT were hepatic metastases. This 
shortcoming  of  ceCT  is  often  due  to  intrahepatic  duct  dilatation  due  to  biliary   130 
obstruction making interpretation difficult. This in our series did not interfere with the 
PET  images.  Where  18F-FDG  PET/CT  seemed  to  be  advantageous  was  also  in 
localizing and differentiating peritoneal deposits from areas of physiological uptake 
within  the  abdominal  cavity.  Due  to  time  constraints  of  this  thesis  however,  the 
incremental value of PET/CT over PET alone was not formally examined. Whilst 
overall 18F-FDG PET\CT resulted in change in radiological stage of the disease in 
31% of proven cancers, the impact on management in this group occurred in 2 cases 
(5%) where the primary disease was deemed to be operable and PET/CT detected 
occult metastases. The impact of 18F-FDG PET\CT on the management of pancreatic 
cancer  is  largely  dependent  on  the  therapeutic  algorithm  that  is  used.  At  our 
institution,  a  curative  pancreaticoduadenectomy  is  offered  to  patients  with  locally 
resectable tumour (operability determined based on ceCT criteria), and the proof of 
absence of distant spread. Conversely, patients with inoperable disease are offered 
palliative chemotherapy and/or a biliary bypass operation. This underlines the vital 
need for accurate pre-operative assessment of local and metastatic disease burden. 
Furthermore, unless changes in PET/CT imaging protocol allow for more accurate 
assessment  of  local  tumour  spread,  the  impact  of  18F-FDG  PET/CT  is  only  best 
demonstrated once tumour respectability is fully assessed using ceCT, where it may 
help to definitively exclude metastatic disease. Overall, 18F-FDG PET/CT changed 
the management of 18% (9/51) of the whole series, predominantly due to its role as a 
means of further characterizing primary lesions. In our series, 7 of the 9 suspicious 
but equivocal lesions in the pancreas seen on ceCT were correctly characterized by 
18F-FDG  PET\CT  as  benign  lesions,  thus  resulting  in  the  patients  avoiding 
unnecessary and potentially futile treatment.   
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3.6 Conclusions 
 
In detecting pancreatic cancer, 18F-FDG PET/CT demonstrated a superior specificity 
compared to ceCT while the sensitivities of the two imaging modalities were similar. 
With regard to loco-regional staging, 18F-FDG PET/CT played a limited role in both 
local (T) and lymph node (N) staging of disease. The indications are therefore that 
18F-FDG PET/CT is best applied as a complimentary imaging tool to conventional 
imaging (ceCT), either as a problem solving tool in assessing equivocal cases or as a 
means of excluding extrapancreatic disease in patients deemed to have an operable 
tumour.    132 
CHAPTER 4 
 
Does 18F-FDG PET/CT provide 
additional information to 
conventional imaging 
in the management of 
colorectal liver metastases? 
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4.1 Background 
Pre-operative  selection  of  patients  for  liver  resection  heavily  relies  on  accurate 
information provided by routine crossectional imaging modalities such as CT and 
MRI.  Although  the  widespread  use  of  contrast  enhanced  CT  (ceCT)  has  made  a 
significant  impact  on  the  management  of  CLM,  pre-operative  staging  remains  a 
clinical challenge. This is obviated by the fact that up to 20% of patients undergoing 
liver resection are found to have inoperable disease at laparotomy and up to 60% are 
reported  to  develop  recurrences  within  3  years  following  a  successful  resection 
(Scheele et al. 1995; Fong et al. 1997).   
 
As discussed in chapter 1, a major limitation of imaging with a stand alone PET 
scanner  is  its  relative  lack  of  anatomical  resolution.  This  is  where  dual  modality 
imaging with PET/CT confers advantages through the co-registration of anatomical 
and  biological  data,  which  arguably  helps  to  combine  the  strengths  of  the  two 
modalities. A number of early studies have consistently suggested 18F-FDG PET to 
be superior to CT in detecting and staging liver metastases. More recently however, 
there are indications that the difference between the two modalities may have been 
somewhat overestimated. The predominant factor may be due to the widespread use 
of multidetector, fine slice ceCT that has narrowed the gap between the capabilities of 
these two modalities (Truant et al. 2005). Overall, 18F-FDG PET seems to provide 
specific advantages over routine imaging in advanced CRC and its clinical impact has 
been shown to occur in up to 29% of cases (Huebner et al. 2000). The question that 
therefore remains is whether 18F-FDG PET or PET/CT should be routinely applied in 
this setting and if not, is there a subgroup of patients that may benefit most from 
having a PET (or PET/CT) scan incorporated into their management algorithm.    134 
 
Currently there are no established protocols for the use of 18F-FDG PET in primary 
or  recurrent  CRC.  Institutional  preferences  are  therefore  heavily  swayed  by  the 
relative cost and availability of PET scanners.  One approach to a rational patient 
selection protocol may be with the use of a clinical scoring tool such the Clinical Risk 
Score (CRS). CRS was first described by Fong et al. (1999a) as a prognostic tool, 
allowing patients to be stratified according to their risk of recurrence prior to hepatic 
surgery for CLM. Multivariate analysis identified five criteria, which are as follows: 
 
1)  Nodal status of the primary tumour 
2)  Disease free interval from the primary to discovery of the liver metastasis of 
<12 months 
3)  Number of tumours of >1 
4)  Pre-operative CEA level of >200 ng/ml 
5)  Size of the largest tumour > 5 cm 
 
Since the original work by Fong et al. a number of studies have validate the use of 
CRS as a reliable predictor of outcome following hepatic surgery for CLM (Mala et 
al. 2002; Mann et al. 2004). More recently, Schussler-Fiorenza et al. (2004) examined 
the relationship between CRS and the clinical yield of 18F-FDG PET in patients with 
hepatic metastases. They demonstrated that patients with a CRS of 1 or more were 
more likely to have extrahepatic disease detected on PET than those with a low score 
(<1). In those with a CRS of 0, 18F-FDG PET resulted in a false positive rate of 57%. 
The authors therefore suggested that patients with an isolated CLM and CRS of 0,   135 
“should undergo conventional imaging alone” (and not a PET scan) before surgical 
exploration.  
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4.2 Aims 
The aims of this study were: 
1)  to investigate if 18F-FDG PET/CT provides additional information to routine 
ceCT in the routine pre-operative assessment of patients with CLM. 
2)  to evaluate the clinical impact PET/CT on the management of patients with 
CLM 
3)  to investigate the incremental value of 18F-FDG PET/CT imaging over that of 
imaging with PET alone 
4)  to examine the relationship between CRS and the clinical yield of 18F-FDG 
PET/CT.   137 
4.3 Methods 
4.3.1 Patient group 
Between October 2003 to October 2005, a database of consecutive patients referred to 
our unit for assessment of colorectal liver metastases was held. Patient demographics, 
tumour characteristics (required for clinical risk score determination) and imaging 
results were recorded and analysed retrospectively. Routine imaging consisted of a 
contrast  enhanced  CT  scan  of  the  abdomen  and  the  pelvis  and  where  applicable, 
imaging of the thorax was also performed. Only patients who underwent imaging with 
ceCT of the thorax, abdomen and the pelvis were compared to whole body 18F-FDG 
PET/CT  scan  acquired  within  2  weeks  of  each  other  were  included  in  the  final 
analysis. Management decisions were decided by consensus in the multidisciplinary 
team setting. Decision plans were made sequentially, first following the results of the 
ceCT scan and subsequently following the 18F-FDG PET/CT findings.  
 
4.3.2 Imaging protocols 
Most ceCT scans were preformed in house using the standard protocol described in 
chapter 2. If the imaging data from referring institutions was insufficient, (i.e.: of poor 
quality or greater than 2 weeks old), they were repeated at our centre. 
 
Imaging protocols for the whole body 18F-FDG PET/CT scans are as described in 
section  2.2.  A  median  dose  of  377  MBq  of  18F-FDG  (range  360  –  400)  was 
administered and scans were acquired at a median time of 62 minutes (range 55-65) 
post  tracer  injection.  All  images  were  acquired  during  normoglycaemia.  No 
intravenous or oral contrast agents were used. 
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4.3.3 Image analysis 
All  ceCT,  PET  and  PET/CT  studies  were  analysed  by  senior  (consultant  grade) 
radiologists  and  nuclear  medicine  physicians.  Imaging  was  used  to  determine  the 
extent of hepatic and extra-hepatic disease burden. All PET/CT images were analysed 
qualitatively (visually). A lesion was reported as positive for malignancy if focal 18F-
FDG PET accumulation was greater than the background. A lesion with activity less 
than or equal to the background was deemed negative. 
 
The analysis of results was performed both on a  “lesion-by-lesion” and “patient-by-
patient” basis. The impact of PET/CT on management was decided by consensus at 
the  specialist  (liver)  MDT  meetings  and  the  outcomes  were  correlated  with  the 
imaging results.  
 
In order to investigate the incremental value of PET/CT over PET alone imaging, the 
same  dataset  acquired  during  the  routine  PET/CT  imaging  was  used.  Here,  the 
standard workstation (Xeleris
®) could  be adjusted to  allow the PET images  to be 
viewed  separately  to  the  CT  and  the  PET/CT  fused  images,  thus  allowing  the 
assessment of PET only data in isolation. For all cases, both the attenuated corrected 
and uncorrected PET images  were viewed simultaneously. The PET only  and the 
PET/CT data were analysed by two independent reporters in order to account for 
inter-observer variability. Each reporter analysed the PET and the PET/CT data with 
at least a 2-week intervening gap between the two in order to minimise recall bias.   
 
A  3-point  scoring  system  was  used  to  record  the  certainty  of  lesions  localization 
(0=Unknown  localization,  1=Probable  localization,  2=Definite  localization).  A  5-  139 
point  scoring  system  was  used  to  record  the  certainty  of  lesion  characterization 
(0=Definitely benign, 1=Probably benign, 2=Equivocal lesion, 3=Probably malignant, 
4=Definitely malignant).  
 
4.3.4 Clinical Risk Score (CRS)   
CRS was determined by adding one point to each of the 5 criteria previously listed 
(section 4.1). The maximum size of hepatic lesions were determined on the axial 
slices of the ceCT scans and not on the CT component of PET/CT. The final score for 
each patient  was  correlated with  the patient  /  tumour characteristics and the final 
imaging results.  
 
4.3.5 Data presentation and statistical analysis 
The  results  from  the  two  imaging  modalities  are  presented  as  true  positives,  true 
negatives,  false  negatives  and  false  positives.  Sensitivity,  specificity,  accuracy, 
positive and negative predictive values were calculated using standard formulae. The 
difference in detection accuracy of the two imaging modalities were compared using 
the  McNemar‟s    test  for  correlated  proportions.  Comparison  between  CRS  scores 
were  performed  using  the  Fisher‟s  exact  test.  Two  tailed  p  values  of <0.05  were 
considered significant. 
 
To compare lesion interpretation with PET only imaging against that with PET/CT, 
the  proportion  of  lesions  that  were  scored  as  “definite”  were  compared  for  each 
observer. To assess whether PET/CT resulted in a change in inter-observer variability, 
the Kappa coefficient factor was used.   140 
4.4 Results 
4.4.1 Patient demographics 
A total of 32 patients (20 men, 12 women) with a median age of 63 years (range 28-
82 years) were included in the analysis. The sites of the primary tumour were in the 
colon in 27 (84%) patients and the rectum in 5 (16%). One patient presented with a 
synchronous CLM and a carcinoma of the sigmoid colon. One patient had received 
chemotherapy 2 months prior to being referred for an 18F-FDG PET/CT scan. The 
patients were followed-up for a median duration of 10 months (range 3-24 months). 
 
4.4.2 18F-FDG PET/CT versus routine ceCT 
A  total  of  55  suspicious  lesions  were  assessed  by  a  combination  of  clinical, 
radiological and surgical follow-up of patients. Histological verification was available 
on 44 (80%) of these, while the true nature of the remaining 11 (20%) lesions was 
confirmed through radiological follow-up with selective use of repeat ceCT, PET/CT, 
MRI or bone scans.  Of the 55 lesions, 49 (89%) were confirmed to be malignant 
deposits and 6 (11%) were benign. Analysed on a lesion-by-lesion basis, the detection 
rates of the two imaging modalities are summarised and compared in table 4.1. 
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Table 4.1: Comparison of detection rates between 18F-FDG PET/CT and ceCT, 
analysed on a lesion-by-lesion basis. [TP = true positive, TN= true negative, FP= false 
positive, FN= false negative, SENS = sensitivity, SPEC= specificity, PPV= positive 
predictive value, NPP= negative predictive value, ACC= accuracy] 
 
PET/CT correctly detected 44 of the 55 malignant lesions compared to ceCT, which 
detected  36  lesions  (sensitivity  90%  vs  73%  respectively; 
2=  12.07,  p=0.0005, 
McNemar‟s  test).  Overall,  18F-FDG  PET/CT  was  also  more  specific  than  ceCT 
however this difference did not reach statistical significance (specificity 67% vs 50% 
resp.;  2 = 0, p = NS). Region-based analysis showed the main differences between 
the imaging modalities to occur in detecting extrahepatic disease where the sensitivity 
of  18F-FDG  PET/CT  was  again  superior  (94%  vs  38%;  2  =14.06,  p=0.0002). 
However, the sensitivity and accuracy of the two imaging modalities for detecting / 
characterizing hepatic metastases was similar.  
ceCT PET/CT ceCT PET/CT ceCT PET/CT
TP 30 29   6 15 36 44
TN 2 3 1 1 3 4
FP 1 0 2 2 3 2
FN 3 4 10 1 13 5
Total 36 36 19 19 55 55
SENS (%) 91 88 38 94 73 90
SPEC (%) 67 100 33 33 50 67
PPV (%) 97 100 75 88 92 96
NPV (%) 40 43 9 50 6 44
ACC (%) 89 89 31 84 71 87
Overall Extraheptic disease Hepatic disease  142 
On a patient-by-patient analysis, the results of PET/CT were discordant with those of 
ceCT in 14 patients (44%). A more detailed breakdown of these results is summarised 
in figure 4.1. 
 
 
Figure 4.1: The distribution of discordant findings between 18F-FDG PET/CT and 
ceCT 
 
18F-FDG PET/CT detected occult hepatic and extrahepatic disease in 9 cases (28%). 
In 2 patients (6%) where ceCT was interpreted as showing solitary liver metastases, 
the  PET/CT  correctly  confirmed  these  to  be  benign  lesions.  Therefore  overall, 
PET/CT provided additional information to ceCT in 11 patients (34%). The remaining 
3  discordant  results  (9%)  occurred  due  to  incorrect  (false  positive  or  negative) 
PET/CT  results.  In  one  case,  PET/CT  detected  18F-FDG  avid  mediastinal  lymph   143 
nodes,  which  in  the  presence  of  a  solitary  CLM  were  therefore  considered  to  be 
metastatic deposits.  Histological  confirmation  using a trans-oesophageal biopsy of 
one  of  these  lymph  nodes  confirmed  active  tuberculosis.  The  patient  therefore 
underwent  a  successful  hepatic  resection  following  initiation  of  anti-tuberculous 
therapy. This case is illustrated in figure 4.2. In the remaining two cases, PET/CT 
yielded false negative results in detecting liver and lung metastases, both of which 
were attributed to a lesion size of less than 1cm.  
 
 
 
Figure 4.2: 18F-FDG PET/CT study demonstrating the presence of false positive 
hilar  and  mediastinal  lymph  nodes.  A  large  solitary  liver  metastasis  can  be  seen 
occupying the right lobe of the liver (Thick black arrow, MIP image). 3 further  
18F-FDG  avid  hot-spots  were  also  seen  in  the  thorax  (Thick  red  and  thin  black 
arrows).  Axial  PET,  CT  and  PET/CT  images  clearly  demonstrating  one  of  these 
tracer avid lesions to be a para-oesophageal lymph node, which on biopsy was  
confirmed to be active tuberculosis.  144 
4.4.3 The impact of 18F-FDG PET/CT on management 
 
18F-FDG PET/CT resulted in a change in the routine management of 11 patients 
(34%). Of these, the management of 8 patients (25%) were positively impacted as 
18F-FDG PET/CT lead to a correct change in diagnosis in one case (a solitary CLM 
suggested on 18F-FDG PET/CT to be consistent with a hepatocellular carcinoma) and 
appropriately altered the radiological staging of the remaining 7 patients. Of note is 
one case where a solitary hepatic lesion seen on ceCT was shown to be negative on 
18F-FDG PET/CT. This lead to avoidance of an unnecessary surgery and the patient 
was radiologically monitored. At the time of writing, the patient had remained disease 
free  over  a  follow-up  period  of  19  months.  Of  the  above  11  patients,  18F-FDG 
PET/CT was also deemed to have a negative impact in 3 cases (9%) due to false 
negative  and  false  positive  results.  A  summary  of  the  impact  of  PET/CT  on 
management is detailed in table 4.2.    145 
 
 
Table 4.2: The impact of 18F-FDG PET/CT on management of patients with CLM. 
 
Chemotherapy   2
Chemotherapy + Monoclonal antibody Rx 1
Radiofrequency abalation 1
Chemotherpy + Radiofrequency ablation 2
No intervention, patient monitored 1
Diagnosis change from CLM to hepatocellular carcinoma 1
TOTAL 8 (25%)
1
1
1
TOTAL 3 (9%)
Change of diagnosis
Down staging of disease
False positive medistinal lymph nodes -> patient underwent 
addional inavsive procedure (transoesophageal biopsy); 
histology confirmed active TB
False negative liver metastases  -> post chemotherpy => 
patient assumed to have dormant disease, and moonitored 
without intervention -> disease recurrence at 4 months
False negative lung metastases; patient underwent liver 
resection -> developed progressive lung disease at 10 months
No. 
patients 
Upstage disease
Management 
Negative impact
Postive impact
Incorrect down staging
Incorrect up staging   146 
4.4.4  Correlation between CRS and the clinical yield of 18F-FDG PET/CT 
Table 4.3 displays the distribution of clinical risk scores (CRS) for the study group. 
The median CRS was 2.  Using this value, CRS were dichotomised into high and low 
risk groups. 
 
 
Table 4.3: The distribution of Clinical Risk Scores (CRS) for the study group 
 
Overall, no significant difference was found in the proportion of discordant findings 
between 18F-FDG PET/CT and ceCT findings in the low and the high CRS groups 
(CRS < 2 = 12 (48%) vs CRS > 2= 3 (43%); p=NS). However, a high CRS (>2) 
corresponded to a higher proportion of ceCT occult hepatic and extrahepatic disease 
being detected with PET/CT. Although at a CRS of >2 PET/CT detected no additional 
liver metastases (3 vs 0 for PET/CT and ceCT respectively), proportionately more 
occult  extrahepatic  disease  was  detected.  None  of  the  above  however  achieved 
statistical significance.  
 
In  terms  of  impact  on  management,  18F-FDG  PET/CT  resulted  in  change  in 
management of 48% of cases with a low CRS, compared to 29% for a high CRS. This 
difference again did not achieve statistical significance. The results are summarised in 
table 4.4. 
CRS n %
0 6 19
1 8 25
2 11 34
3 4 13
4 2 6
5 1 3  147 
 
 
Table 4.4: Break down of results according to dichotomised Clinical Risk Scores 
(CRS); Low score =<2; High score >2 
 
4.4.5  The incremental value of PET/CT over that of imaging with PET alone 
The aim of this section of the study was to test the hypothesis that PET/CT image 
fusion allows for a more accurate and definite interpretation  of  abnormal  lesions, 
compared to imaging with PET alone. Interestingly both observers detected a greater 
number  of  abnormal  18F-FDG  avid  foci  on  the  PET  only  images  compared  to 
PET/CT. This was in keeping with the finding that the certainty of lesion localization 
(ie: the proportion of lesions scored < 2) was also poorer on the PET only scans. For 
both  observers,  PET/CT  resulted  in  an  improvement  in  the  certainty  of  lesion 
interpretation,  with  an  average  of  15%  improvement  in  the  certainty  of  lesion 
localization and 12.5% improvement in the certainty of lesion characterization. These 
findings are summarized in table 4.5. 
 
 
 
n  %  n  % 
Discordant findings with ceCT  12  48  3  43  NS 
8  32  3  43  NS 
3  12  0  0  NS 
5  20  3  43  NS 
  
Management change  12  48  2  29  NS 
Additional extrahepatic disease 
Additional liver metastases 
Detected occult disease not seen on  
conventional imaging (ceCT) 
18F-FDG PET/CT findings 
CRS < 2  Fishers exact  
test (2 tailed)             
p 
CRS >2   148 
    Observer A  Observer B 
    PET Only  PET/CT  PET Only  PET/CT 
Total no of lesions  48  44  53  46 
Definite 
locallization  85% 
 
98% 
 
78%  94% 
Improvement  +13%  +17% 
Definite diagnosis  86%  99%  72%  94% 
Improvement  +13%  +22% 
 
Table 4.5: Tabulated summary of the difference in the certainty of lesion 
interpretation with PET only imaging compared to that with PET/CT. Results showed 
PET/CT imaging to improve the certainty of lesion localization and as well as the 
certainty of lesion characterization (ie: certainty of diagnosis) compared to PET 
imaging alone.  
 
Next the inter-observer variability between the two observers was assessed using the 
Kappa coefficient factor. As shown in table 4.6, PET/CT also resulted in an 
improvement in concordance between the observers, both in terms of lesion 
localization as well as lesion characterization.    149 
 
 
      PET only  PET/CT 
     
Kappa 
coefficient  95% CI  Kappa coefficient  95% CI 
Anatomical Localization  0.21  
(Poor)  -0.08 - 0.51  0.66 
 (Good)  0.36 - 1.28 
Lesion Characterization  0.62  
(Good)  0.57 - 0.87  0.88  
(V. good)  0.77 - 1.00 
 
 
Table 4.6: The difference in inter-observer variability between PET only scans and 
PET/CT. PET/CT resulted in a better correlation between the observers in both lesion 
 localization and lesion characterization.   150 
4.5 Discussion 
 
The role of PET in the routine diagnosis and staging of primary CRC still remains 
under dispute. However, the strength of PET in assessing the extent of metastatic 
burden has been a particular focus of attention. The evidence to date has consistently 
shown 18F-FDG PET to be more sensitive and specific than conventional imaging 
(CT) in detecting hepatic and extrahepatic disease in colorectal cancer. The meta-
analysis by Heubner et al. (2000) gave 18F-FDG PET a weighted average sensitivity 
and specificity of 96% and 97% respectively for detecting hepatic metastases. It is 
however important to note that many of the earlier studies compared PET data with 
CT results that were not homogenous, thus arguably suggesting a bigger difference 
between the two modalities  than may be present.  Advances  in  contrast  enhanced, 
multidetector  CT  technology,  coupled  with  its  widespread  use  has  also  lead  to  a 
narrowing of the gap between the detection accuracy of CT and PET, so much so that 
two  recently  published  studies  have  failed  to  show  any  difference  in  sensitivities 
between the two modalities in detecting intrahepatic metastases (Selzner et al. 2004; 
Truant et al. 2005).  
 
Our  study  population  consisted  of  routine  referrals  to  a  tertiary  liver  unit  where 
management decisions  were made in  a multidisciplinary setting. During the study 
period, the multidisciplinary team came to a consensus decision to included 18F-FDG 
PET/CT as part of the routine diagnostic work-up of patients with suspected CLM. 
This decision was principally made on the grounds of the availability of a PET/CT 
scanner at our institution. However, it must be noted that at the time of writing, this 
did not mirror the situation nationally. None the less, it provided the opportunity to 
compare the routine application of ceCT and PET/CT.   151 
The primary aim of the study was to compare the diagnostic accuracy of the two 
imaging modalities. Overall for all lesions analysed, 18F-FDG PET/CT was more 
sensitive, specific and accurate than ceCT (Sensitivity90% vs 73%, Specificity= 67% 
vs  50,  Accuracy=  87%  vs  71%  for  18F-FDG  PET/CT  and  ceCT  respectively). 
Subgroup analysis however showed this difference to be mainly as a result PET/CT‟s 
accuracy in detecting extrahepatic disease, whereas the sensitivity of the two imaging 
modalities in detecting liver metastases was similar. This finding is consistent with 
that reported by Truant et al. (2005) where the sensitivities for PET and CT were 
found to be equal (sensitivity of 79% for both).  Furthermore similar to our results, 
their  study  also  demonstrated  PET  to  be  overall  more  specific  in  detecting  liver 
metastases.  It is important to note that neither ceCT nor PET/CT could detect all 
lesions. With PET/CT in particular, there were 5 false negative lesions, of which 4 
were  intrahepatic  and  one  extrahepatic  (lung)  metastasis.  Majority  of  these  (5/8 
lesions) were also small, sub-centimetre hepatic lesions.  Although a size threshold of 
5-8 mm is frequently reported as the spatial resolution of 18F-FDG PET, the actual 
volume of disease is the main determinant of whether a lesion accumulates enough 
18F-FDG to be detected. In the lungs, motion artefact can also lead to the partial 
volume effect, thus resulting in a lesion being missed. Within the liver, the detection 
of low grade tracer uptake is further hampered by background accumulation of 18F-
FDG in hepatocytes, thus resulting in under-detection of hepatic metastases (Beets et 
al. 1994).  
 
In detecting small hepatic lesions, the CT component of PET/CT did not add to its 
diagnostic accuracy, as our established PET/CT imaging protocols acquires the CT 
images at a lower power (80mA), thicker slice width (4.5 mm) and without the use of   152 
the intravenous contrast agents. The use of high-density contrast agents have been 
suggested to results in image artefacts by affecting the CT attenuation correction of 
PET  images.  The  use  of  contrast  material  has  more  recently  been  re-examined 
(Blodgett  et  al.  2006;  Mawlawi  et  al.  2006).  Mawlawi  and  colleagues  in  fact 
demonstrated that the maximal variation in SUV values occurred where there was 
maximal  accumulation  of  contrast  material  (eg:  the  heart,  major  vessels).  In  the 
remaining  tissue  compartments,  SUV  changes  were  minimal  and  thus  considered 
clinically  insignificant.  In  the  future  therefore,  it  is  likely  that  in  selective  cases 
PET/CT may be performed with a CT acquired at full diagnostic capability and with 
the use of intravenous contrast agents. The feasibility of this approach requires further 
scrutiny in future studies, with particular focus on the resource implications of adding 
a full diagnostic CT to the routine dedicated PET/CT protocols. 
 
The strength of 18F-FDG PET lies in its accuracy of detecting extrahepatic disease. In 
our series, 9 out of 14 discordant cases (64%) occurred due to PET/CT detecting 
additional (occult) metastases missed on ceCT. Of these, 6 cases were found to have 
occult extrahepatic disease, 2 cases with occult liver metastases and 1 case with both. 
The remaining 2 discordant cases were due to  false positive ceCT findings being 
correctly characterized by PET/CT. Thus excluding the 3 incorrect PET/CT results, 
PET/CT provided useful additional information to ceCT that impacted the clinical 
management of patients in over one third of cases (11/32, 34%).  
 
When considering the impact of 18F-FDG PET/CT on patient management, incorrect 
results also needed to be taken into account. Overall, PET/CT resulted in a change in 
the routine management (as planned following the ceCT results) of 11 patients (34%).   153 
Of these, 8 cases (25%) were considered to be positively impacted by PET/CT, as the 
final  PET/CT  result  changed  the  clinical  management  for  a  more  appropriate 
treatment regimen. Here the accuracy of PET/CT in detecting metastases missed by 
conventional imaging was its predominant strength, whereby 6 patients were correctly 
upstaged  thus  resulting  in  avoidance  of  futile  surgery.  False  positive  and  false 
negative results on the other hand lead to an adverse clinical impact as additional 
intervention was undertaken in order to confirm the nature of these findings. It is 
noteworthy that our study group represents a cohort of patients with suspected CLM 
who were routinely assessed with both ceCT and PET/CT. In 2 cases where PET/CT 
yielded false negative results, one patient underwent a hepatectomy but whom on 
subsequent follow-up was found to have multiple enlarging lung metastases. Incorrect 
PET/CT findings can be argued to have resulted in an inappropriate management of 
the  patient,  with  resultant  need  for  additional  invasive  investigations  (e.g:  trans-
oesophageal biopsy of mediastinal lymph nodes; figure 4.2) and possibly poorer long-
term  outcomes  in  the  two  patients  who  were  incorrectly  down  staged.  While 
limitations of PET/CT may be subject to further scrutiny, it must be noted that in our 
series, the 9% negative impact of PET/CT was in face of a 24% positive impact. 
When compared to the overall sensitivity and specificity of 73% and 50% for ceCT, 
there still remains a strong argument for the routine use of PET/CT in the routine pre-
operative assessment of CLM.  
 
As previously mentioned in the introductory sections, the main limitations of imaging 
with  a  stand-alone  PET  scanners  have  been  their  relative  lack  of  anatomical 
resolution, which when assessing intra-abdominal pathology can lead to diagnostic 
uncertainty  and  inaccurate  results.  Dual  modality  imaging  with  PET/CT  can   154 
potentially  overcome  this  problem  through  accurate  co-registration  of  biological 
(PET) and anatomical (CT) data. In staging primary CRC, Cohade and colleagues 
have  shown  this  to  reduce  diagnostic  uncertainty  in  50%  of  cases  and  improve 
anatomical localisation by up to 30% (Cohade et al. 2003a). Our results were also in 
agreement with the above. Two aspects of image interpretation were assessed namely 
that of the certainty of lesion localization and the certainty of lesion characterization. 
The latter examined the certainty by which the reporting physician would interpret an 
18F-FDG avid lesion as malignant or benign. Our results demonstrated that for both 
observers, PET/CT lead to a more certain anatomical localization of lesions with an 
average  improvement  of  15%.  There  was  also  an  improvement  in  lesion 
characterization  by  an  average  of  12.5%  between  the  observers  with  PET/CT 
compared  to  PET  alone.  As  is  the  case  with  visual  assessment  of  all  imaging 
modalities,  there  can  be  subjective  differences  between  reporters.  When  inter-
observer  variability  was  also  examined,  PET/CT  resulted  in  a  better  concordance 
between observers compared to that seen with PET alone. Although the results are 
from a limited number of patients with a heterogeneous spread of metastatic deposits, 
overall indication are that PET/CT image fusion can improve the accuracy of image 
interpretation in the routine clinical setting.  
 
The final aim of this study was to examine if CRS could be useful as a means of 
selecting patients who would most benefit from having a PET scan. The rationale for 
this stems from the fact that although PET may provide additional information to 
conventional imaging, its clinical impact ranges between 20-40%. In other words, up 
to 80% of cases may not benefit from an additional PET scan in their management 
algorithm. Given the cost and availability of PET scanners, justification for its routine   155 
use can therefore be made if a tight selection criteria for imaging is made. Here we 
utilized CRS as means of dichotomizing patients into a low and high risk groups to 
see if it would help select the most appropriate patients for PET imaging. Unlike the 
study  by  Schussler-Fiorenza  et  al.  (2004),  the cut–off  point  in  our  study  was  the 
median CRS for the cohort. Overall no significant difference was seen between the 
two CRS groups in terms the proportion of discordant findings between ceCT and 
PET/CT, the detection of occult disease missed on ceCT and the proportion in which 
PET/CT resulted in a change in management. In terms of the change in management 
however, there seemed to be a trend towards a low CRS (<2) yielding clinically more 
relevant PET/CT results, where management change was seen in 48% of cases in the 
low risk group compared to 29% in the high risk CRS group. This finding further 
suggests that 18F-FDG PET/CT is unlikely to alter management patient with CLM 
who are found to have widespread metastatic disease. Given the small sample size of 
this  study,  no  concrete  conclusions  can  be  made  from  this.  However  overall 
indications are that CRS is unlikely to be value in selecting which patients should 
undergo PET/CT imaging in pre-operative staging of colorectal liver metastases.    156 
4.6 Conclusions 
18F-FDG PET/CT is a powerful adjunct to routine ceCT in the pre-operative staging 
of  patients  with  CLM.  The  advantage  of  PET/CT  fusion  over  PET  alone  is  in 
improving the certainty of lesion localization and interpretation, thus giving a more 
robust means of assessing patients in the routine clinical setting.  
 
When compared to ceCT, discordant findings occurred predominantly as a result of 
18F-FDG  PET/CT  detecting  additional  metastases  at  extra-hepatic  sites.  The 
sensitivity  and  accuracy  of  detecting  hepatic  lesions  were  similar  for  the  two 
techniques. Although PET/CT resulted in a change in the routine management of 34% 
of cases, false positive and negative results did occur that made a negative impact on 
patient management. Therefore PET/CT was deemed to be clinically useful in 25% of 
cases.  Finally, CRS was found not to be a clinically useful tool for pre-selecting 
patients in whom PET/CT would provide the most useful information.   
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CHAPTER 5 
 
Targeting proliferation in  
pancreatic cancer  
 using 18F-FLT PET –  
A comparative study with 18F-FDG.   158 
5.1 Background 
 
In previous chapters, the role of 18F-FDG PET/CT in the routine management of 
pancreatic cancer was examined. Targeting glycolysis in cancer inherently gives 18F-
FDG its exquisite sensitivity. However, in the presence of an inflammatory process, 
problems with specificity emerge. While results from chapter 3 demonstrated that a 
negative  18F-FDG  PET/CT  scan  may  be  helpful  in  excluding  malignancy,  false 
positive results occurred in two cases of mass forming pancreatitis and in one case of 
a tuberculous deposit in the pancreas. 
 
As outlined in chapter 1.6.5, 18F-FLT is suggested to be more tumour specific as 
compared to 18F-FDG. van Waarde et al. (2004) tested this hypothesis in vivo in an 
animal model of malignancy versus inflammation. While 18F-FDG accumulated in 
both  the  foci  of  inflammation  and  malignancy,  18F-FLT  uptake  seemed  to  be 
confined to the cancer xenograft. At the time of writing, there had been no published 
reports of imaging pancreatic cancer with 18F-FLT PET. The feasibility of its use has 
been suggested from an in vitro study by Seitz et al. (2002), who showed human 
pancreatic cancer cell lines to have a higher expression and activity of pyrimidine 
salvage  enzyme  TK-1.  Consequently,  a  higher  rate  of  18F-FLT  uptake  was 
demonstrated in pancreatic cancer cell lines compared to normal pancreatic cells oand 
those  of  chronic  pancreatitis.  In  addition  to  its  tumour  specificity,  quantifying 
proliferation with 18F-FLT PET may also have important prognostic implications. 
This chapter therefore sets out to examine the feasibility of imaging pancreatic cancer 
using 18F-FLT PET. 
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5.2 AIMS 
The aims of this chapter were: 
1.  to examine the feasibility of imaging pancreatic cancer with 18F-FLT PET 
and compare its accuracy to the routine PET tracer 18F-FDG. 
2.  to investigate whether 18F-FLT uptake in vivo correlates with proliferative 
activity of tumours as measured by Ki-67 immunostaining. 
3.  to investigate whether 18F-FLT uptake correlates with overall survival.   160 
5.3 Methods 
5.3.1 Patient recruitment 
Patients were prospectively recruited from routine referrals to the local hepatobiliary 
unit. Ten patients with clinical and radiological suspicion of pancreatic cancer were 
included. The diagnosis of pancreatic adenocarcinoma was histologically confirmed 
in all ten cases. Following routine staging with pancreatic protocol contrast enhanced 
CT (ceCT), each patient underwent a whole body PET/CT scan using the routine 
tracer 18F-FDG and the thymidine analogue tracer 18F-FLT. The PET/CT studies 
were  performed  with  a  median  intervening  period  of  3  days  (range  1-12  days) 
between the two.  
The study was conducted following local hospital ethics committee approval and with 
full informed consent of the patients as outlined in chapter 2.1. 
  
5.3.2 Imaging protocols 
Routine staging with pancreatic protocol ceCT and imaging protocols for whole body 
18F-FDG and 18F-FLT PET/CT scans are as described in chapter 2.  
The median administered doses of tracers were 374 MBq (range 342 – 412) for 18F-
FDG and 313 MBq (range 229 – 435) for 18F-FLT. The PET images were acquired at 
a median of 61 minutes post-injection for both tracers. The CT component of PET/CT 
was acquired without oral or intravenous contrast enhancement. 
 
5.3.3 Image Analysis 
The 18F-FDG and 18F-FLT PET images were qualitatively (visually) assessed by two 
experienced (consultant grade) nuclear medicine physicians. Each observer was aware 
of  the  presence  of  a  suspicious  pancreatic  mass,  but  was  blinded  to  the  final   161 
histological diagnosis. The final results were reached by consensus between the two 
observers. 
Lesions were deemed as positive where focal tracer accumulation was above that of 
the surrounding normal tissues. A 3-point grading system was also used as a visual 
measure of the intensity of tracer accumulation for each lesion. These were recorded 
as; 
 
-    -    = A definite negative lesion 
-   +/-    = A positive but low grade 
-    +    = A definite positive lesion 
-    
Tracer uptake was semi-quantified using SUVs (corrected for body weight) and using 
1cm circular ROIs. SUVMax and SUVMean values were determined semi- automatically 
using the Xeleris
® workstation. The methodologies used for SUV measurements are 
detailed in chapter 2.4.2. 
  
Where  a  lesion  was  deemed  to  be  “negative”  for  18F-FLT  uptake,  the  region  of 
interest was placed over the anatomical area corresponding to the lesion detected on 
the ceCT and the CT component of PET/CT. These were correlated with the 18F-
FDG PET results.    
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5.3.4 Histological analysis 
5.3.4.1 Specimen preparation 
All histological specimen were examined by a senior histopathologist, blinded to the 
results of the PET scans. The specimens were obtained from whole tumour resections 
in 4 patients and percutaneous core biopsies in the remaining 6. Routine histological 
examination was performed on 4µm thick Haematoxylin and Eosin (H&E) stained 
sections.  Immunohistochemical analysis was performed on 3µm thick sections cut 
from paraffin blocks and dried overnight at 60
o C. Sections were taken from xylene  
(2 changes) and ran twice through graded alcohols (100% and 70%) and finally water. 
Antigen retrieval was performed by pressure cooking for 2 minutes in a conventional 
15 lb pressure cooker and the slides were then flushed with running tap water. The 
slides were then rinsed in 0.05% Tween-20 in Tris buffered saline (TBS-T) in an 
incubation tray. Endogenous peroxidase activity was blocked for 10 minutes using a 
commercially available peroxidase blocking solution (DAKO UK Ltd, cat #S2023). 
The sections were rinsed in TBS-T and then the primary mouse monoclonal antibody 
MIB-1 (DAKO UK Ltd, cat #M7240) diluted 1/50 in TBS was applied for 60 minutes 
at room temperature. 
 
The sections were rinsed in TBS-T and secondary antibody (goat anti-rabbit/mouse), 
(DAKO UK Ltd, cat #K5001) was applied for 30 minutes. The sections were again 
rinsed  in  TBS-T  and  streptavidin-horseradish  peroxidase  (DAKO,  UK  Ltd,  cat 
#K5001)  was  applied  for  30  minutes.  After  rinsing  in  TBS-T,  diaminobenzidene, 
(DAKO,  cat  #K5001)  was  used  as  a  chromogen  and  applied  for  7  minutes.  A 
haematoxylin  counter  stain  was  applied  for  2mins.  The  sections  were  dehydrated   163 
through graded alcohols (70% and 100%), cleared in xylene (2 changes) and mounted 
with DPX resin. 
 
5.3.4.2 Examination of histological sections 
Sections of tumour were first identified on the H&E slides. Twenty high power fields 
(x40 objective lens) were examined per case and the total number of tumour nuclei 
were counted. The corresponding area was then examined for positive staining with 
MIB-1  antibody.  Positive  nuclear  staining  was  regarded  as  staining  of  the  entire 
nucleus. Nuclei with no staining or only nucleolar staining were regarded as negative. 
A labelling index (LI) was calculated as a percentage of positive staining nuclei out of 
all nuclei examined.  
 
5.3.5 Statistical analysis 
All statistical calculations were performed using the GraphPad statistical Software (V 
4.0,  Califorania,  USA).  Correlations  between  tracer  SUVs,  and  MIB-1  LI  were 
performed  by  linear  regression  analysis  and  Pearson‟s  correlation  coefficient. 
Survival  analysis  as  a  function  of  the  SUVs  was  estimated  by  the  Kaplan-Meier 
method  and  compared  by  the  log  rank  test.    p  values  <0.05  were  considered 
significant. 
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5.4 Results 
5.4.1 Patient demographics and tumour characteristics  
 
Ten patients with a median age of 64 years (range 55-81 years) were included in the 
study.  All  pancreatic  lesions  were  histologically  confirmed  as  adenocarcinoma. 
Patient demographics and tumour characteristics are summarised in table 5.1. Overall, 
4 (40%) patients underwent a resection with curative intent. The remaining 6 (60%) 
patients were deemed to have an inoperable disease on routine imaging (ceCT) and 
were treated palliatively.    165 
 
F
i
g
u
r
e
 
5
.
1
:
 
T
h
e
 
d
e
m
o
g
r
a
p
h
i
c
s
 
a
n
d
 
t
u
m
o
u
r
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
p
a
n
c
r
e
a
t
i
c
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
i
m
a
g
e
d
 
w
i
t
h
 
1
8
F
-
F
D
G
 
a
n
d
 
1
8
F
-
F
L
T
 
P
E
T
.
 
 
[
A
C
=
a
d
e
n
o
c
a
r
c
i
n
o
m
a
;
 
+
=
d
e
f
i
n
i
t
e
l
y
 
p
o
s
i
t
i
v
e
 
l
e
s
i
o
n
,
 
+
/
-
=
P
o
s
i
t
i
v
e
 
b
u
t
 
l
o
w
 
g
r
a
d
e
 
t
r
a
c
e
r
 
u
p
t
a
k
e
,
 
-
=
d
e
f
i
n
i
t
e
l
y
 
n
e
g
a
t
i
v
e
 
l
e
s
i
o
n
]
   166 
5.4.2 Detection of primary pancreatic disease – comparison between 18F-FDG 
and 18F-FLT PET imaging 
 
18F-FDG PET/CT visualized all 10 pancreatic tumours, whereas 18F-FLT visualized 
7 out of 10 (70%). Of these, 2 showed a strong (definitely positive 18F-FLT uptake) 
and in the remaining 5, 18F-FLT uptake was interpreted as low grade (See table 5.1). 
In one patient, 18F-FDG PET/CT detected a focal colonic lesion, which was later 
found to be an adenomatous polyp. This lesion was not visualised on the 18F-FLT 
PET/CT scan.  
In two patients who underwent a pancreatic resection, microscopic peri-pancreatic 
nodal (N1) spread was detected. No nodal or extra-pancreatic disease was detected by 
either tracer. This was confirmed on routine imaging, clinical and surgical follow-up 
of the patient. 
 
Table 5.1 also summarises the SUV measurements for 18F-FDG and 18F-FLT PET 
detected lesions. On average, pancreatic lesions showed a significantly higher 18F-
FDG  uptake  compared  to  18F-FLT  (SUVMax  :  6.1  vs  3.1  respectively,  p=0.0005; 
SUVMean:  4.9  vs  2.5  respectively,  p=0.0002;  Paired  t-test).  No  correlation  was 
observed between 18F-FDG and 18F-FLT SUVs (figure 5.1) 
   167 
 
Figure 5.1: Graphs representing the correlation between tumour SUVs for the two 
tracers (18F-FDG vs 18F-FLT)   168 
5.4.3 Correlation between tracer uptake and proliferative activity 
The median MIB-1 LI was 15.2% (range 11.6 - 50.5). As demonstrated by graphs in 
figure  5.2,  no  correlation  was  detected  between  18F-FDG  SUVs  and  MIB-1  LI 
(SUVMax; R= 0.21, p= 0.469; SUVMean: R= 0.26, p=0.467). However, 18F-FLT SUVs 
showed a statistically significant correlation with MIB-1 labelling (SUVMax: R= 0.65, 
p=0.042; SUVMean: R= 0.86, p=0.0012).  
 
 
 
 
 
 
 
 
 
 
 
Correlation between 18F-FDG SUVMax and MIB-1 LI   169 
 
 
 
 
 
 
 
 
 
Correlation between 18F-FDG SUVMean and MIB-1 LI 
Correlation between 18F-FLT SUVMax and MIB-1 LI   170 
 
 
 
 
 
Figure 5.2 (A-D): Graphs illustrating the correlation between 18F-FDG and 18F-
FLT SUVs and MIB-1 LI (%). A statistically significant correlation was seen between 
MIB-1 LI and 18F-FLT SUVs but not 18F-FDG SUVs (A&B).  
Correlation between 18F-FLT SUVMean and MIB-1 LI   171 
Figure 5.3 below illustrates the three grades of 18F-FLT uptake in relation to 
measured SUVMean and MIB-1 LI.  
 
Figure 5.3: Comparative 18F-FDG and 18F-FLT PET images for three patients with 
pancreatic  cancer  demonstrating  three  grades  of  18F-FLT  uptake  and  their 
corresponding MIB-1 LI. (Note: Red arrows represent the primary pancreatic lesion; 
black arrow represents tracer excretion in the renal tract).  172 
5.4.4 Correlation tumour SUVs and overall survival 
 
The patients were followed-up for a median duration of 10.52 months (range 7.82 - 
21.30). SUVMean values were dichotomised into “high” and “low” levels using their 
respective mean values as cut-off points (18F-FDG SUV=4.85; 18F-FLT SUV=2.50).  
As seen in figure 5.4 (A-B), there was a divergence of survival curves between high 
and low tracer SUVs for both 18F-FDG and 18F-FLT. However, differences between 
groups did not reach statistical significance (18F-FDG SUVMean: p=0.420; 18F-FLT 
SUVMean: p=0.097; Log rank (Chi squared) test). 
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A: Survival difference between low & high 18F-FDG SUVMean 
(SUV threshold = 4.85)   173 
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Figure 5.4: Kaplan-Meier survival graphs of patients with high and low tracer SUVs. 
No statistically significant differences in overall survival was seen between the two 
 SUV thresholds for (A)18F-FDG  SUVMean and (B)18F-FLT SUVMean.
B: Survival difference between low & high 18F-FLT SUVMean 
(SUV threshold = 2.50)   174 
5.5 Discussion 
 
This pilot study examined the use of the novel thymidine analogue tracer 18F-FLT in 
imaging pancreatic cancer. The aims of this study were three fold. Firstly the accuracy 
of  imaging  with  the  two  tracers  in  visualising  pancreatic  lesions  were  compared. 
Secondly, it tested the hypothesis that tumour 18F-FLT uptake correlates with the 
proliferation fraction of the tumour and finally, it examined whether tracer SUVs 
could be used as a prognostic marker in predicting survival. 
 
Overall,  pancreatic  lesions  demonstrated  a  significantly  higher  18F-FDG 
accumulation compared to 18F-FLT. This resulted in all 10 lesions being correctly 
identified with 18F-FDG PET (sensitivity of 100%), whereas the lower sensitivity of 
18F-FLT PET resulted in visualisation of only 7 lesions (sensitivity of 70%). This 
difference between the two tracers was also demonstrated semi-quantitatively using 
tracer  SUVs.  Overall,  SUVs  (compared  as  average  SUVMax  and  SUVMean  
measurements) were higher for 18F-FDG compared to 18F-FLT.  
 
It is noteworthy however that 5 out of 7 18F-FLT avid lesions showed low-grade 
tracer accumulation, so much so that they were only reliably detected by correlating 
the PET findings with the CT component of PET/CT. If only the PET images were 
viewed, the true sensitivity of 18F-FLT PET could have been 20%, where only 2 out 
of 10 lesions were confidently detected by the PET only images. In the two cases 
where the primary lesions were found to be highly 18F-FLT avid, maximum SUV 
(SUVMax)  values  were  found  to  be  greater  than  4.  This  may  represent  an  upper 
threshold at which 18F-FLT avid pancreatic tumours may become visually detectable. 
As all 10 lesions were visualized with 18F-FDG and not 18F-FLT PET, tumour blood   175 
supply (and thus tracer delivery) is unlikely to be a limiting factor in 18F-FLT uptake. 
Therefore mechanisms such as the transport of tracer into cells or the levels of the 
phosphorylating enzyme TK-1 may be implicated. In vitro, Seitz et al. (2002) have 
shown pancreatic cancer cell lines to have a markedly increased TK-1 activity and 
thus  increased  18F-FLT  uptake.  In  their  study,  TK-1  mRNA  levels  in  pancreatic 
cancer  specimen  were  shown  to  be  significantly  higher  than  that  for  chronic 
pancreatitis and cells from a normal pancreas. While this may be true for transformed 
cells in vitro, our results suggest that this may not be applicable to whole tumour 18F-
FLT uptake in vivo. Therefore, future in vivo studies correlating 18F-FLT uptake, TK-
1 activity and proliferation indices such as Ki-67 expression would provide important 
additional information to help better understand the difference observed between 18F-
FLT and 18F-FDG in pancreatic cancer.  
 
Aside from its use as a diagnostic tool, our results also suggest that 18F-FLT PET is 
unlikely to be of value as a routine staging tool in pancreatic cancers. As discussed in 
previous chapters, the spatial resolution of PET does not allow accurate local (T) 
staging of disease. Given our early results of imaging with 18F-FLT, it is apparent 
that this would be the case regardless of the type of tracer used. Peri-pancreatic nodal 
stations may also be missed by both 18F-FDG and 18F-FLT PET, as small volume 
disease and proximity to the primary tumour can obscure their detection and result in 
false negatives. This was seen in the above series as both tracers failed to detect 
microscopic  (N1)  peri-pancreatic  nodal  disease  later  confirmed  on  histological 
analysis of resected specimen. Another drawback of imaging with 18F-FLT is the fact 
that it is catabolized in the liver by glucuronidation, which results in high background 
hepatic levels (Shields et al. 1998a). Although, this was not formally examined in this   176 
cohort of patients (as none had metastatic disease at presentation), detection of small 
liver  deposits  that  may  exhibit  low-grade  18F-FLT  uptake  may  be  severely 
compromised.  In fact  in  a similar study of patients  with  advanced  and metastatic 
colorectal cancer, Francis et al. (2003a) showed the sensitivity of 18F-FLT PET for 
detecting liver metastases to be 30% compared to 98% for 18F-FDG PET. Therefore 
despite suggestion from early in vitro studies, our preliminary results suggest that 
18F-FLT PET is not a feasible tool for routine diagnosis nor for staging of pancreatic 
cancer.  
 
The second aim of this study was to examine the correlation between 18F-FLT uptake 
and  cellular  proliferation  as  measured  by  MIB-1  immunostaining.  Both  18F-FLT 
SUVMax (r=0.65) and SUVMean (r=0.85) values correlated strongly with MIB-1 LI. 
These results are consistent with that of others that examined the role of 18F-FLT 
PET  as  surrogate  marker  of  proliferation  in  a  range  of  solid  and  haematological 
cancers  (a  summary  of  published  data  is  found  in  table  1.2).  Therefore,  our 
preliminary results support the hypothesis that 18F-FLT is as an in vivo marker of 
proliferation.  
 
In contrast to 18F-FLT, 18F-FDG uptake did not correlate with MIB-1 LI. This has 
also  been  shown  by  other  groups.  For  example,  in  pancreatic  cancer  Buck  et  al. 
(2001) found no correlation between 18F-FDG uptake and proliferative activity. In 
colorectal cancer, Francis et al. (2003a) also showed a lack of correlation between 
18F-FDG uptake and proliferation. Similar to our findings, their results also did not 
show a correlation between 18F-FLT and 18F-FDG SUVs. Although it is postulated 
that  a  rapidly  proliferating  cell  may  need  an  increased  energy  supply  by  glucose   177 
metabolism, metabolic activity is also needed for other cell functions. Furthermore, 
the enhanced glycolysis exhibited in cancer cells can be regarded as an “exaggerated” 
consequence  of  the  malignant  phenotype,  which  would  occur  independent  of  the 
DNA  turnover.  Therefore  as  suggested  by  our  results  and  others  alike,  tumour 
glycolysis and proliferation seem to be metabolically independent functions.  
 
Finally this study examined the relationship between 18F-FLT uptake and overall 
survival. There are at present no accepted thresholds for tumour SUVs and therefore 
the data was dichotomised using an average value of SUVMean measurements, as an 
arbitrary  cut-off  point.  Although  a  divergence  in  survival  curves  was  observed, 
neither tracer showed a significant correlation with overall survival. Drawing any firm 
conclusions  from  this  finding  is  limited  by  our  small  sample  size  and  the 
heterogeneity of the patient group. However, should a real survival difference exist 
between high and low 18F-FLT SUVs, there may be important clinical implications in 
terms of the use of 18F-FLT PET in directing the timing and the choice of neo-
adjuvant  /  adjuvant  treatments.  This  coupled  with  the  use  of  18F-FLT  PET  as  a 
surrogate marker of response to non-surgical treatments, is an avenue that requires 
further investigation.  
 
When interpreting our results, some of the methodological limitations of our study 
need to be borne in mind. The small sample size of this study limits the robustness of 
conclusions as our results are subject to type II errors. None the less, as a pilot project 
it  represents  a  platform  for  future  avenues  of  investigation.  The  additional 
shortcoming in the study was the fact that histological analysis was performed on core 
biopsies in 6 out of 10 cases, due to patients‟ having inoperable disease at initial   178 
staging.  As  single  tissue  specimen  cannot  account  for  tumour  heterogeneity,  the 
immunohistochemical  results  may  arguably  not  be  representative  of  the  whole 
tumour.  This  limitation  can  be  addressed  in  a  larger  patient  series  where  only 
surgically resected tumours can be assessed. As a study, this however would be a 
much  larger  undertaking  given  the  relatively  low  incidence  of  pancreatic  cancer 
coupled  with  the  fact  that  majority  of  patients  present  with  late  stage  and  thus 
inoperable disease. This was not achievable within the time constraints of this thesis.    179 
5.6 Conclusion 
18F-FLT PET is not a feasible tracer for use in the routine diagnosis and staging of 
pancreatic carcinoma and 18F-FDG seems to remain the PET tracer of choice. A 
strong association was however observed between 18F-FLT uptake and proliferative 
activity  as  measured  by  Ki-67  antigen  expression  (MIB-1  labelling  index).  This 
finding  may  have  implications  for  monitoring  treatment  and  prognosticating 
pancreatic cancer that requires further investigation.    180 
CHAPTER 6 
 
Staging of  
advanced colorectal cancer 
using 18F-FLT PET –  
A comparative study with 18F-FDG. 
   181 
6.1 Background 
 
18F-FDG PET is undoubtedly playing an increasing role in the routine management 
of advanced CRC. The study in chapter 4 illustrated that in the cohort of patients with 
CLM, 18F-FDG provided additional information that lead to a change in management 
of up to 25% of cases. This finding has also been mirrored in a number of other 
studies of PET imaging in primary and recurrent colorectal cancer.  
 
Despite  its  superior  sensitivity,  the  limitation  posed  by  imaging  with  18F-FDG 
remains its lack of specificity. While aerobic glycolysis is a predominant biochemical 
phenotype of most cancers, glucose metabolism and hence 18F-FDG uptake is not 
exclusively seen in cancer cells. Uptake of 18F-FDG has been frequently reported in 
inflammatory tissue. This often leads to diagnostic uncertainty where post-treatment 
inflammatory  changes  showing  18F-FDG  avidity  may  be  mistaken  for  tumour 
recurrence.  Peri-tumoural  aggregation  of  inflammatory  cells  as  part  of  the 
desmoplastic reaction of a tumour may also lead to aberrant 18F-FDG accumulation. 
Thus far, much effort has been focused on developing a more cancer specific PET 
tracer. An emerging candidate is the thymidine analogue PET tracer, 18F-FLT. 
 
18F-FLT has been shown both in vitro and in vivo to preferentially accumulate in 
cancer  cells.  Pre-clinical  studies  in  models  of  tracer  uptake  in  tumour  versus 
inflammation have also backed up the hypothesis that relative uptake of 18F-FLT by 
inflammatory  cells  is  minimal,  thus  suggesting  it  to  be  more  tumour  specific.  In 
addition  to  this,  18F-FLT  is  shown  to  correlate  well  with  other  markers  of 
proliferative activity, thus introducing itself as a potential surrogate marker of tumour 
proliferation.    182 
To date, there is only one published study of imaging CRC with 18F-FLT PET. In 
their  study,  Francis  et  al.  (2003b)  found  18F-FLT  to  be  a  more  specific  tracer 
compared to 18F-FDG, but its poor sensitivity in detecting hepatic lesions made it a 
poor candidate as a routine staging tool in the management of CRC. This pilot study 
therefore aimed at validating these findings in a cohort of patients with advanced 
CRC.  These  findings  were  to  be  used  as  stepping  stone  towards  future  research 
examining the use of 18F-FLT as a prognostic tool as well as a means of monitoring 
response to medical treatment.    183 
6.2 Aims 
The aims of this chapter were:  
1.  to  compare  the  accuracy  of  imaging  advanced  CRC  with  18F-FLT  PET 
compared to the gold standard 18F-FDG. 
2.  to examine the relationship between 18F-FLT and 18F-FDG tumour SUVs   184 
6.3 Material and methods  
 
6.3.1 Patient recruitment 
 
Patients  were  prospectively  recruited  from  routine  referrals  to  the  surgical  and 
oncology outpatients. 10 patients with locally advanced and/or metastatic CRC were 
included. All patients underwent conventional imaging with contrast enhanced CT 
(ceCT) of the thorax, abdomen and the pelvis. Each patient also underwent a whole 
body PET/CT scan using the routine tracer 18F-FDG and the thymidine analogue 
tracer 18F-FLT. The two PET/CT studies were performed with a median intervening 
period  of  2  days  between  the  two  (range  2-5  days).  The  study  was  conducted 
following local hospital ethics committee approval and with full informed consent of 
the patients as outlined in chapter 2.1. 
 
6.3.2 Imaging protocols 
Routine staging with ceCT was performed as described in chapter 2.5. The imaging 
protocol for whole body 18F-FDG and 18F-FLT PET/CT scans are also as described 
earlier. The median administered doses of tracers were 373 MBq (range 342-412) for 
18F-FDG  and  313  MBq  (range  229  –  435)  for  18F-FLT.  The  PET  images  were 
acquired at a median of 60 (range 58-65) and 61 (range 58-65) minutes post-injection 
for 18F-FDG and 18F-FLT respectively. The CT component of PET/CT was acquired 
without oral or intravenous contrast enhancement.  
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6.3.3 Image Analysis 
The PET images were qualitatively (visually) assessed by two experienced nuclear 
medicine physicians, blinded to the results of conventional imaging. To reduce recall 
bias, 18F-FDG and 18F-FLT images were analysed with at least 2 weeks between 
each  other.  Final  results  were  reached  by  consensus  between  the  two  observers. 
Images  were analysed on a lesion-by-lesion  basis and grouped  according to  body 
region. Lesions were deemed as positive where focal tracer accumulation was above 
that of the surrounding normal tissues. 
 
Tracer  uptake  was  semi-quantified  according  to  the  methods  described  in  chapter 
2.4.2. 1cm circular ROIs were used to calculate SUVs (corrected for body weight). 
SUVMax and SUVMean values were determined semi-automatically using the Xeleris
® 
workstation. Only lesions that were deemed positive with both tracers were included 
in the analysis.  
 
6.3.4 Statistical analysis 
All statistical calculations were performed using the GraphPad statistical Software (V 
4.0,  California,  USA).  The  correlation  between  tracer  SUVs  was  tested  using  the 
Pearson‟s  correlation  coefficient.  For  statistical  analyses,  a  two-tailed  p  value  of 
<0.05 was considered as statistically significant.   186 
6.4 Results 
 
6.4.1 Patient demographics  
Ten patients with a median age of 67 years (range 45-76 years) were included in the 
study. These consisted of 6 men and 4 women. A total of 34 abnormal lesions were 
detected  by  a  combination  of  routine  imaging  with  ceCT,  MRI  and  18F-FDG 
PET/CT. Of these, histological confirmation was obtained for 15 lesions (44%). In the 
remaining  cases  (19  lesions,  56%),  the  colorectal  MDT  deemed  the  sampling  of 
lesions inappropriate due to the extent of the patients‟ tumour burden. As for this, 
clinical and radiological follow-up of the patients for a median duration of 19 months 
(range 5-25 months) was used in confirming the diagnoses.  
 
6.4.2 Comparison of 18F-FDG and 18F-FLT PET in detecting malignant lesions 
Of the 34 suspicious lesions, final histological / radiological follow-up confirmed 29 
(85%) to be consistent with a malignant deposit. Lesions were grouped according to 
whether they were primary or recurrent/metastatic deposits. Metastatic deposits were 
further grouped according to body region. Table 6.1 summarises the imaging results 
for 18F-FDG and 18F-FLT PET according to the number of positive lesions detected.   187 
 
   
18F-FDG  18F-FLT 
True lesion 
status on 
follow-up 
   
   
              
Primary  Colon/rectum  2  2  2 
              
              
Recurrence / 
metastases 
Liver  13  1  14 
          
Lung  10  5  8 
          
Peritoneal  4  4  4 
          
Other abdominal 
(adrenal)  1  0  1 
              
   TOTAL  30  12  29 
 
 
Table 6.1: Number of PET positive lesions detected with 18F-FDG compared to 
18F-FLT PET scans. Lesions divided according to body region. True lesion status 
(indicating the presence of a malignant lesion) was determined by subsequent 
histological and/or radiological follow-up.   
 
 
In two patients with synchronous primary and metastatic disease, both primary sites 
were  detected  by  both  PET  tracers  (one  primary  sigmoid  and  one  primary  rectal 
carcinoma). Although visual analysis of 18F-FLT PET images identified both primary 
sites, tumour SUVs for 18F-FDG were higher for both lesions compared to that for 
18F-FLT. This difference is demonstrated in figure 6.1 for the rectal cancer.    188 
 
 
 
Figure 6.1: Sagittal CT, PET and PET/CT fused images of a rectal cancer imaged 
with 18F-FDG and 18F-FLT. Images demonstrate relatively lower uptake of 18F-
FLT compared to 18F-FDG.  
 
 
A total of 14 liver metastases were confirmed on subsequent follow-up. Initial staging 
with ceCT identified 15 liver lesions of which there were 2 false positive and 2 false 
negative findings. 18F-FDG PET detected 13 (93%) hepatic lesions of which there 
was one false negative result. This was subsequently found at laparotomy to be a sub-
18F-FDG 
PET/CT 
 
SUVMax = 8.7 
18F-FLT 
PET/CT 
 
SUVMax = 3.4   189 
centimetre lesion on the liver capsule with a concurrent larger lesion in the right lobe 
of the liver, both of which were resected and histologically confirmed. The two false 
positive ceCT lesions were correctly characterized as negative on 18F-FDG PET. In 
comparison  to  18F-FDG,  only  1  hepatic  metastasis  was  visualized  with  18F-FLT 
(7%). This was a 2cm solitary lesion in the right lobe of the liver (figure 6.2). Both 
liver  lesions  that  were  incorrectly  characterised  as  metastases  on  ceCT  (ie:  false 
positives) were also negative on 18F-FLT PET.  
 
 
 
 
Figure 6.2: Coronal slices of 18F-FDG and 18F-FLT PET scans demonstrating a 
tracer avid solitary metastasis in the right lobe of the liver. 
  
With  regard  to  metastases  to  other  regions,  both  18F-FDG  and  18F-FLT  PET 
correctly identified all 4 peritoneal metastases. Of the 10 lung lesions identified on the 
initial ceCT scans, all 10 showed 18F-FDG avidity but 2 of these lesions were later 
18F-FDG PET  18F-FLT PET   190 
confirmed to be false positives as follow-up imaging with ceCT was suggestive of 
them being of infective aetiology (lesions disappeared on follow-up scans). 18F-FLT 
PET on the other hand detected 5 lung lesions, all of which were confirmed to be true 
positive findings. The 2 false positive lesions (infective nodules) seen on the 18F-
FDG scans were negative for 18F-FLT. There were also 3 false negative lung lesions 
missed by the 18F-FLT PET scan.  
 
In one patient with lung and liver metastases, an adrenal mass was also seen on the 
routine ceCT scan. Assessment with MRI further confirmed this be highly suggestive 
of  a  metastatic  deposit.  This  lesion  was  visualized  on  18F-FDG  but  was  falsely 
negative on 18F-FLT PET study.  
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6.4.3 Comparison between 18F-FDG and 18F-FLT SUVs 
Of the 29 malignant deposits, 12 lesions were confidently visualized on the 18F-FLT 
PET/CT scans. SUVs for these were compared to that of 18F-FDG, results of which 
are presented in table 6.2.  
 
    18F-FDG  18F-FLT 
Lesion  Site of lesion  SUVMean  SUVMax  SUVMean  SUVMax 
1  Rectum  6.3  8.7  2.2  3.4 
2  Colon  6.7  7.3  2.0  6.7 
3  Liver  2.6  5.5  1.5  4.5 
4  Lung  2.2  3.2  1.0  1.3 
5  Lung  3.1  4.0  0.9  2.3 
6  Lung  2.9  4.0  1.7  1.2 
7  Lung  5.5  7.1  1.5  2.2 
8  Lung  3.9  4.5  0.9  2.0 
9  Peritoneal  4.4  5.3  1.7  2.3 
10  Peritoneal  4.6  6.1  2.1  2.3 
11  Peritoneal  3.9  5.5  2.7  4.5 
12  Peritoneal  5.5  6.3  1.7  1.9 
 
Table 6.2: Tabulated summary of SUVs measured for 18F-FDG and 18F-FLT avid 
lesions. 
 
On average, 18F-FDG SUVs were between 1.95 (SUVMean) to 2.59 (SUVMax) fold 
higher than 18F-FLT This difference was statistically significant and is represented in 
figure 6.3.    192 
 
Figure 6.3: Graph demonstrating the difference between the average SUVMean and 
SUVMax figures for 18F-FDG and 18F-FLT. The difference between the two reached 
strong statistical significance (Student’s t-test).  
 
*p < 0.05 
**P < 0.05   193 
There was no correlation seen between 18F-FDG and 18F-FLT SUVs  as shown in 
figure 6.4.  
 
 
Figure 6.4: Correlation between 18F-FDG and18F-FLT SUVs for all detected lesion. 
There was no statistically significant correlation seen between 18F-FDG and 18F-
FLT SUV.   194 
6.5 Discussion 
The aim of this pilot study was to examine the feasibility of imaging advanced CRC 
with 18F-FLT PET compared to the routine tracer 18F-FDG. Consistent with several 
published reports, the overall uptake of 18F-FLT in malignant deposits was lower 
than for 18F-FDG (Francis et al. 2003b; Cobben et al. 2004b; van Westreenen et al. 
2005). Furthermore, the lack of correlation between 18F-FDG and 18F-FLT SUVs 
supports  the  hypothesis  that  tumour  glycolysis  and  cellular  proliferation  are 
independent processes in tumorogenesis.  
 
Overall,  18F-FDG  PET  correctly  characterized  26  of  the  29  malignant  lesions 
(Sensitivity = 96%), whereas 18F-FLT PET visualized only 12 (sensitivity = 41%). In 
detecting non-primary foci of disease, 18F-FLT PET identified all peritoneal deposits 
and 5 out of 8 (63%) lung metastases. In the latter group, 2 lung lesions were found to 
be  falsely  positive  on  the  18F-FDG  scan  as  they  were  later  confirmed  to  be  of 
infective  aetiology.  Both  these  lesions  did  not  show  any  18F-FLT  avidity,  thus 
correctly characterizing the lesions as non-malignant. This therefore gave 18F-FLT a 
specificity  of  100%  compared  to  50%  for  18F-FDG.  Consistent  with  previously 
published reports, this suggests 18F-FLT to be a more specific tracer. However, the 
small  proportion  of  false  positive  findings  in  our  series  makes  drawing  a  firm 
conclusion from these results difficult. In particular it can be argued that in our series, 
the negative nature of these two lesions may be related to 18F-FLT‟s overall poor 
sensitivity. This argument can only be clarified in a study with a larger sample size, 
which would allow subgroup analysis of all apparent false positive lesions that are 
found on conventional imaging and 18F-FDG PET.  
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In staging the liver, 18F-FLT also performed poorly, visualizing 1 out of 14 (7%) 
lesions. The above results are inferior to that reported by Francis et al (2003). In their 
series of 23 CRC patients, 5 out of 6 (83%) lung and all peritoneal lesions seen with 
18F-FDG  PET  were  also  correctly  visualized  with  18F-FLT.  Their  reported 
sensitivity for detecting liver metastases with 18F-FLT PET was 34% (11/32 lesions), 
which was also poor. In the management of CRC, accurate detection and staging of 
liver metastasis remains a clinical challenge as 30% of patients ultimately develop 
liver secondaries. Although advances in imaging technology (eg: with the routine use 
of multidetector CT, MRI and micro-bubble contrast ultrasound scans) have improved 
the accuracy of detecting disease in the liver, there is still no consensus as to the 
imaging modality of choice in characterizing small (sub-centimetre) liver lesions. In 
this respect 18F-FLT PET does not seem to have an additional advantage.  
 
It must be noted that the apparent success of 18F-FDG PET in imaging the liver is 
related to the high degree of contrast achieved between the high 18F-FDG avidity of 
CLM and low background accumulation of the tracer in normal liver parenchyma. 
Our results are consistent with published reports to date that have consistently shown 
the sensitivity of 18F-FLT PET in detecting liver metastases to be poor. This finding 
can in part be attributed to the high background uptake of the tracer in the liver. This 
phenomenon was first described by Shields et al. (2003) in their original description 
of imaging with 18F-FLT using canine models and later in human subjects.  The 
underlying  mechanism  for  this  has  been  explained  by  examining  the  hepatic 
metabolism of AZT, an antiretroviral drug from which FLT was initially developed. 
Aside  from  phosphorylation  within  cells,  AZT  is  metabolised  in  hepatocytes  by 
glucuronidation,  a  process  that  is  catalysed  by  the  hepatic  enzyme  UDP-  196 
gluocoronosyltransferase. This makes the compound more water soluble and therefore 
more  easily  excreted  in  urine  and  bile.  As  18F-FLT  PET  images  are  on  average 
acquired at about 60 minutes post tracer injection, only excreted tracer is seen to 
accumulate  in  the  renal  tract.  There  are  currently  no  reports  of  biliary  excretion 
resulting in image artefact within the gastro-intestinal tract. The problem that arises is 
due to the high background accumulation of 18F-FLT in hepatocytes, which hinders 
the  detection  of  small  hepatic  metastases  that  are  exhibiting  relatively  low-grade 
tracer uptake. Previous work at our unit has shown significantly higher normal liver 
18F-FLT uptake (median SUV=4.2, range 2.7-5.6) compared to 18F-FDG (median 
SUV= 2.1, range 1.5-2.4). The above suggests that a minimum threshold for tracer 
uptake needs to be reached before a hepatic lesion can be clearly visualized. As for 
this, 18F-FLT PET is unlikely to supersede 18F-FDG as a routine tracer in staging 
colorectal cancer and colorectal liver metastases.    
 
While  the  inferior  sensitivity  of  18F-FLT  for  detecting  liver  metastases  may  be 
explained by the liver‟s high background tracer uptake, its relatively poor detection 
rate of lung lesions may have other explanations. In our series, 50% of lung lesions 
with avid 18F-FDG uptake were negative for 18F-FLT, although of these 2 were truly 
negative in the face of false findings with 18F-FDG. In the lungs, background 18F-
FLT  accumulation  is  minimal  and  therefore  problems  with  tumour-to-background 
contrast are not implicated. However, inaccuracies may arise in small lung lesions 
where partial volume effect  and motion  artefacts  can reduce 18F-FLT‟s detection 
accuracy. In fact coupled with the limitations posed by the spatial resolution of PET, 
the challenge of visually detecting small volume disease is one that continually limits 
the  overall  detection  accuracy  of  PET.  Newer  generation  PET  detector  units  are   197 
reported to have a better spatial resolution, which may help to address this problem. 
Furthermore, the use of PET/CT image fusion is increasingly allowing a two-pronged 
approach (metabolic + anatomical imaging) to characterizing small lesions. The latter 
at present seems to be only clinically relevant if the CT component of PET/CT has 
full  diagnostic  capability.  Overall  however,  one  cannot  disregard  the  underlying 
disease biology, which dictates the pharmacokinetics of tracer uptake at cellular level. 
There is therefore a real need for validating studies that examine the true relationship 
between what is seen on a PET scan and the biology of the tumour.  
 
There  is  mounting  evidence  supporting  the  hypothesis  that  18-FLT  uptake  is  a 
surrogate marker of proliferation. In CRC, Francis et al. (2003b) showed a strong 
correlation between 18F-FLT SUV and Ki-67 antigen expression . Table 1.2 (Chapter 
1.6.5) also summarised the results of several other published studied that have shown 
a strong correlation between 18F-FLT accumulation and proliferation in a number of 
other  solid  and  haematological  cancers.  Based  on  this  assumption,  18F-FLT 
negativity may have important prognostic implications. On the one hand, tumours 
with a lower proliferation index may confer a survival benefit. On the other, they may 
confer a poorer response to certain cycle dependent chemotherapy regimens. Future 
avenues of research would therefore need to examine the relationship between 18F-
FLT accumulation and the clinical and biological behaviour of colorectal cancer.  At 
present there is growing interest in examining the role of 18F-FLT PET in monitoring 
response  to  treatment  (eg:  radiotherapy,  chemotherapy  or  monoclonal  antibody 
treatment). A potential pitfall that may complicate this line of research is the high 
false negative rate of imaging with 18F-FLT PET. If lesions exhibit no 18F-FLT 
accumulation at the outset of the treatment regimen, then the routine morphological   198 
parameters  (ie:  tumour  dimensions)  would  remain  the  only  mode  of  monitoring 
response. As thus, 18F-FLT PET would be of no added value. However as mentioned 
above, baseline 18F-FLT uptake parameters may have a predictive value, which may 
potentially  influence  the  selection  of  the  most  appropriate  treatment  regimen, 
particularly when deciding which chemotherapy agents are used. To the best of my 
knowledge, this hypothesis has not yet been tested and requires further investigation.  
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6.6 Conclusion 
This study further confirms previous reports that 18F-FLT PET is a poor candidate as 
a routine diagnostic and staging tool, in both primary and metastatic CRC. Lack of 
correlation between 18F-FDG and 18F-FLT SUVs supports the hypothesis that there 
is a poor relationship between glucose metabolism and thymidine turnover. Although 
not tested in this study, the prognostic implication of 18F-FLT uptake as a predictor 
and measure of response to medical treatment warrants further investigation.    200 
CHAPTER 7 
 
Measuring early adaptive response 
to 5-fluorouracil with  
18F-FLT  -  
an in vitro study.   201 
7.1 Background 
 
At present, the mainstay of monitoring response to treatment involves a combination 
of  measuring  serial  serum  tumour  marker  levels  and  the  visualisation  of 
morphological changes with cross-sectional imaging techniques such as CT or MRI. 
The limitations of these techniques are their lack of specificity as well as the fact that 
they  represent  temporally  delayed  changes  in  tumour  biology  in  response  to 
treatment.  Being  able  to  detect  response  early  in  the  course  of  treatment  has  the 
advantage of allowing appropriate and timely changes in treatment regimen, which 
may ultimately impact overall survival. Attempts at molecular profiling of cancer in 
monitoring and predicating response to treatment have been largely limited by the 
need to obtain tissue specimen, which in turn may not always account for tumour 
heterogeneity. Molecular imaging  can be used  to  address  this  problem. Assessing 
whole tumour biology in vivo not only provides a non-invasive means of monitoring 
early response to treatment, but may also aid future investigation into novel molecular 
targeted treatments. 
 
In previous chapters, the feasibility of imaging with 18F-FDG and 18F-FLT PET was 
investigated  in  the  routine  clinical  setting  of  pancreatic  and  advanced  colorectal 
cancer (CRC). In both cancer types, 18F-FDG is shown to provide a sensitive means 
of detecting cancer burden. Its role as a surrogate marker of tumour viability also has 
the potential to contribute to the paradigm shift, which is the monitoring of therapy 
response on at a biological level. In the management of CRC for example, a number 
of studies  have  examined the role of  18F-FDG PET in  assessing early biological 
response  to  radiotherapy  (Cascini  et  al.  2006),  chemotherapy  (Weber  and  Wieder 
2006)  or  radiofrequency  ablation  of  liver  metastases  (Donckier  et  al.  2003).  The   202 
results  have consistently indicated a strong  correlation  between early reduction in 
18F-FDG  uptake  and  a  positive  response  to  treatment.  Despite  18F-FDG‟s 
widespread use, targeting tumour glycolysis represents one of a number of potential 
surrogate end points of disease. Therefore, being able to quantify tumour proliferation 
with the thymidine analogue tracer 18F-FLT, has recently attracted intense interest. 
 
The  challenge  of  predicting  response  to  chemotherapeutic  agents  is  perhaps  best 
exemplified  by  the  use  of  5-fluorouracil  (5-FU)  in  advanced  colorectal  cancer. 
Despite its widespread use, overall response rates to 5-FU alone are reportedly no 
greater than 10-15% (Longley et al. 2003). The mode of action of 5-FU is complex. It 
exerts its main cytotoxic effect by inhibiting the enzyme Thymidylate Synthase (TS). 
TS, which is the rate-limiting enzyme of the de novo pathway of pyrimidine synthesis, 
catalyses  the  reductive  methylation  of  deoxyuridine-5‟-monophosphate  (dUMP)  to 
deoxy-thymidine-5‟-monophosphate (dTMP). This provides the sole de novo source 
of thymidine required for DNA repair and synthesis. Inhibition of TS results in an 
imbalance of intracellular nucleotide pools (such as deoxyribonucleotide triphosphate 
(dNTP)) and subsequent lethal DNA damage (Parker and Cheng 1990). More minor 
and less well understood mechanisms of 5-FU cytotoxicity are also believed to result 
from the direct incorporation of metabolites of 5-FU into RNA and DNA.  
 
Much  effort  has  been  focused  on  developing  predictive  biomarkers  of  5-FU 
resistance.    However,  the  mechanisms  of  resistance  to  5-FU  are  also  complex, 
involving numerous changes that may include; deletions of key activating enzymes, 
increased expression of catabolising enzymes, lack of reduced folate substrate, gene 
amplification  and  alterations  in  protein  expression  of  TS.  Although  there  are   203 
conflicting reports in the literature, the salvage pathway of nucleotide synthesis has 
also  been  implicated  as  a  potential  mechanism  of  5-FU  resistance  (Pickard  and 
Kinsella 1996; Kinsella et al. 1997). So far, no one marker has emerged as more 
specific above others. 
 
The rationale behind this study uses 5-FU as a model for TS inhibition. In response to 
the imbalance of intracellular dNTP pools outlined earlier, cells acquire exogenous 
pyrimidines through activation of the salvage pathway (TK-1) (Parker  and Cheng 
1990; Pickard and Kinsella 1996). This shift from one enzyme system (TS) to the 
other (TK-1) may potentially be monitored in vivo with 18F-FLT PET. We therefore 
hypothesized that cellular 18F-FLT uptake represents a potential tool for monitoring 
early biological response to 5-FU therapy. This hypothesis was tested in a colorectal 
cancer cell line model, where early biological effects of 5-FU on cellular uptake of the 
two tracers 18F-FDG and 18F-FLT were compared. Cisplatin, which does not directly 
influence pyrimidine metabolism, was used as a control drug to 5-FU.   204 
7.2 Aims 
 
The principal aim of this study was to examine in vitro, the early changes in uptake of 
18F-FLT compared to 18F-FDG following treatment with 5-FU. This was carried out 
in two colorectal cancer cell lines and by determining the response to 5-FU in terms 
of: 
1) cell cytotoxicity (ie: tumour viability). 
2) changes in the cell cycle pattern using flow cytometry. 
3) changes in Thymidine kinase-1 (TK-1) protein expression.   205 
7.3  Methods 
 
7.3.1  Materials and cell lines 
i) Materials: Plastic consumable items were bought from Nunc (VWR, Poole, Dorset, 
UK), while chemicals were obtained from Cambrex Biowhittaker (Woking, Berks, 
UK), unless otherwise stated. 
 
ii) Cell lines: Two human colorectal cancer cell lines were used; SW480 is derived 
from a primary colorectal cancer and SW620 is derived from a colorectal lymph node 
metastasis. Both cell lines were obtained from the European Collection of Animal 
Cell Cultures (Porton Down, Wilts, UK).  
 
7.3.2   Routine cell line maintenance 
SW480  and  SW620  cells  were  routinely  grown  in  75cm
2  flasks  in  Dulbecco‟s 
Modified  Eagle‟s  Medium  (DMEM)  (supplemented  with  L-glutamine,  10%  (v/v) 
foetal calf serum (FCS), 50 mg/ml Gentamicin) at 37
oC.  All work described below 
was  carried  out  within  15  cell  passages  in  order  to  minimize  differences  due  to 
phenotypic drift. 
 
To  prepare  cells  for  propagating  a  rolling  stock  or  for  carrying  out  the  proposed 
experiments, the following steps were followed:  
 
  Cells were allowed to grow to near confluence levels (approximately 90%), 
washed three times; twice in phosphate buffered saline (PBS) followed by one 
wash with a 0.02% solution of Ethylenediamine tetracetate (EDTA) in PBS. 
The latter step was necessary to remove FCS (which has an inhibitory effect   206 
on trypsin used for enzymatic disaggregation) and furthermore EDTA chelates 
membrane bound Ca
2+, which aids in the disaggregation process. 
  A 1mg/ml solution of trypsin (in EDTA/PBS) was then used for enzymatic 
disaggregation. 
  The disaggregated cells were harvested in medium supplemented with FCS to 
partially neutralise trypsin, centrifuged (400g,  5min) to separate cells from 
trypsin containing supernatant and again re-suspended in fully supplemented 
medium.  
 
Cells were then either (i) passaged into flasks (at 1:3 to 1:10 ratios) and maintained as 
above  for  later  use,  or  (ii)  counted  using  a  haemocytometer  and  re-suspended  at 
appropriated dilutions for experiments as described below. 
 
7.3.3 The basic experimental protocol 
For all experiments, 2 x 10
5 cells / well were seeded in six-well plates and kept in a 
humidified  incubator  at  5%  CO2  /  air.    The  optimum  seeding  densities  were 
determined by earlier pilot studies, details of which will not be outlined in this thesis.  
The reason for using six-well plates (growth area of 9.5 cm
2 per well) for the 5-FU 
toxicity  and  radiotracer  uptake  experiments,  was  so  that  at  the  end  of  each 
experiment, harvesting would result in cell numbers sufficient for counting under a 
light microscope and would give cells suspension volumes large enough (minimum of 
2 ml required) for the gamma well counter used for radiotracer uptake measurements.  
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48 hours after seeding, cells were incubated with 5-FU and assayed for tracer uptake, 
S-phase fraction (SPF) and TK-1 expression. This will be outlined in more detail in 
the following sections.  
 
7.3.4  Defining dug dose parameters 
5-FU  was  purchased  from  Calbiochem  (MERK  biosciences  Ltd,  Nottinghamshire, 
UK) and Cisplatin from Faulding Pharmaceuticals Plc (Warwickshire, UK).  
To study the effect of 5-FU on cellular viability,  cells were plated for 48 hours (as 
above) and were exposed to a dose range (1 –250  g/ml) of 5-FU for 2 hours. Control 
experiments  were  drug  free,  but  as  5-FU  solutions  were  made  up  in  fully 
supplemented culture media, at each corresponding time point the control cells also 
received a medium change.  After 2 hours of drug exposure, the drug was removed 
and both the treated and untreated cells were washed 3 times with PBS.  They were 
then allowed to recover for 30 minutes, 24 and 48 hours (represented as days 0, 1 and 
2 respectively). At each time point following cell recovery, the cells were harvested 
by trypsynisation and their viability detected by Tryphan blue (Sigma, Dorset, UK) 
exclusion on a haemocytometer. All cytotoxic assays were performed in triplicate. 
   
Both  SW480 and SW620 cells  showed similar dose response cytotoxicity (Figure 
7.1a). Dose response curves were used to determine the optimum cytotoxic dose for 
5-FU at which 50% cell killing was observed on day 1. For 5-FU exposure of 2 hours, 
this dose was found to be 50  g/ml.  
 
As a control experiment to 5-FU, comparative experiments were carried out using 
Cisplatin.  Earlier  pilot  studies  determined  the  optimal  dose  of  Cisplatin  to  be  50   208 
g/ml (data not shown). The cytotoxic effect of this dose was demonstrated using the 
cell viability counts on days 0-2 (figure 7.1b). 
 
7.3.5 Tracer uptake experiments: 
Radiopharmaceuticals 
18F-FDG and 18F-FLT were purchased from sources previously detailed in sections 
2.2 and 2.3. Radiopharmaceuticals used in each experiment were obtained from the 
same stock of tracer that was used for clinical studies. 
 
Experimental protocol 
Each experiment involved preparing a batch of 5-FU treated and untreated cells, as 
described in section 7.3.3. Experiments at each respective time point  (days 0, 1 and 
2) were prepared in separate 6 well plates. Each plate was divided into two halves; 3 
wells for the treated group and 3 wells for the untreated group. Cells from one well in 
each experimental group was used for cell viability counts. This arrangement allowed 
2 repeats per experiment and with each experiment being repeated 3 times, it gave 6 
repeats per experimental data set.   
 
At 2 hours post 5-FU exposure, the drug was aspirated, cells were washed (PBS x3) 
and allowed to recover in fresh supplemented medium for 30 minutes. To determine 
tracer  uptake,  cells  were  immediately  incubated  with  fully  supplemented  culture 
medium containing 100 KBq total activity of either  18F-FLT or 18F-FDG for 90 
minutes (incubated  at  37
oC in  5% CO2).  Following tracer incubation,  cells  were 
washed three times with ice cold PBS in order to stop further tracer uptake and to   209 
remove  unbound  radiotracer.  The  cells  were  then  harvested  by  trypsinisation  as 
described before.  
 
Tracer uptake was quantified by measuring the radioactive counts in a gamma well 
counter (Wallac, Turku, Finland) over 1 minute. Radioactivity measurements were 
decay  corrected.  Tracer  uptake  was  calculated  as  a  percentage  of  total  applied 
radioactivity and corrected for cell numbers.  
 
Using SW480 cells only, 18F-FLT uptake was also measured following treatment 
with  an  increasing  dose  of  5-FU  (dose  range  1-250  g/ml).  Control  experiments 
examined the effect of Cisplatin on tracer uptake. The same experimental protocols as 
that used for 5-FU were again followed.  
 
7.3.6 Cell cycle phase determination 
5-FU treated (dose 50  g/ml) and untreated cells were grown in  6 well plates as 
described earlier. At each time point (days 0, 1 and 2), the cells were labelled with 
Bromodyoxyuridine  (BrdU)  and  analysed  by  flow  cytometry  as  described  below. 
Cells in each experimental group were labelled for 20 minutes with BrdU (10mM) in 
culture medium, harvested by trypsinisation, fixed in ice cold 70% (v/v) ethanol and 
stored at 4
oC until used. Single cell suspensions were pelleted, washed with 0.5% 
BSA/PBS, and re-suspended in 0.1M HCL (10 minutes) to unwind DNA. Following 
three washes with 0.1% Tween-20/PBS (PBS-T), cells were incubated with  -BrdU 
antibody (Becton Dickinson, CA, USA; 1:20 dilution for 15 min.), washed twice and 
stained  with  a  flourecein  isothiocynate  (FITC)-conjugated  goat  -mouse  antibody 
(Dako, Cambridgeshire, UK; 1:10 dilution for 15 min).   210 
 
After  a  final  wash  (PBS-T),  cells  were  treated  with  50  ml  of  RNAse  A  (Sigma, 
Dorset, UK; 100 mg/ml for 15 min) and 300 ml of propidium iodide (Sigma, Dorset, 
UK;  50  mg/ml  for  30  min).  Samples  were  analysed  on  a  FACSCalibur  (Becton 
Dickinson, USA). Propidium iodide fluorescence was measured above 670nm and 
FITC fluorescence between 515 and 545nm. 20,000 events from each sample were 
recorded and data analysed using the FlowJo software (TreeStar, California, USA). 
 
7.3.7 TK-1 protein expression  
Changes in TK-1 expression were investigated in response to 5-FU treatment. Cells 
were grown in 75cm
2 flasks to approximately 60% confluence and incubated with 5-
FU (as described above). Untreated controls were run in parallel.  
 
7.3.7.1 Protein extraction 
At each time point, cells were harvested by trypsynisation as described in section 
7.3.4. Protein was extracted by adding an equal volume of distilled water to the cell 
pellet in order to osmotically lyse cell membranes. The cell suspensions were further 
lysed by freeze / thawing cycles [6 freeze cycles in liquid nitrogen for 3 minutes 
followed  by  thawing  in  a  30
oC  water  bath  for  5  minutes].  The  lysed  cells  were 
centrifuged at 4
oc and 10,000rpm for 10 minutes in order to separate cell debris. The 
supernatants were then transferred into labelled Eppendorfs™. 
 
7.3.7.2 Protein assay 
The concentration of protein lysates were determined by using the Bradford protein 
assay  kit  (Biorad  Ltd,  UK).  Serial  dilutions  of  BSA  (concentration  range  of  0  –   211 
2mg/ml) in distilled water were prepared for determination of standard curves (see 
appendix E).  
 
Samples were prepared by mixing 10 l of the lysate to 10 l of 0.1M HCL and 80 l 
of water. 3.5 ml of Bradford reagent (diluted 1:5) was then added to the solution, 
vortexed for 10 seconds and allowed to incubate at room temperature for 5 minutes. 
The optical density readings were taken at 595nm using a “Perkin Elmer Lambda” 
photospectrometer.  The  optical  density  readings  were  used  to  calculate  the 
concentration of protein extracts using the BSA solution as the standards curve.  
 
 
7.3.7.3  Gel electrophoresis and Western blots 
 
Western blots were performed according to the technique described by Sambrook and 
Russell (2001), using the protocols detailed in appendix F.  
 
20  g aliquots of total protein from cell lysates were mixed with an equal volume of 
Laemmli sample buffer (Laemmli 1970) and were boiled at 100
oC for 3 minutes to 
denature the proteins (reducing condition). Samples were then loaded onto pre-cast 
12%  Tris-Glycine  polyacrylamide  gels  (Biorad  Ltd,  Herts,  UK)  together  with  a 
rainbow  molecular  weight  marker  (Color  Burst
TM,  Sigma-Aldrich,  Dorset,  UK). 
Electrophoresis was carried out at 150 V for 1 hour.  
 
Proteins were transferred to polyvilinidine difluoride membrane (PVDF) (Hybond-
P™ –Amersham, Bucks, UK) at 0.25 amps per mini-gel blot for 20 minutes. The 
blots were blocked overnight with 1% BSA (in PBS-T) at room temperature. TK-1 
was detected with a mouse monoclonal antibody (Abcam, Cambridgeshire, UK). The   212 
membranes  were  incubated  with  the  -TK-1antibody  (1:800  dilution  in  0.5% 
BSA/PBS-T) for 2 hours, at room temperature. The blots were then washed with PBS-
T  and  then  incubated  with  a  goat  -mouse  horse  raddish  peroxidase  (HRP) 
conjugated secondary antibody (1:600 dilution, 1h; DAKO, Glostrup, Denmark). The 
membranes were visualized by a calorimetric reaction using 3-3‟-diaminobenzidine 
tetrahydrofluoride (DAB – Sigma Aldrich, Dorset, UK) as a substrate. Lanes were 
standardized for protein loading by detecting  -tubulin expression (mouse  -tubulin; 
Sigma-Aldrich UK).  
 
7.3.8 Statistical analysis 
Statistical  analyses  were  carried  out  using  the  software  GraphPad  Prism  (Version 
4.03;  California,  USA).  Analysis  of  variance  was  performed  using  a  one-way 
ANOVA. Differences between paired data were tested for significance using a two-
tailed Student‟s t-test. p values of <0.05 were considered to be statistically significant. 
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7.4 Results 
7.4.1 Cytotoxic effects of 5-FU and Cisplatin  
Figure 7.1 (a and b) demonstrate the percentage cell killing by 5-FU (50  g/ml) and 
Cisplatin (50  g/ml) for SW480 and SW620 cells. Both cell lines exhibited a similar 
cytotoxic response to the drugs, with minimal cell killing observed on day 0 (5-FU: 0-
7%) ; Cisplatin: 0-13%). However, on subsequent days (days 1 and 2), the cytotoxic 
effect of both drugs are seen to increase. For all subsequent experiments, only the 
above 5-FU and Cisplatin doses were used.  
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Figure 7.1 (a and b): Cytotoxic effect of 5-FU (50  g/ml for 2 hours) and Cisplatin 
(50  g/ml for 2 hours) on cell numbers. Minimal cell kill was observed on day 0 (ie: 
at 2 hours post drug exposure) for both drugs. The increasing cytotoxic effect of the 
drugs on subsequent days post-treatment (day 1 & 2) are demonstrated. 
 
 
 
b) Cisplatin treated cells   215 
7.4.2
 18F-FLT vs 18F-FDG uptake following 5-FU treatment 
 
Figure 7.2 (a-d) graphically represents changes in tracer uptake (18F-FLT vs 18F 
FDG) on day 0, in response to treatment with 5-FU and Cisplatin.  
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(b) 18F-FLT uptake in Cisplatin treated cells
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(c) 18F-FDG uptake in 5-FU treated cells
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(d) 18F-FLT uptake in 5-FU treated cells
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Figure 7.2:  Changes in uptake of 18F-FDG (a & c) and 18F-FLT (b & d) on day 0, 
in response to treatment with 5-FU (50  g/ml for 2 hours) and Cisplatin (50  g/ml for 
2 hours). 
 
After a two hours pulse treatment with 5-FU, there was a mean 2.8 fold increase in 
18F-FLT  uptake  SW480  (p<0.0001)  and  2.9  fold  for  SW620  cells  (p  =0.0004).   217 
Cisplatin treatment under identical conditions resulted in a minor reduction in mean 
18F-FLT  uptake,  but  this  did  not  reach  statistical  significance  (SW480:  p=0.55; 
SW620: p=0.19; t-test). In comparison to 18F-FLT, 18F-FDG uptake changed little 
for SW480 cells (5-FU: p=0.92; Cisplatin: p=0.81; t-test). SW620 cells on the other 
hand, showed a reduction in tracer uptake in response to both cytotoxics but this 
difference  again  did  not  reach  statistical  significance  (5-FU:  p=0.05,  Cisplatin: 
p=0.05; t-test). 
 
In order to determine if changes in 18F-FLT uptake following 5-FU treatment were 
dose dependent,  a parallel experiment  on SW480 cells  was  carried out  on day 0. 
Across 5-FU dose of range of 1-250  g/ml, a statistically significant dose dependent 
increase in 18F-FLT uptake was seen (p = 0.005; one way ANOVA) (figure 7.3).  
 
 
Figure 7.3: Dose dependent increase in 18F-FLT uptake in SW480 cells, across a 
range of 5-FU doses. A statistically significant difference between the groups was 
observed (n=6, p=0.005; one way ANOVA).    218 
7.4.3 Cell cycle changes in 5-FU treated cells 
 Flow-cytometric analysis of BrdU incorporation was used to detect changes in the 
SPF at three time points following 5-FU treatment (days 0-2). The distribution of S-
phase cells at each time point is summarised in table 7.1.  
 
                 
    % S-phase cells   
    Treated        Untreated    
    Mean  SD 
    
Mean  SD  p 
        
S
W
6
2
0
 
                       
Day 0  52.4  11.0        47.0  8.1  NS 
                     
Day 1  77.7  14.0        28.7  11.5  0.002 
                     
Day 2  46.0  19.5        34.7  0.1  NS 
                     
S
W
4
8
0
 
                       
Day 0  57.6  4.5       49.4  4.0  NS 
                    
Day 1  61.1  3.1       35.8  6.6  0.004 
                    
Day 2  32.5  23.6       21.8  4.4  NS 
                       
 
Table 7.1 :  The distribution of S-phase cells at different time points in the 5-FU 
treated and untreated groups. 
 
On day 0, no significant change in SPF was observed between the treated and control 
(untreated) cells. This is better demonstrated by the representative scatter plots in 
figure 7.4 (a-d).   219 
 
Figure 7.4 (a-d): Scatter plots representing the distribution of S-phase cells on day 0 
following 5-FU treatment [SW480 cells: a) Control cell, b)5-FU treated cells; SW620 
cells: c)Control cells, d) 5-FU treated cells].  
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On subsequent days, there appeared to be a cell cycle phase shift in response to 5-FU 
treatment. On day 1 both cells lines showed a statistically significant increase in S-
phase  accumulation  (Fold  change  in  SPF:  SW480  =  1.76  +  0.43  (p=0.002); 
SW620=2.88  +  0.69  (p=0.004)),  with  SW620  cells  demonstrating  a  higher  fold 
change in SPF as compared to SW480 cells (figure 7.6). By day 2, the proportion of 
S-phase  cells  seemed  to  decrease  again.  This  corresponded  to  the  cell  viability 
changes observed earlier. At this time point, there was again no statistical difference 
seen in the proportion of S-phase cells in 5-FU treated and untreated group (Mean 
fold change in SPF: SW480 = 1.41+ 0.81(p = 0.48); SW620 = 1.32 + 0.56 (p = 0.50)). 
 
 
Figure 7.5: Fold change in SPF of cells on days 0 to 2 following treatment with 5-
FU. On day 0, there was no significant change in SPF, whereas a significant increase 
in S-phase cells was seen on day 1 [Mean fold change (SD) on day 1: *SW480 = 1.76 
+ 0.43 (p=0.002),  **SW620 = 2.88 + 0.69 (p=0.004)]. 
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7.4.4 Changes in TK-1 expression 
Protein  separations  were  carried  out  under  reducing  conditions  and  therefore  the 
expression of TK-1 in its monomeric form (24 kDa) was detected. The level of  -
tubulin  in  each  sample  was  used  as  an  internal  standard  to  ensure  equal  protein 
loading.  As  demonstrated  in  Figure  7.7,  for  both  cell  lines  5-FU  treatment  was 
associated with an increase in TK-1 protein expression. This was also in line with the 
observed increase in 18F-FLT uptake seen in 5-FU treated cells. Analysis of bands by 
densitometry (corrected for protein loading) showed this difference to be statistically 
significant (SW480: p=0.012, SW620: p=0.013; Student‟s t-test).   222 
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Figure 7.6: (a) Western blot analysis for TK-1 (24 kDa) expression (representative 
result of 3 independent experiments). (b) Densitometric analysis of bands (expressed 
as Integrated Optical Density (IOD)). For both cell lines, a statistically significant 
increase in expression of TK-1 was observed in 5-FU treated cells compared to the 
untreated controls (p < 0.05),  
a) 
b) 
SW480  SW620 
                Control    5-FU Treated  Control   5-FU Treated   223 
7.5 Discussion 
This study examined the early effects of TS inhibition with 5-FU, on uptake of the 
two PET tracers 18F-FDG and 18F-FLT. The time point at which the experiments 
were carried out was of particular importance as at 2 hours after drug exposure (day 
0), there were no changes observed in either cell numbers, nor the cell cycle phase of 
the drug exposed cell lines (shown in figures 7.1 and 7.2). The chosen drug doses 
were  however  demonstrated  to  be  cytotoxic  as  a  reduction  in  cell  viability  was 
observed on days 1 and 2 post-treatment with both 5-FU and Cisplatin. This setting 
therefore  represented  a  time  point  when  biological  response  to  5-FU  could  be 
assessed before changes in morphology were apparent.  
 
On day 0, no significant change in 18F-FDG uptake was seen in response to 5-FU. 
This  correlated  with  the  unchanged  cellular  viability.  Conversely,  5-FU  treatment 
resulted in a dose dependent increase in 18F-FLT uptake as compared to the untreated 
controls. Treatment with Cisplatin (which exerts its cytotoxic effect by causing DNA 
chain  termination  and  not  directly  through  altering  pyrimidine  (thymidine) 
metabolism) did not result in the same increase in uptake of 18F-FLT, thus suggesting 
that the observed increase in 18F-FLT uptake may be a specific response to 5-FU. 
These finding were consistent with that of Dittmann et al. (2002) where in an human 
oesophageal cancer cells line (OSC-1), a 5-10 fold increase in 18F-FLT uptake was 
seen within 24 hours of cells being exposed to antimetabolites 5-FU, methotrexate 
and Gemcitibine, but once again not Cisplatin. Also in a very similar study to ours,  
Yau et al. (2006) also demonstrated an increase in uptake of 11C-thymidine at 2 and 6 
hour following pulse treatment with 5-FU and Nolatrexate (AG337), the latter being a 
novel selective TS inhibitor.   224 
In our in vitro model, 5-FU treatment was shown to result in an increased expression 
of  TK-1.  This  finding  was  consistent  with  our  initial  proposed  hypothesis  that 
treatment with 5-FU may result in activation of the salvage pathway of pyrimidine 
synthesis. However, it must be noted that the increase in TK-1 protein expression, 
may only represent one arm of the mechanism involved in thymidine salvage. Earlier 
work in a bladder cancer cell line showed TS  inhibition to result in an increased 
expression of both nucleoside transporters (NT) as well as TK-1 activity (Pressacco et 
al. 1995). Their study suggested a common regulatory pathway for the TK-1 and NT 
expression, which may be dependent on intracellular thymidine pools, a function that 
is affected by TS inhibition. More recently, Perumal et al. (2006) re-examined the 
cellular response mechanisms to 5-FU in a mouse model bearing a RIF-1 tumour 
xenograft.  Consistent with our results and other earlier studies, once again a 1.8 fold 
increase  in  tumour  uptake  of  18F-FLT  was  observed  within  1  hour  following 
treatment with 5-FU. Their study went on to assay tumour and plasma deoxyuridine, 
TK-1, ATP and type-1 equilibrative nucleoside transporter (ENT) levels. Tumour and 
plasma deoxyuridine levels increased significantly whereas contrary to our findings, 
TK-1 (and ATP levels) were unchanged. Furthermore, they observed an increase in 
ENT binding sites, but no changes in transporter affinity was observed. This lead 
them to suggest that early changes observed in 18F-FLT uptake may be related to 
changes  in  re-distribution of nucleoside transporters  to  plasma membrane and not 
changes in TK-1 expression. It can be argued that a significant upregulation of TK-1 
expression to 5-FU treatment may take a longer while than the 2 hour time limit of 
our  experiments  would  allow.  In  this  scenario,  an  enhanced  re-distribution  of 
membrane  nucleoside  transporters  would  be  a  more  plausible  mechanism  for  the 
increased 18F-FLT uptake that is seen. Currently there are no published studies that   225 
have quantified the amount of time it takes for TK-1 gene translation/transcription. 
While our finding of increased TK-1 expression may be in keeping with our original 
hypothesis,  this  finding  requires  further  validation  in  light  of  the  above  recent 
findings.  A correlative study that compares TK-1 gene and protein expression would 
be of great value.  
 
Following on from the above, in considering TK-1 protein as the principal target for 
why cellular uptake of 18F-FLT increases, there are other consideration that need to 
be  made.  Much  of  our  understanding  of  TK-1‟s  biological  activity  stems  from 
mechanistic  studies  carried  out  in  vitro.  It  is  understood  that  TK-1  undergoes  a 
complex array of transcriptional and translational modifications that regulate its cell 
cycle control (Coppock and Pardee 1987; Ito and Conrad 1990; Chang and Huang 
1993; Frederiksen et al. 2004). As such, alteration in dimmer-tetramer transformations 
of the protein or post-transcriptional mechanisms of protein induction that may alter 
TK-1‟s enzymatic activity, may be also be highly relevant to drug induced effects on 
18F-FLT uptake. In our study, the protein samples from cell lysates were prepared in 
reducing conditions, and thus the predominant form of TK-1 detected  by the Western 
blot technique was its monomeric form at 24 kDa.  It would therefore be of value to 
examine TK-1in its native, non-reduced form in order to further assess the effect of 5-
FU on its function as well as its sub-unit configuration.  
 
Interestingly,  our  results  suggest  that  TK-1  expression  and  SPF  do  not  directly 
correlate. As previously mentioned, TK-1 is believed to be tightly regulated by the 
cell cycle. It is maximally expressed during S/G2 phase of the cell cycle, after which 
its levels decline to background levels by the end of the M phase (Sherley and Kelly   226 
1988). A possible explanation for our results may lie in the fact that the maximal 
requirement  for  nucleotides  during  DNA  synthesis  is  the  principal  reason  for  the 
inherent S-phase specificity of TK-1. Activation of the salvage pathway shortly after 
5-FU  treatment  may  therefore  represent  a  fail-safe  mechanism  to  counteract  the 
deleterious effects of 5-FU on intracellular thymidine pools. The fact that 18F-FLT 
uptake shows a dose dependent pattern, further suggests that the pyrimidine salvage 
mechanism  may  represent  an  adaptive  and  not  simply  an  “on-off”  response.  This 
assumption  requires  further  investigation  and  future  experiments  should  aim  at 
correlating TK-1 activity / enzyme expression with changes in intracellular thymidine 
pools following 5-FU treatment.   
 
A pitfall of our experimental model is related to the complex mode of action of 5-FU. 
Although  TS  inhibition  is  believed  to  be  the  principal  mechanisms  of  5-FU 
cytotoxicity,  it  has  also  been  shown  to  have  deleterious  effect  through  direct 
incorporation into DNA and RNA. Future studies should therefore aim at defining the 
relative effects of the various metabolites of 5-FU on 18F-FLT uptake. Furthermore, 
as suggested by recent studies such as that of Prumal et al. (2006) and Yeu et al. 
(2006) (mentioned above), 18F-FLT may in fact be a more appropriate tracer for 
monitoring the effects of selective TS inhibitors such as Nolatrexate and not 5-FU.  
 
18F-FLT at present is the second most commonly available PET radiopharmaceutical 
after  18F-FDG.  The  feasibility  of  using  18F-FLT  PET  in  monitoring  response  to 
therapy has been shown in a number of in vivo animal models (Barthel et al. 2003; 
Oyama et al. 2004; Leyton et al. 2005; Waldherr et al. 2005). Early results in human 
subjects have also been reported in a small series of breast cancer patients (Kenny et   227 
al.  2007).  At  one-week  post  treatment  with  FEC  (5-fluorouracil,  Epirubicin, 
Cyclophosphamide)  chemotherapy,  a  reduction  in  18F-FLT  uptake  was  seen  in 
responders  ahead  of  changes  in  tumour  size.  Serial  imaging  also  demonstrated  a 
reduction in 18F-FLT uptake, corresponding to a change in tumour proliferation. The 
main focus of all these studies has been to monitor the anti-proliferative effects of 
cytotoxics  with  18F-FLT  PET.  Our  experimental  model  however,  takes  the 
application of 18F-FLT one step further back to a time point when 5-FU has not had 
any  effect  on  cellular  viability  and  /  or  proliferation.  The  observed  paradoxical 
increase in 18F-FLT at this early time point may represent a surrogate marker of TS 
inhibition, thus raising the possibility of its application as a means of differentiating 
between tumours that may be sensitive to TS inhibitors from  those which may not be. 
If these early changes in 18F-FLT uptake can be mirrored in the clinical setting, then 
potentially 18F-FLT PET can be used to determine 5-FU responsiveness after a small 
test dose, before the full treatment regimen has begun.  
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7.6 Conclusions 
In  an  in  vitro  cell  line  model  we  have  demonstrated  an  early,  dose  dependent 
biological  response  to  TS  inhibition  with  5-FU,  which  is  measurable  with  the 
thymidine analogue PET tracer 18F-FLT and not the routine glucose analogue 18F-
FDG. Quantifying such changes in the salvage pathway of pyrimidine synthesis with 
18F-FLT PET, may therefore provide a potential tool for predicting response to TS 
inhibition, before changes in tumour morphology and volume become apparent. 
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Chapter 8 
 
 
Summary of results  
and overall conclusions 
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8.1 Summary of results  
The  modern  management  of  cancer  increasingly  utilizes  patient  specific 
characteristics to provide patient centred care. Within this framework, crossectional 
imaging has played a predominant role in dictating the course of treatment. More 
recently however, our enhanced understanding of the molecular biology of disease is 
shifting the focus in cancer management to a more tumour specific one. This for 
example has lead to the emergence of targeted biological treatments such as that with 
monoclonal antibodies. This concept shift in disease management has also paved the 
way for molecular imaging to  develop  as  a discipline, which once  a  concept  has 
become a clinical mainstay of imaging with the use of dedicated PET scanners.  
 
The routine application of PET in cancer management can be considered with a two-
pronged  approach.  In  the  first  instance,  molecular  imaging  may  be  used  as  an 
alternative  tool  to  conventional  crossectional  imaging  to  improve  diagnosis  and 
staging of disease. With PET, this has largely been as a result of the success of 18F-
FDG as a universally sensitive probe in targeting glycolysis, a process that is common 
to most cancers. The alternative approach is the application of PET imaging as a 
quantitative and a functional imaging tool. In this respect, a specific molecular probe 
may be applied both globally and individually to provide in vivo measures of disease 
biology.    This  paradigm  can  then  be  used  not  only  to  prognosticate,  but  also  to 
monitor temporal changes in disease behaviour in response to treatment that can be 
measured at an earlier time point than what is achievable using morphological criteria.  
 
This thesis aimed to examine the above two facades of molecular imaging with PET.  
To do this, two solid gastrointestinal cancers were chosen, each providing a model for   231 
the  routine  use  of  PET  that  was  able  to  highlight  many  of  the  strengths  and 
weaknesses of this imaging modality. In chapters 3 and 4, the role of multimodality 
imaging with PET/CT using 18F-FDG was examined when applied routinely to the 
multidisciplinary management of pancreatic cancer and as tool to decision making in 
managing colorectal liver metastases. The main question raised was: “Does 18F-FDG 
PET/CT provide additional (clinically useful) information to routine imaging with 
CT?”  
 
In  the  routine  management  of  pancreatic  cancer,  18F-FDG  PET/CT  was  more 
sensitive and specific than routine ceCT in detecting the disease at the primary site. 
Although  more  specific  than  ceCT,  false  positive  results  with  18-FDG  PET/CT 
occurred where there was tracer accumulation in focal areas of inflammation, namely 
in that of mass forming chronic pancreatitis. None the less, PET/CT was particularly 
useful where ceCT results were equivocal but suspicious, where the lack of tracer 
accumulation within a pancreatic mass was correctly interpreted as benign disease. 
The role of 18F-FDG PET/CT in staging locoregional disease was also limited. Poor 
spatial  resolution  of  PET  and  the  suboptimal  (non-diagnostic)  nature  of  the  CT 
component of PET/CT did not allow for an accurate assessment of local (T) stageof a 
tumour. As for this, decisions about resectability of malignant lesions could not be 
made  with  PET/CT  alone.  Our  results  also  indicated  that  accurate  detection  of 
locoregional  lymph  node  involvement  with  18F-FDG  PET/CT  may  also  not  be 
superior to ceCT and overall poor. Therefore ultimately, the advantage conferred by 
18F-FDG PET/CT was in determining / excluding the extent metastatic disease in 
patient who were deemed to have an operable tumour based on convention ceCT 
criteria.     232 
 
In advanced colorectal cancer, it was similarly demonstrated that 18F-FDG PET/CT 
was  more  accurate  than  CT  in  detecting  the  extent  of  extrahepatic  disease  and 
provided a means of characterising equivocal liver lesions seen on CT. The sensitivity 
of 18F-FDG PET/CT and ceCT for detecting  hepatic lesions  were similar.  Once 
again,  the  impact  of  18F-FDG  PET/CT  on  clinical  management  was  through  its 
accuracy  in  assessing  the  extent  of  metastatic  disease  both  above  and  below  the 
diaphragm. This potentially lead to a better patient selection for resection of liver 
metastases.  Due  to  the  small  sample  size  of  the  study  and  limited  time  frame  of 
follow-up, this impact of PET/CT on overall survival could not be assessed. However, 
similar studies previously published have shown pre-operative staging of CLM with 
18F-FDG PET to correlate with an improved 5-year survival when compared with 
conventional CT (Fernandez et al. 2004).  
 
One of the challenges faced by the routine use of PET/CT technology remains its 
relative high costs and the availability of PET/CT scanners particularly in the UK. An 
approach to tackling this is to define precise criteria based on parameters that predict 
which patient would most benefit from imaging with 18F-FDG PET/CT. One such 
potential selection criteria is the Clinical Risk Score, (CRS) originally described as a 
means  of  predicting  the  probability  of  recurrence  in  patient  undergoing  hepatic 
resection for CLM. We hypothesized that the CRS could identify patients in whom 
the clinical yield of 18F-FDG PET/CT would be the greatest. Our results however 
failed to show a significant correlation between CRS and the clinical yield of 18F-
FDG PET/CT. It is likely that the study‟s small sample size may have resulted in such 
a trend not to become statistically apparent. On the other hand it can be argued that   233 
18F-FDG PET could provide additional information regardless of prognostic scores 
of disease, thus justifying the routine application of 18F-FDG PET/CT. None the less, 
this hypothesis requires further examination in larger patient series and possibly with 
the use of alternative prognostic scoring systems.  
 
Despite its high sensitivity, one of the drawbacks of the imaging with 18F-FDG PET 
has been its lack of tumour specificity. In the routine setting, false positive results 
often  resulted  in  patients  undergoing  additional  invasive  diagnostic  procedures. 
Should  18F-FDG  PET  become  the  mainstay  of  routine  imaging  in  cancer,  false 
positive results could results in considerable wasted resources, as patients may need to 
undergo unnecessary investigations, treatments and/or be refused curative therapies. 
Therefore  in  interpreting  18F-FDG  PET  studies,  a  clear  knowledge  of  disease 
behaviour and understanding of tracer uptake patterns are paramount, in order so that 
truly malignant and benign lesions are not misinterpreted. Furthermore, alternative 
strategies  to  improve  the  specificity  of  PET,  with  for  example  the  use  of 
multimodality PET/CT scanners or the use of alternative radiopharmaceuticals (such 
as 18F-FLT) need to be further investigated. 
 
Following on from the above, two pilot studies also examined the potential role of 
18F-FLT PET in our two gastrointestinal cancer models. Consistent with the results of 
other published studies, the relative amount of 18F-FLT uptake within lesions was 
lower than that for 18F-FDG, thus resulting in poorer detection rates of malignant 
foci. In fact, any advantage conferred from 18F-FLT being a more cancer specific 
tracer was counteracted by its overall high false negative rate. Despite our two studies 
lacking adequate sample size and thus statistical power, the results strongly indicated   234 
that 18F-FLT PET would be an unlikely candidate to supersede 18F-FDG as a routine 
PET tracer.  
 
Access to tissue specimen in the cohort of pancreatic caner patients allowed us to test 
the  hypothesis  of  whether  18F-FLT  uptake  was  a  surrogate  measure  of  cellular 
proliferation.  The  strong  correlation  between  tumour  18F-FLT  SUVs  and  Ki-67 
antigen expression was again in keeping with other similar studies supporting the role 
of 18F-FLT as a marker of proliferation. Survival analysis although did not reveal 
statistically significant results, did show a divergence of survival curves between high 
and low 18F-FLT SUV thresholds. Unfortunately due to a lack of tissue specimen, the 
above  hypothesis  could  not  be  tested  for  our  group  of  patients  with  advanced 
colorectal cancer. However, earlier work in our unit has shown a similar positive 
correlation between 18F-FLT SUV and MIB-1 labelling in colorectal primary and 
metastatic  lesions  (Francis  et  al.  2003b).  The  results  from  this  thesis  and  that  of 
previously published data therefore support the role of 18F-FLT PET as a means 
quantifying the proliferation index of lesions and potentially as a means of obtaining 
prognostic information. However future larger scale studies are required to further 
ascertain the clinical relevance 18F-FLT, particularly in directing decision making 
prior to the start of neoadjuvant and adjuvant therapies.  
 
Finally,  the  last  chapter  in  this  thesis  examined  a  potential  role  for  18F-FLT  to 
monitor  response  to  chemotherapy  using  an  in  vitro  cell  line  model  of  CRC.  An 
increase  in  uptake  of  18F-FLT  was  seen  with  5-FU  treatment  and  not  Cisplatin.  
Furthermore,  this  response  was  also  not  seen  with  18F-FDG  uptake.  The  dose 
dependant response of 18F-FLT occurred at a time point before any changes in cell   235 
number and cell cycle phase were observed thus supporting the notion that PET can 
potentially  quantify  biological  changes,  before  changes  in  morphology  become 
apparent.  Interestingly,  the  increase  in  uptake  of  18F-FLT  with  5-FU  treatment 
corresponded  to  an  increase  in  expression  of  the  phosphorylating  (and  trapping) 
enzyme, TK-1. The time constraints of this thesis did not allow for examination of 
any changes in TK-1 activity nor gene expression. Moreover, the recent study by 
Perumal  et  al.  (2006) attributed a similar  pattern of increased 18F-FLT uptake to 
redistribution  of  nucleoside  transporters  to  the  plasma  membrane  and  not  to  an 
increase expression of TK-1. Therefore, despite our findings supporting our original 
working hypothesis, the mechanism underlying the observed thymidine / 18F-FLT 
uptake in response to TS inhibition requires further validation. Future studies are also 
required to examine whether 5-FU resistant cell lines would exhibit a higher or lower 
18F-FLT  uptake  response.  This  can  potentially  be  used  in  the  clinical  setting  to 
predict good responders early in the course of treatment (ie: within hours), negating 
the need to undergo a futile course of chemotherapy before traditional measures of 
morphological response declare the treatment a success or not. 
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8.2 Overall conclusions 
In  conclusion,  there  are  clear  indications  that  molecular  imaging  with  PET  has 
emerged as a powerful adjunct to our conventional crossectional imaging techniques. 
Its  routine  application  at  present  however  seems  to  be  best  directed  towards  the 
assessment of overall disease / metastatic burden but, as our primary mode of curative 
treatment  is  still  surgery,  there  remains  a  heavy  reliance  on  accurate  anatomical 
information that current PET and PET/CT imaging protocols fail to fulfil. Despite 
this, there is a real potential for a one-stop approach to diagnosing and staging cancer 
using  18F-FDG  PET/CT.  However,  there  are  practical,  logistical  and  cost 
implications that need to be addressed. At present 18F-FDG remains the gold standard 
tracer for PET imaging, which despite its limitations, is overall the most sensitive and 
specific  tracer  available  for  the  routine  clinical  application  of  PET  in  oncology. 
Where alternative tracers such as 18F-FLT may be of value is in providing additional 
prognostic information which when used selectively, could in turn provide specific 
information required to treat cancer on an individualized basis.  
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SOP:  PET_7  TITLE:  Measuring FDG upon arrival in the PET Suite 
Rev:  1.0  Date:  22/10/2001  Review:  Oct 2002 
Group:  PET  Author:  CET / WW  Authorised:  PJE 
 
OVERVIEW 
This SOP addresses the checks which must be performed on each consignment of 18F-FDG before it may be 
used to dispense patient dose preparations that day. 
RELEVANT STAFF 
INM practitioners and operators working in the PET Suite. 
BACKGROUND 
The PET Unit obtains 18-F FDG from three centres : 
  Addenbrooke‟s Hospital, Cambridge (Wolfson Brain Imaging Centre) 
  Hammersmith Hospital (MRC Cyclotron Unit) 
  St Thomas‟ Hospital (PET Centre) 
 
Before any FDG may be injected into a patient there must be notification from the producing cyclotron that it 
has passed its QC. 
 
  Cambridge dispatches the FDG and will then fax to confirm if the consignment has passed the QC. The 
fax will be sent to the fax machine in the PET Suite.   
  St Thomas‟ Hospital do the same. 
  Hammersmith Hospital perform QC testing before the FDG leaves them, and confirmation that the 
FDG has passed its QC is on the delivery note. 
PROCEDURE 
Pre-Dispensing Checks to be done daily : 
 
  Daily QC testing must be performed on the Dose Calibrator before the FDG consignment can be 
assayed.  Refer to the SOP for Dose Calibrator QC in PET. 
 
  The FDG will arrive in a lead shielded container. (Take care when lifting it, as it is heavy.) 
 
  Display a sign at the door of the dispensing lab  - „Please do not enter: Dose dispensing in progress. 
Radioactive sources in use‟. Ensure that you are wearing a white coat, film badge, and finger dose TLDs. 
 
  Take a new Radiopharmaceutical Holding Record Sheet. (See Appendix). Indicate on the record sheet that 
you have received confirmation that the consignment of FDG has passed its QC. From the delivery note 
mark the volume of liquid dispensed into the FDG vial, the time at which the FDG was measured prior to 
despatch, and the assayed activity.  
 
  Remove the glass vial containing the FDG from the lead shielded container using the tongs provided; 
check that it has a label on saying FDG. Place in the dose calibrator.  
 
  Check that the dose calibrator is set to the correct radioisotope setting (18-F). Measure the activity and note 
this, together with the time at it was measured. 
 
  Using the 18F decay chart displayed on the wall, check that the activity that was dispatched matches the 
activity that has arrived to within   10%. If it does circle the appropriate box on the sheet, and initial this. 
 
  Put the FDG vial in the lead shielded dispensing station and screw on the top. 
 
  File the delivery notes and the QC confirmation notes in the file in the dispensing suite. 
GLOSSARY 
   275 
APPENDIX 
 
   276 
 
SOP:  PET_11  TITLE:  Whole Body FDG PET-CT  
Rev:  1.0  Date:  Oct 2004  Review:  Oct 2005 
Group:  Diagnostic  Author:  CET/JCD  Authorised:   
 
OVERVIEW 
The PET CT exam is a combined imaging study where both CT and PET images are acquired over the same 
area of the patient. The PET images provide a functional image of the radiopharmaceutical distribution in the 
patient, while the CT images provide an image of the anatomy which is used for localizing the 
radiopharmaceutical uptake and for attenuation correction of the PET images 
REQUEST 
Valid reasons for examination: 
  Staging of disease 
  Recurrence of disease 
  Post treatment 
Valid referrers: 
See SOP V_2 
Persons who may vet: 
All Consultant staff 
Vetting: 
See SOP P_1 
Booking: 
  Patient is asked to arrive 60 minutes before the due time for injection. This is to allow time for them to 
have valium and relax. 
  Patient or ward is sent an appointment letter. This letter asks the patient to starve, eating and drinking 
nothing but water for 6hours prior to the study. 
  Letter also asks them to contact us if they are diabetic. 
  Tells patient that they will be given valium so not to drive. 
  If the patient is a private patient refer to SOP for private patients/ FDG. Patient‟s bill should be settled 
prior to scan starting. 
PATIENT PREPARATION 
  Patients should starve for 6 hours prior to the scan. 
  They may drink water only. 
  Patients on TPN should have this discontinued for 4-6 hours. 
  Patients on glucose drips should have this discontinued for 4-6 hours. 
  The appointment letter asks patients to contact the department if they are diabetic. Patients who are 
insulin dependent diabetics should speak with the duty practitioner about scheduling their scan. SOP- 
  The weight limit for the PET scanner is 180kgs. If it is know in advance that the patient approaches this 
weight ask them to come to the department prior to giving them an appointment to see if they will fit 
the scanner‟s aperture. 
  Children under 10 should be asked to arrive 60-90minutes before the appointment time to have emla 
cream. 
RADIOPHARMACEUTICAL AND ADMINISTRATION 
Radiopharmaceutical:  18FDG 
ARSAC Serial No:   
DRL: (Maximum usual activity)   400MBq 
ED:   
Minimum dose for paediatrics:  6MBq/Kg minimum dose of 100MBq 
Advice re breastfeeding:  ARSAC 
Persons who may administer:   
Procedure:  See below 
 
Route of administration: (IV etc)  IV 
Advice after administration:  Patient should lie still for the 45-60 minutes after the injection and 
before the scan. This reduces the uptake of FDG in muscles of the   277 
arm, voice etc. 
PROCEDURE 
 
Daily Checks 
 
1.  Blank scan acquisition, reconstruction and correction. PET_05 
2.  Tube Warm-up and CT Fast Calibration CT_01 
3.  QC of dose calibrator to be done before measuring first FDG/ Fluoride dose of the day. PET_09 
4.  No injection is to be done before the QC for the dose has been received from the dispensing hospital. 
 
Weekly Checks 
 
1.  Volumetric QC 
2.  Water phantom QC 
 
Patient Preparation 
 
1.  Check the patient‟s name and DoB. INM_EP09 
2.  Check that the patient is not pregnant or breastfeeding. INM_EP03 
3.  If the patient needs to be accompanied by a nurse or parent and this person is a female make sure that 
they are not pregnant. Make sure that this person keeps as far as is reasonably possible from the patient. 
4.  Take the height of the patient in centimetres, mark on the clerking sheet. 
5.  Take the weight of the patient in kilograms, mark on  the clerking sheet. These are used for SUV 
calculations on the Discovery. 
6.  Take a brief history from the patient. 
7.  Ask patient to lie on the patient trolley, make sure that they are comfortable. Explain the procedure to 
them. 
 
Administration 
 
8.  Cannulate the patient, using a pink or blue venflon. Attach a 3-way tap and check that the line is patent 
with a saline flush. 
9.  Leave the patient to relax for 30 minutes. Show them the red pull cord which when pulled will alert the 
technologist. Put up the sign saying the patient „Patient examination in progress‟. 
10.  Draw up the FDG using a 5ml syringe in the lead syringe holder. Note the time the dose is calibrated, 
from  the  clock  in  the  dispensing  bay.  This  clock  should  be  set  with  the  Discovery,  and  checked 
regularly to make sure that they are in synch. 
11.  Note the activity in MBq and the volume (all on the clerking sheet). 
12.  Before giving the patient the FDG check that they do not wish to go to the toilet. 
13.  Explain the procedure one more time make sure that they do not have any questions. Give the patient 
the injection; note the time (from the same clock in the dispensing bay). Assay the syringe and needle 
again after the injection, note the activity and time on the clerking sheet. 
14.  The injector should sign the clerking sheet. 
15.  The technologist as the operator will sign the patient‟s request card. 
16.  Make sure the patient is warm enough. 
17.  Turn the lights off above their head and leave them alone. Make sure the red pull cord is within their 
reach. Change the sign „Patient post injection present‟. 
 
Imaging 
 
18.  After 1 hour take the venflon out of the patient‟s arm, cover the site with cotton wool. Change the 
cotton wool for a clean piece just prior to the scan. 
19.  Ask patient to empty their bladder. 
20.  Take the patient into the scanning room 
21.  Ask patient to change into a gown, check for other metal objects. 
22.  Place sign on door to read „Do not enter. Clinical Scan in progress‟. 
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ACQUISITION TECHNIQUE 
 
Patient Positioning 
 
1.  Ask the patient to go to the toilet prior to positioning on the bed. 
2.  If oral contrast is being given ask the patient to have a couple of mouthfuls before lying on the bed. See 
SOP for Oral Contrast. 
3.  Position the patient on the bed with the feet facing away from the gantry. 
4.  Put a pillow under the patient‟s knees for comfort. 
5.  Make sure the patient is warm and comfortable. 
6.  If possible, ask the patients to place their arms above their heads, occasionally patients may to have 
their arms by their side. Raise the bed up slightly to ensure that the bed will fit in the bore of the 
scanner.  
7.  Tell patient to lie still. 
8.  Make patient aware of the voice intercom between them and the control room. 
9.  If the patient cannot speak give them the hand held alarm. 
 
Acquisition Preparation 
 
10.  On the Scan monitor, click the New Patient icon. Enter the patient‟s details. Patient ID is the INM 
database number. Patient Name  enter as SMITH John. 
11.  Enter the rest of the details. 
12.  The scan protocols are classified in two main groups adults and infants. If the patient is a child, click on 
the infant icon. 
13.  Under Protocol Selection, the PET-CT protocol for whole body scan is defined in the Routine Chest 
selection No 5. Click on the chest, select protocol 5.13 INMPET_CTBody_Head_In. 
14.  Check the CT parameters. Ask patient to close their eyes. 
15.  On the gantry control press Laser Lights. 
16.  Move the bed inside the gantry until the laser lights is level with the midbrain. 
17.  On the gantry control press the internal landmark button. 
18.  Remind the patient to lie still. 
 
Acquiring the Image 
 
19.  Check all staff are clear of the scanning room before the CT starts. 
20.  Confirm CT prescription, and press Move to Scan 
21.  Press Start to start scout view. The bed will then move. 
22.  At the end of the scout view, select Next Series. The scout will be displayed on the Image Monitor with 
the PET FOVs overlaid. Select as many FOV as necessary to cover midbrain to upper femora. Click 
Confirm. 
23.  Check CT parameters are correct and then acquire CT by pressing Start Scan. 
24.  Click PET series. 
25.  The PET screen is displayed on the PETOWS / Scan Monitor. The patient name and scan details will 
have  been  transferred  from  the  CT  system.  Add  the  FDG  data  under  additional  tracer  info.  Click 
Prospective Recon, and select  PROSP_NO_AC and PROSP_WB_AC, this  will enable prospective 
reconstruction to occur. 
26.  Click Accept Setup. Press Move to Scan, and then press Start Scan 
27.  Following the completion of the acquisition the system will automatically store the data and clean up 
the  acquisition  processor  (final  message  displayed  should  be  acquisition  completed  successfully). 
Under Options, Quit screen. 
28.  Under options, click Options/Quit Screen to close the PET acquisition window. 
29.  Then on the image monitor, click on Exam RX to bring up the CT window. Click End Exam, to 
complete the whole examination. 
ADVICE TO PATIENT ON DISCHARGE 
Do not allow the patient to leave the hospital through the INM. If relations or transport comes to collect the 
patient get them to come to the PET suite and leave from there. 
Make sure the patient knows how they will obtain the results of the study. 
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DATA ANALYSIS 
 
Reformatting Images 
 
1.  From Screens select Display, the from the Display window select Reformat. 
2.  From the displayed list select Orthogonal (MIP), and then on the resulting screen, click Load. 
3.  Select the required patient name and under then the “WB Emission CTAC” image reconstructed above. 
4.  Click the Re-slice control button. 
5.  Adjust the number of sagittal and coronal slices to cover the patient. 
6.  Change the slice thickness to 11.72mm. Click Re-slice. 
7.  Review images prior to patient departure. Ensure there is no need for further acquisitions. If a further 
acquisition is needed, remember to contact a Doctor to get it justified.  
8.  Under Options, select Save/Coronal. Name the slices „Generated Coronals, WB+CTAC 11.72 mm‟ 
 
Transferring the data to the Xeleris 
 
1.  From  Screens,  select  Network.  Source  should  be  set  to  „INMPET01‟,  destination  should  be 
„ews_DICOM‟, and Sort by „Date Time‟. 
2.  Select the patient, and select Coronals, WB emission CTAC and No AC recon. Click on Select, and 
click Transfer Items. Ensure that the images are transferred successfully. 
DATA DISPLAY 
On the Entegra. 
 
1.  Select the patient and „Generated Coronals‟. 
2.  Click on the Templates tab. Choose Generated FDG Coronals, and click Start Review Template. This 
will display 5 x 3 coronal images. Ensure that the slices cover the whole body and are centred on the 
review pane from front to back. 
3.  Alter black and white intensity to 30,000 Bqml. 
4.  Check that the images look OK, and print one copy to the „Codonics‟ and one copy to the „Windows 
Printer‟. 
REPORTING 
Persons who may report: All consultant staff. 
 
Reporting procedure: 
 
DATA ARCHIVE 
Raw data is archived twice onto DAT tapes. One tape is called TAPExx, the other is called WEEKxx. The 
current tape called TAPExx will be kept in the fireproof safe in the PET scanning room. The older ones will be 
kept in the basement storeroom. Archive the raw data, the 2D Whole body Emission, 5 mins/step and 
corresponding CTAC client. 
 
On the Xeleris, archive the CT slices, Generated Coronals, WB Emission CTAC, and No AC Recon to Optical 
disk and PETARC. Also upload the same data to Xel_Sem (reporting Xeleris to PET). Details of Xeleris 
archiving are given in General Nuclear Medicine SOPs. 
 
Detailed procedure for DAT tape archiving: 
 
From Screens select Archive.  
Place the current raw data DAT tape in the tape drive. 
Once the light one the tape deck stops flashing click Ready on the Archive screen. If Ready is not displayed the 
program has already started running.  
Depending on the amount of data already archived on the tape this may take up to 10 minutes. During this 
period the Archive screen is blank. 
After the reading of the tape is completed a list of the datasets in the tape will be displayed.  
From Data type select Raw. 
Select Archive. A list of the system image database will appear. 
Select the patient name. 
Click Start. A dialogue box will be displayed containing all the raw data files contained under the patient‟s   280 
folder and will ask for confirmation of the start archiving command. Click ok. 
During the process of archiving none of the buttons in the Archive screen can be pressed. A bar with the process 
progress will be displayed. The number appearing under the bar is the percentage of the process completed. 
Following completion of the raw data archive click Remove tape. This will rewind the tape and it will also eject 
the tape from the tape drive. On the database book tick under the raw data archive column. 
The procedure should be repeated for the image data archive using the current image DAT tape and selecting 
Image in the Data type.  
Warning: Never start the archive process of a particular patient data if any other process currently uses data 
from this particular patient. 
ADDITIONAL COMMENTS 
Once the emission scan has been acquired reconstruct and reformat it. Show the duty doctor in case there is a 
need to acquire a single slice. 
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SOP:  PET_21  TITLE:  Whole Body FLT PET-CT  
Rev:  1.0  Date:  Oct 2004  Review:  Oct 2005 
Group:  Diagnostic  Author:  CET/JCD  Authorised:   
 
OVERVIEW 
FLT is a novel radiopharmaceutical that potentially allows imaging of proliferation (cellular growth 
potential) with PET. Currently, FLT is being used as part of comparative research study protocols, comparing 
it to the routine FDG PET. The aims of these studies are to determine whether imaging with FLT PET 
provides better images or additional information that would be relevant to treatment of patients with cancer. 
REQUEST 
Valid reasons for examination: 
Current running research protocols include: 
  Comparison of FLT and FDG PET in locally advanced and metastatic colorectal cancer 
  Comparison of FLT and FDG PET in locally advanced & metastatic cancer (includes: breast cancer, 
head & neck cancer, melanoma, connective tissue tumours, prostate cancer, thyroid cancer, Ovarian  
/ gynaecological malignancies, lymphoma, pancreatic cancer, lung cancer, hepatocellular carcinoma, 
brain tumours, renal cancer and neuroendocrine tumours) 
  Comparison of FLT and FDG in monitoring response to radiation therapy of head and neck cancers 
Valid referrers: 
See SOP V_2 
Persons who may vet: 
All Consultant staff 
Vetting: 
See SOP P_1 
Booking: 
  Patient is asked to arrive 60 minutes before the due time for injection. This is to allow time for them 
to have valium and relax. 
  Patient  or  ward  is  sent  an  appointment  letter.  This  letter  asks  the  patient  to  starve,  eating  and 
drinking nothing but water for 6hours prior to the study. 
 
PATIENT PREPARATION 
  Patients should starve for 6 hours prior to the scan. 
  They may drink water only. 
  Patients on TPN should have this discontinued for 4-6 hours. 
  Patients on glucose drips should have this discontinued for 4-6 hours. 
  The weight limit for the PET scanner is 180kgs. If it is know in advance that the patient approaches 
this weight ask them to come to the department prior to giving them an appointment to see if they 
will fit the scanner‟s aperture. 
 
RADIOPHARMACEUTICAL AND ADMINISTRATION 
Radiopharmaceutical:  18FLT 
ARSAC Serial No:   
DRL: (Maximum usual activity)   400MBq 
ED:   
Minimum dose for paediatrics:  6MBq/Kg minimum dose of 100MBq 
Advice re breastfeeding:  ARSAC 
Persons who may administer:   
Route of administration: (IV etc)  IV 
Advice after administration:  Patient should lie still for the 45-60 minutes after the injection and 
before the scan.  
PROCEDURE 
For the remaining procedural SOP’s for whole body FLT PET/CT imaging, please refer to 
SOP_11 (Whole Body FDG PET/CT protocol). 
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Appendix E 
 
(Protein assay and standard curve 
estimations)   283 
In  order  to  determine  the  concentration  of  the  protein  lysate,  first  a  standard 
concentration  curve  using  serial  dilutions  (concentration  range  of  0-2  mg/ml)  of 
Bovine Serum Albumin (BSA) was made. Using the method described earlier (section 
7.3.7.2)  the  Bradford  protein  assay  kit  was  used  to  give  corresponding  light 
absorbance values using a photospectrometer.  Linear regression analysis allows a 
best fit line to be applied to the BSA standard curve values, thus giving rise to graph 
similar to that below. Using the formula for the best fit line (ie: y = 0.1802x in the 
example shown), the concentration of protein lysates was extrapolated by determining 
the  corresponding  light  absorbance  values  using  the  photospectrometer  and  the 
Bradford  assay  kit.  Table  below  illustrates  an  example  of  concentration  values 
obtained.   
 
BSA standard curve             
Concentration (mg/ml)  0  0.125  0.25  0.5  1  2 
Absorbance (nm)  0  0.009  0.041  0.099  0.195  0.352 
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    Day 0  Day 1  Day 2 
5-FU untreated 
cells (SW480) 
Absorbance (595 nm)  0.009  0.063  0.06 
Concentration (mg/ml)  0.05  0.35  0.33 
          
5-FU treated cells 
(SW480) 
Absorbance (595 nm)  0.004  0.034  0.005 
Concentration (mg/ml)  0.02  0.19  0.03 
 
Example of protein concentration of cell lysates, extrapolated from the above 
standard curve.    285 
Appendix F 
 
(Protocol for gel electrophoresis  
and Western blots)   286 
General recipes: 
 
Reducing sample buffer 
1.51g Tris 
dissolve in 25ml distilled water 
pH to 7.5 with conc. HCL 
 
then add- 
40ml of 10% SDS solution 
10ml mercaptoethanol 
0.002g bromophenol blue 
10g sucrose or 20ml glycerol 
 
Make up to 100 ml with distilled water 
Divide into 1ml aliquots and store frozen 
 
 
Running buffer 
(x5 concentrated stock solution) 
 
70g glycine 
15g Tris 
5g SDS 
Make up to 500ml in distilled water 
For use dilute 1/5 in distilled water. 
Store in dry cool place 
 
Blotting buffer for semi-dry electroblotting 
 
Anode buffer I 
9.24g Tris 
500ml of 20% methanol in distilled water 
 
Anode buffer II 
1.52g Tris 
500ml of 20% methanol 
 
Cathode buffer 
1.52g Tris 
2.62g aminocaproic acid 
500ml of 20% methanol 
 
 
Recipe for making aliquots of DAB 
1) Dilute 1g DAB in 200ml of distilled water 
2) Put 1ml aliquots into 200 tubes (as quickly as possible as oxidises at room 
temperature) 
3) Cap tube and store frozen  287 
Preparation of samples 
 
1) Sample should be as clean as possible -> centrifuge/filter to remove solid 
particles/de-lipidise by chloroform/methanol precipitation 
 
2) Protein should be at a concentration of 1-10mg in distilled water or 0.1% SDS 
solution (Laemmli sample buffer) 
 
3) Add equal volume of protein solution to reducing or non-reducing sample buffer. 
Vortex to mix. 
 
4) If reducing conditions are required, boil sample in water bath for 30 sec-2 minutes. 
Allow to cool.  
 
5) Samples are ready to load onto gels 
 
 
 
Loading and running gels 
 
1) Insert prepared gels into electrophoresis chamber (can load two gels) 
 
2) Fill upper and lower buffer reservoirs up to the indicator marks 
 
3) Load samples (15-30 l depending on gel size) 
 
4) Attach leads to power pack 
 
5) Run at 150-180 volts for 1-1.5 hours, until bromophenol blue marker reaches the 
end of gel. 
 
After the run:- 
 
6) Turn the voltage down slowly to zero, remove lid from electrophoresis chamber 
 
7) Wear gloves -> remove adhesive tape around plates and ease plates apart. Trim off 
stacking segment and carefully remove gel. 
 
Transfer to: 
-Coomassie blue or silver stain (for total protein) 
-Blot 
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Instructions for semi-dry electroblotting (Western blot) 
 
Wear gloves! 
 
1) Soak 1 sheet of fliter paper in Anode buffer I 
2) Soak 2 sheets of fliter paper in Anode buffer II  
3) Soak 3 sheets of fliter paper in cathode buffer  
4) Soak a sheeth of nitrocellulose/PVDF sheeth in distilled water 
5) Position Anode buffer I paper on anode -> roll flat to exclude air bubbles 
6) Position Anode buffer II paper on top-> roll flat as above 
7) Postion the PVDF sheeth on top -> roll 
8) Postion the gel on top 
9) Cut all layer to size of gel-> replace on anode 
10) Postion the cathode buffer paper on top . Trim to size and roll 
11) Lower cathode (lid) into place and secure gently  
12) Blot at 0.25 amps per mini-gel for 30 minutes 
After blotting:- 
1) Slowly decrease power to zero 
2) gently remove PVDF sheets from sandwich 
3) Stain with Ponceau red to assesses transfer (destain in distilled water until pink 
bands show on white background. Destain completely in distilled water.) 
4) Immunostain 
 
Instructions for Immunostatining 
1) Block blots (to avoid background binding) with 1% BSA in PBS-T overnight at 
room temperature 
2) Apply primary and secondary antibodies according to pre-determined 
concentration / incubation time protocols  
3) Wash blots with TBS-T 5 times and with TBS alone 5 times 
4) For calorimetric analysis use DAB -> an aliquot of DAB made up to 10ml with 
TBS. 2ml of 30% H2O2 is then added to the solution and immediately poured over 
blot. Keep blot in DAB for 15 minutes (or until desired staining achived), remove and 
wash with distilled water.  
5) Store developed blots in a dry, dark place.    289 
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